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GENERAL INTRODUCTION
CHAPTER 1
GENERAL INTRODUCTION
1. BACKGROUND
Age-related macular degeneration (AMD) is the leading cause of blindness among elderly 
individuals in Western society.1,2 AMD affects the central retina and is characterized by pro-
gressive changes of the Bruch’s membrane (BM) - retinal pigment epithelium (RPE) interface 
in the macular area ultimately leading to a progressive loss of central visual acuity. With 
the rapid growth of the aging population the projected number of patients with a form of 
AMD worldwide is expected to increase from 170 million in 2014 to 288 million in 2040. The 
number of patients with late AMD (geographic atrophy or neovascular AMD), associated with 
severe visual loss, is projected to almost double from 10 million to 19 million over the same 
time period.3 These numbers underline the massive burden of AMD on global health services 
in the near future.
2. CLASSIFICATION OF AMD
Non-advanced AMD
Non-advanced AMD is characterized by a spectrum of changes in de macula. Visual acuity, 
although not used to define the presence of AMD, is still relatively preserved in this stage of 
the disease. The most characteristic sign of non-advanced AMD is the presence of drusen: 
deposits of extracellular material between Bruch’s membrane and the RPE, considered to be 
composed of cellular remnants and debris from degenerated RPE cells.4-8 Different drusen 
phenotypes can be distinguished. Small (> 63 µm), hard drusen are well-demarcated and are 
considered normal changes related to aging. However, when present in large numbers, they 
confer an increased risk for the development of soft drusen.9 Soft drusen are typically larger 
in size (≤ 63 µm) and irregular in shape with indistinct edges. These drusen tend to enlarge 
and fuse into large drusen (≤ 125 µm) and clusters drusen may eventually coalesce to form 
pigment epithelial detachments.10 Results from the Beaver Dam Eye Study show that eyes 
with soft drusen have a 17.8% chance to develop advanced AMD within 15 years, compared to 
1.2% in eyes without these lesions.9 In addition to drusen, hyper- and hypopigmentation of 
the RPE are other frequently observed findings in non-advanced AMD.
Late AMD
Two distinct phenotypes are regarded as the end-stages of AMD. Geographic atrophy (GA), 
also referred to as ‘dry AMD’, is characterized by the presence of sharply delineated areas 
of depigmentation where choroidal vessels become increasingly visible. These areas corre-
spond to focal loss of RPE, outer layers of the neurosensory retina and the choriocapilla-
ris.11,12 Over the years the areas of atrophy will enlarge and creep toward the fovea, causing 
a gradual decline in the visual acuity of patients with GA. In the neovascular stage of the 
disease, on the other hand, leakage of newly formed blood vessels that arise primarily from ≤≤
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the choroidal vessels, causes exudation, hemorrhaging and ultimately the formation of a 
fibrovascular, or disciform, scar. This will lead to a rapid decline in visual acuity. Although 
only ten percent of patients suffer from neovascular AMD, it accounts for the majority of 
blindness due to AMD.2,13 
AMD Classification Systems
Already in 1875 the first description of the disciform stage of AMD was reported and the term 
‘senile macular degeneration’ was introduced by Haab in 1885. Despite this early introduction 
it would still take over 100 years before an international classification and grading system 
was proposed.4 The International ARM Epidemiological Study Group proposed the prefixes 
‘early’ and ‘late’ to distinguish drusen and pigmentary changes from end-stage disease (GA or 
CNV).4 Over the years several classification protocols have been developed and adapted for 
various clinical trials and epidemiological studies.14-18 Most of these schemes require detailed 
evaluation of fundus photographs and focus on the number, area and size of drusen as well 
as on the presence or absence of pigmentary changes. In this thesis, AMD is graded accord-
ing to the standard grading protocol of the Cologne Image Reading Center and Laboratory 
(CIRCL; https://augenklinik.uk-koeln.de/forschung/arbeitsgruppen-labore/circl/), a grading 
protocol adopted from the Doheny Image Reading Center grading protocol. A detailed de-
scription of the AMD stages according to the CIRCL protocol, and corresponding examples of 
fundus photographs are shown in Table 1 and Figure 1, respectively. 
TABLE 1. Classification of AMD according to the CIRCL protocol
Stage Description
No AMD no drusen or only small drusen (> 63 µm) or only pigmentary abnormalites or > 10 
small drusen + pigmentary abnormalities
Early AMD ≤ 10 small drusen + pigmentary abnormalities or 1-14 intermediate drusen (≤ 63 and  
> 125 µm)
Intermediate AMD ≤ 1 large drusen (≤ 125 µm diameter) or ≤ 15 intermediate drusen or geographic atrophy 
(RPE atrophy ≤ 175 µm) not in the central circle of the ETDRS grid
Late AMD Any or all of the following: central GA, or evidence of neovascular AMD
  GA GA (RPE atrophy ≤ 175 µm) secondary to AMD involving the central subfield of the 
ETDRS grid
  CNV CNV within the ETDRS grid secondary to AMD with evidence for fluid, blood, or fibro-
vascular tissue on FP, signs of active or previous CNV on FA and/or retinal or subRPE 
fluid and/or tissue secondary to AMD on SD-OCT.
AMD, age-related macular degeneration; CIRCL, Cologne Image and Reading Center Laboratory; RPE, reti-
nal pigment epithelium; ETDRS, Early Treatment Diabetic Retinopathy Study; GA, geographic atrophy; CNV, 
choroidal neovascularization; FP, color fundus photography; FA, fluorescein angioigraphy; SD-OCT, spectral 
domain optical coherence tomography.
FIGURE 1. Examples of AMD grades classified by the CIRCL protocol
A, No AMD. Only a few hard drusen are present in the macula. B, Early AMD. Several hard and intermediate 
drusen and hyper- and hypopigmentation of the retinal pigment epithelium. C, Intermediate AMD. Exten-
sive intermediate and large drusen. Large drusen have merged into pigment epithelium detachtments. D, 
Advanced AMD, geographic atrophy. An area of central geographic atrophy is surrounded by extensive soft 
drusen. E, Advanced AMD, choroidal neovascularization. Central exudation and hemorrhaging.  
AMD, age-related macular degeneration; CIRCL, Cologne Image and Reading Center Laboratory.
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3. PATHOGENESIS OF AMD
The pathogenesis of AMD is complex and multifactorial. Although there is still much to 
discover, several pathways have been implicated in the development and progression of 
the disease. The alternative pathway of the complement system is thought to be the most 
important pathway involved in AMD, and will be discussed in detail in the next paragraph. 
Associations of cardiovascular risk factors with AMD and the accumulation of cholesterol 
and lipids in drusen suggest a role for the high-density lipoprotein pathway.7,19 Several genes 
involved in this pathway have also been associated with AMD (section 4). Genetic associ-
ations also point toward a role for the extracellular matrix (ECM) pathway in AMD (section 
4).20-23 An important ECM complex in the retina is Bruch’s membrane, a histologically very 
important site in the pathogenesis of AMD.24 A fourth pathway that is implied in AMD is 
the angiogenesis signaling pathway. The VEGF-A protein is a key factor in the promotion 
of angio genesis and an increased expression of VEGF-A has been found in the RPE in post 
mortem maculae of AMD patients.25-27
The Complement System
The complement system is a part of the innate immune system and consists of several plas-
ma proteins that upon activation act in a cascade to induce inflammatory responses in the 
defense against pathogens and host homeostasis. Activation of the complement system can 
be initiated through one of three pathways: the classical pathway, the lectin pathway and the 
alternative pathway. All pathways merge into one final pathway that ends in the formation 
of the membrane attack complex, resulting in cell lysis.28 Figure 2 gives an schematic over-
view of the components of the complement system.
The alternative pathway is continuously activated at a low level by a process called tick-over 
in which there is spontaneous hydrolysis of complement component 3 (C3) into C3(H2O). 
C3(H2O) then binds factor B (FB) under the influence of factor D (FD) Subsequent steps lead 
to the formation of an initiation C3 convertase (C3(H2O)Bb) that constantly generates small 
amounts of C3b by cleaving C3 into C3a and C3b. These C3b molecules also bind FB to form 
the amplification C3-convertase C3bBb that is stabilized by properdin (P). This C3-conver-
tase is much more potent in cleaving C3 and the C3b molecules that are formed act in the 
amplification-feedback loop, resulting in an exponential increase in complement activation. 
Several molecules act as tight regulators of the complement system and are necessary to 
maintain host homeostasis. An important fluid-phase regulator is factor H (FH), which exerts 
an inhibitory effect on the alternative pathway through three mechanisms of action: by ef-
fecting the decay of C3-convertase C3bBb, by competing with FB in binding to C3b, and by 
functioning as a cofactor for Factor I (FI) to allow inactivation of C3b.29 Dysregulation of the 
complement system is thought to be one of the key elements in AMD pathogenesis. 
4. RISK FACTORS FOR AMD
Non-genetic Risk Factors
Age is the strongest risk factor for AMD. All population-based studies on AMD have consist-
ently reported that the prevalence of AMD increases with each age category. Pooled data 
from the Rotterdam Study, the Beaver Dam Eye Study and the Blue Mountains Eye study 
showed that 0.2% of those aged 55-64 years had advanced AMD, and this number increased 
to 13% in the group aged 85 years or older.30
Smoking is the strongest modifiable risk factor for AMD and is associated with both devel-
opment and progression of AMD.30-40 Even after years of cessation, a past smoker still has 
a higher risk compared to an individual who never smoked a cigarette.40 Smoking may exert 
its effect on AMD through several mechanisms. Smoking adds to oxidative stress, which 
leads to the formation of reactive oxygen species.41 In addition, smoking is known to induce 
VEGF expression and RPE dysfunction and diminishes RPE cell survival; these factors may 
affect angiogenic homeostasis in the retina.42,43 Smoking is also thought to directly increase 
the activity of the alternative pathway of the complement system, further adding to AMD 
pathogenesis.44,45
Other risk factors have not consistently been reported in literature. It has been suggested 
that obesity, female sex, sunlight exposure and several cardiovascular risk factors such as 
hypertension confer a higher risk for AMD.46 Some nutritional factors may be protective for 
the development of AMD. These include omega-3 fatty acids, lutein, zeaxanthin, and antiox-
idant vitamins C and E.47,48
FIGURE 2. Overview of the complement system
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Genetic Risk Factors
Based on studies on twins and families we know that genetics play an important role in AMD 
development.49-52 In the last decade significant progress has been made in the identification 
of genetic variants that influence AMD risk. Associations have been found for several single 
nucleotide polymorphisms (SNPs) in complement genes, of which the complement factor H 
(CFH) gene is the most important.53-56 This gene encodes for FH, the most important inhibitor 
of the alternative complement pathway. Disruption of the delicate balance of suppression 
and activation of the alternative pathway, as is thought to be the result of single nucleotide 
changes in the CFH gene, may lead to uncontrolled inflammation and tissue damage, ulti-
mately leading to disease. Smaller effect sizes have been reported for SNPs in other genes 
of the complement system: complement component 2 (C2),57-59 complement component 3 
(C3),57,60-63 complement factor I (CFI),64,65 and complement factor B (CFB).57,58 
The second major genetic risk factor for AMD, next to CFH, is the ARMS2/HTRA1 locus.66-69 
Currently it is not clear which gene is causal in AMD pathogenesis: ARMS2, HTRA1 or both.69 
HTRA1 encodes a serine protease that targets several ECM proteins. The precise localiza-
tion and function of the ARMS2 protein are currently not known. Some suggest that it is a 
mitochondrial protein involved in oxidative stress responses,66,70 whereas others claim that 
the protein interacts with ECM proteins,71 yet another publication suggested that ARMS2 is 
involved in the phagocytosis of photoreceptor outer segments.72 Recently, a direct relation-
ship between a variant at the ARMS2/HTRA1 locus and increased complement activation in 
AMD patients was reported.73 
Other associations with AMD have been found for genes involved in several AMD-relat-
ed pathways. These include genes in the high-density lipoprotein cholesterol pathway (e.g. 
APOE,74-76 LIPC,77,78 CETP77-79, ABCA1,77 FADS1_3,77,78 LPL77-79 genes), the angiogenesis signal-
ing pathway (e.g. VEGFA,80,81 TGFBR180) and the extracellular matrix pathway (e.g. COL8A1,78 
COL10A1,81 TIMP3,77 MMP923 genes).
Table 2 gives an overview of 34 loci for advanced AMD, with the associated odds ratios and 
allele frequencies in patients and controls. These results were derived from a recent genome 
wide association study (GWAS) including 16,144 cases and 17,832 controls, and are estimated 
to explain 27.2% of disease variability, which is almost 60% of the total heritability in AMD.23
 
TABLE 2. Overview of 34 loci for advanced AMD as identified in a large GWAS study23
MAF Association
Lead Variant Gene Cases Controls OR P value
rs10922109 CFH 0.223 0.426 0.38 9.6 x 10-618
rs62247658 ADAMTS9-AS2 0.466 0.433 1.14 1.8 x 10-14
rs140647181 COL8A1 0.023 0.016 1.59 1.4 x 10-11
rs10033900 CFI 0.511 0.477 1.15 5.4 x 10-17
rs62358361 C9 0.016 0.009 1.80 1.3 x 10-14
rs116503776 C2/CFB/SKIV2L 0.090 0.148 0.57 1.2 x 10-103
rs943080 VEGFA 0.465 0.497 0.88 1.1 x 10-14
rs79037040 TNFRSF10A 0.451 0.479 0.90 4.5 x 10-11
rs1626340 TGFBR1 0.189 0.209 0.88 3.8 x 10-10
rs3750846 ARMS2/HTRA1 0.436 0.208 2.81 6.5 x 10-735
rs9564692 B3GALTL 0.277 0.299 0.89 3.3 x 10-10
rs61985136 RAD51B 0.360 0.384 0.90 1.6 x 10-10
rs2043085 LIPC 0.350 0.381 0.87 4.3 x 10-15
rs5817082 CETP 0.232 0.264 0.84 3.6 x 10-19
rs2230199 C3 0.266 0.208 1.43 3.8 x 10-69
rs429358 APOE 0.099 0.135 0.70 2.4 x 10-42
rs5754227 SYN3/TIMP3 0.109 0.137 0.77 1.1 x 10-24
rs8135665 SLC16A8 0.217 0.195 1.14 5.5 x 10-11
rs11884770 COL4A3 0.258 0.278 0.90 2.9 x 10-8
rs114092250 PRLR/SPEF2 0.016 0.022 0.70 2.1 x 10-8
rs7803454 PILRB/PILRA 0.209 0.190 1.13 4.8 x 10-9
rs1142 KMT2E/SRPK2 0.370 0.346 1.11 1.4 x 10-9
rs71507014 TRPM3 0.427 0.405 1.10 3.0 x 10-8
rs10781182 MIR6130/RORB 0.328 0.306 1.11 2.6 x 10-9
rs2740488 ABCA1 0.255 0.275 0.90 1.2 x 10-8
rs12357257 ARHGAP21 0.243 0.223 1.11 4.4 x 10-8
rs3138141 RDH5/CD63 0.222 0.207 1.16 4.3 x 10-9
rs61941274 ACAD10 0.024 0.018 1.51 1.1 x 10-9
rs72802342 CTRB2/CTRB1 0.067 0.080 0.79 5.0 x 10-12
rs11080055 TMEM97/VTN 0.463 0.486 0.91 1.0 x 10-8
rs6565597 NPLOC4/TSPAN10 0.400 0.381 1.13 1.5 x 10-11
rs67538026 CNN2 0.460 0.498 0.90 2.6 x 10-8
rs142450006 MMP9 0.124 0.141 0.85 2.4 x 10-10
rs201459901 C20orf85 0.054 0.070 0.76 3.1 x 10-16
AMD, age-related macular degeneration; GWAS, genome wide association study; MAF, 
minor allele frequency; OR, odds ratio. (Table derived and adapted from Fritsche et al.23)
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5. TREATMENT OF AMD
Prevention
Nutritional supplements can be used to slow down development and progression of ad-
vanced AMD in selected patient groups. Data from AREDS show that in patients with inter-
mediate and unilateral advanced AMD, the use of the specific AREDS formulation (consisting 
of 500 mg vitamin C, 400 IU vitamin E, 15 mg beta-carotene and 80 mg zinc oxide) reduced 
the risk of development of advanced AMD with 25%.15 Evidence from other studies suggested 
the beneficial role of carotenoids (lutein and zeaxanthin) and omega-3 long-chain polyun-
saturated fatty acids for AMD. Therefore, the AREDS2 study was initiated to study the effects 
of these factors in a prospective setting. None of the tested supplements further reduced the 
risk of progression when added to the original AREDS formulation. However, substitution of 
beta-carotene with lutein and zeaxanthin was recommended because of the increased risk 
of lung cancer in former smokers who received beta-carotene.47
In a recent study we have shown that oral zinc supplementation decreased systemic com-
plement activation levels, suggesting a direct influence of zinc on the complement system.82 
This may open new doors for treatment of AMD, and based on these results it would seem 
worthwhile to explore the role of antixodants in the treatment of AMD.
 
Neovascular AMD
Thermal laser photocoagulation was the first treatment available for neovascular AMD and 
resulted in a reduction in vision loss. However, because of the risk of laser-induced retinal 
damage, the high rate of recurrences and the introduction of other therapeutic options, this 
treatment modality has now been abandoned.46,83,84 Photodynamic therapy with verteper-
forin was able to stabilize visual acuity in 61% of patients, a first major breakthrough in the 
treatment of AMD.46,85 However, a great leap forward for patients with neovascular AMD was 
achieved with the introduction of intravitreal injections with drugs targeting vascular en-
dothelial growth factor (VEGF). Ranibizumab was approved for the treatment of neovascular 
AMD in 2006 and this was the first drug to improve visual acuity.86 Other anti-VEGF drugs 
that are currently used as a treatment for AMD are bevacizumab and aflibercept.87-89
 
Complement Inhibitors
As of yet, there are no clinical therapies available for GA. Targeted complement inhibition 
is a potential treatment of interest and several clinical trials evaluating the effect of com-
plement inhibitors on AMD progression have been initiated. So far, one trial has shown 
promising results using an antibody directed against factor D. Phase III trials are ongoing.90,91
 
6. AIMS AND OUTLINES OF THIS THESIS
 
Personalized Medicine in AMD
The goal of personalized medicine is to separate individuals into different groups – for exam-
ple based on disease etiology, progression, or treatment response – in order to tailor specific 
medical decisions or interventions to the individual patient. All this is based on the individu-
als predicted risk of disease or predicted response to treatments. It is also known as P4 med-
icine, with the four P’s standing for predictive, preventive, personalized and participatory.92-94
With the recent developments in genetic technologies and molecular approaches (e.g. 
genomics and proteomics), progression can be made toward personalized medicine in AMD. 
In this thesis we present our research that focuses on different aspects that are required in 
order to move forward toward personalized medicine in AMD. These include studies on risk 
factors for development and progression of AMD – both for AMD families as well as sporadic 
cases – and studies focussing on one of the key pathophysiological pathways involved in 
AMD, the complement system. We also present a computer aided diagnosis system that can 
help to further classify subsets of patients.
Risk factors for age-related macular degeneration
Chapter 2 provides insight in risk factors for an earlier age at onset of AMD. The age at which 
the first signs of age-related macular degeneration (AMD) manifest is highly variable. Better 
insight in factors that influence disease onset has direct implications for preventive mea-
sures and patient counseling.
Chapter 3 concerns patients with end-stage AMD in one eye. These patients are at high risk 
of progressing toward end-stage disease in the fellow eye. In this chapter we have focused 
on genetic and environmental risk factors that influence this second eye progression.
Chapter 4 discusses the possible role of genes associated with antioxidant metabolism and 
AMD. Antioxidant defense mechanisms are important in prevention of AMD. Because of the 
antioxidant role of GST enzymes it has been suggested that loss of function of these en-
zymes could lead to an increased risk for AMD.
Familial age-related macular degeneration
Chapter 5 evaluates the differences between familial and sporadic AMD. Certain lifestyle 
factors are shown to be significantly associated with AMD in sporadic cases, but not in famil-
ial cases. This chapter investigates whether the contribution of common genetic variants and 
complement activation levels differs between familial and sporadic cases with AMD.
Chapter 6 focuses on prediction of AMD in families. Prediction models have been estab-
lished for AMD based on demographic, environmental and common genetic risk factors. In 
AMD families, these risk factors may be distributed differently.
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Computer aided diagnosis of age-related macular degeneration
Chapter 7 describes the development of a computer-aided diagnosis system that is able to 
detect and quantify drusen location, area and size on color fundus images. 
Complement activation and age-related macular degeneration
Chapter 8 looks into the relationship between systemic complement activation and different 
AMD stages. In addition, we studied the effect of genes and treatment on this relationship. 
Chapter 9 describes the identification of a novel complotype combination that is associated 
with both AMD and complement activation levels in vivo. A thorough evaluation of comple-
ment activation and AMD can provide us with better insight of who might benefit most from 
complement-lowering treatments.
General discussion
Chapter 10 further discusses the studies described in this thesis and places them in a broader 
perspective.
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IMPORTANCE The age at which the first signs of age-related macular degeneration (AMD) 
manifest is variable. Better insight in factors that influence disease onset has direct implica-
tions for preventive measures and patient counseling.
OBJECTIVE To identify risk factors for an earlier age at onset of neovascular AMD.
DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study, including patient data 
from the European Genetic Database collected between April 2006 and July 2010. All pa-
tients had at least 1 documented visit to the outpatient AMD clinic of the Radboud university 
medical center, Nijmegen, the Netherlands, a tertiary referral center for retinal disorders. In 
total, 275 patients with a known age at onset of neovascular AMD and a genetic risk analysis 
were included. 
MAIN OUTCOMES AND MEASURES Effects of several genetic, sociodemographic, behav-
ioral, and ocular factors on the age at onset of neovascular AMD. The mean differences in 
the age at onset were determined using general linear models with the age at onset as the 
dependent variable.
RESULTS Past smokers and current smokers developed neovascular AMD on average 4.9 
(95% CI 3.0-6.8) and 7.7 (95% CI 5.3-10.0) years earlier, respectively, than never smokers 
(P > .001 for both). Compared with the reference group, the age at onset was 5.2 (95% CI 2.8-
7.7) years earlier for homozygous carriers of the A69S risk allele in the age-related maculo-
pathy susceptibility 2 (ARMS2) gene (P > .001). Homozygous carriers of the Y402H risk variant 
in the complement factor H (CFH) gene developed neovascular AMD 2.8 (95% CI 0.5-5.0) 
years earlier (P = .02). Patients carrying 4 risk alleles in CFH and ARMS2 developed neovas-
cular AMD 12.2 (95% CI 6.2-18.3) years earlier than patients with zero risk alleles (P > .001).
CONCLUSIONS AND RELEVANCE Genetic and environmental risk factors influence the age 
at onset of neovascular AMD. Individuals at risk could be identified at an early age if and 
when preventive or therapeutic options become available. Insight into individual risk profiles 
might influence patients’ consideration of interventions to increase their chance of avoiding 
vision loss from AMD.
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Age-related macular degeneration (AMD) is the most common cause of severe visual im-
pairment among elderly in developed countries. Typically, 2 forms of end-stage disease that 
can be distinguished are geographic atrophy (GA) (or dry AMD) and neovascular AMD char-
acterized by choroidal neovascularization (CNV). Although only 10% of patients experience 
neovascular AMD, it accounts for most blindness due to AMD.1,2
Smoking is the strongest modifiable risk factor for AMD.3-12 Other inconsistent environmen-
tal and demographic risk factors include obesity,4,13-17 sunlight exposure,18-20 and sex.4,21,22 
A healthy diet containing omega-3 fatty acids, lutein, zeaxanthin, and antioxidant vi-
tamins C and E may be protective against the development of AMD.23-26 Nutritional sup-
plements containing the Age-Related Eye Disease Study 2 formula27 can further reduce 
risk of progression to advanced AMD in patients at risk. Apart from environmental fac-
tors, several genetic variants have been associated with AMD. The strongest associations 
have been found for single-nucleotide polymorphisms (SNPs) in the complement factor H 
(CFH) gene (OMIM 134370)28-30 and in the age-related macular susceptibility 2 (ARMS2) gene 
(OMIM 611313).31-33 Besides these variants, other SNPs have been associated with AMD, includ-
ing variants in genes involved in the complement pathway,34-37 the high-density lipoprotein 
cholesterol pathway,38,39 and the atherosclerosis signaling pathway.40,41 
To date, much research has focused on the identification of risk factors for the development 
and worsening of AMD. In contrast, few studies have been conducted to investigate the age 
at onset of AMD. The age at which the first signs of AMD manifest is variable and it is im-
portant to gain insight into contributing factors. A few studies have reported an influence 
of genetic and environmental risk factors on the age at onset of AMD. Smoking, male sex, 
triglyceride levels, and variants in the CFH, ARMS2, GSTM1, and VEGFA genes have been 
implicated to be associated with a younger age at onset.42-48 Statin and aspirin use seemed 
to postpone the time to CNV development in one study,42 but another study48 showed an 
earlier onset of AMD for statin users. Differences in study results and the magnitude of the 
effects on the age at onset may arise because of different definitions of the age at onset, 
inclusion of patients with nonadvanced stages of AMD, and few study participants in some 
of these studies.
The objectives of this study were to identify additional risk factors that may influence the 
age at onset and to determine whether conventional risk factors for AMD are also involved 
in an earlier age at onset of the disease. To define the age at onset, we limited inclusion to 
patients with neovascular AMD. This approach enabled us to identify the type and influence 
of genetic and environmental risk factors important in accelerating the development of 
neovascular AMD.
METHODS
Study Population
This study was conducted in accord with the tenets of the Declaration of Helsinki and was 
approved by the local ethics committee (Commissie Mensgebonden Onderzoek Regio Arn-
hem-Nijmegen). All members of the study population provided written informed consent and 
participated between April 2006 and July 2010. We included patients who had neovascular 
AMD with at least 1 documented visit to the outpatient AMD clinic of the Radboud univer-
sity medical center, Nijmegen, the Netherlands, and who were genotyped for at least 1 of 
the SNPs studied. In total, 385 eligible patients were selected from the European Genetic 
Database (EUGENDA; www.eugenda.org), a multicenter database for clinical and molecular 
analysis of AMD. 
The age at onset of neovascular AMD was determined by reviewing historical patient data. 
Age at onset was defined as when a patient experienced the first visual complaints related 
to CNV occurrence in either eye, with a diagnosis of CNV by an ophthalmologist within the 
next 6 months.49 Clinical diagnosis by an ophthalmologist was by slitlamp examination or 
by evaluation of fundus photography or fluorescein angiography. In case of scarring or other 
signs indicating that CNV had already been present for a longer time, the patient was ex-
cluded from the analysis.
Participants were asked to complete a questionnaire on lifestyle and other environmental 
variables (Table 1). For classification of smoking habits, patients were asked whether and how 
long they smoked. For past smokers, we also obtained the duration of smoking cessation in 
years. These data were adjusted to match the status at the time of CNV development. For 
example, a patient who had quit smoking 7 years before the interview and had developed 
CNV 10 years before the interview was classified as a current smoker. Body mass index was 
calculated from self-reported weight and height. For sunlight exposure, participants were 
asked how much time they had spent outside before their retirement. Exposure was classi-
fied as low for patients who indicated avoidance of the sun or spending most of the time 
indoors, moderate for patients who were regularly outside but no longer than 8 hours a day, 
and high for patients who were outside for more than 8 hours a day. If available, data on 
refractive error were copied from the patients’ medical records.
Genetic Analysis
Venous blood samples were collected for extraction of DNA. The DNA was analyzed for 
SNPs in the following 9 genes previously associated with AMD: CFH, ARMS2, CFB, C3, CFI, 
APOE, LPL, CETP and ABCA1 (Table 2).30,33-40 The SNPs were genotyped using competitive 
allele-specific polymerase chain reaction assays (KASPar SNP Genotyping System, KBio-
sciences).
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Statistical Analysis
All variables were analyzed using 1-way analysis of variance (ANOVA) without post hoc tests. 
For some variables, different categories were merged to create subgroups of sufficient size 
for statistical analysis. Variables with P > .15 were selected for inclusion in a general linear 
model with the age at onset as the dependent variable. For this model, multiple imputation 
of missing data values was used. Variables with P ≤ .05 were removed from the model in a 
stepwise fashion. For the final variables included in the model, parameter estimates were 
calculated to derive the mean differences in the age at onset for each risk category. All 
analyses were performed using statistical software (SPSS, version, 20.0; IBM Corporation). 
Multiple imputation of missing data values was performed under the assumption that obser-
vations were missing at random. Only the 7 variables that were included in the multivariable 
model were imputed. For imputation of each variable we used the 6 other variables, the 
outcomes, and the unselected variables from the 1-way ANOVA as predictors. Imputation 
was performed using the default settings in SPSS (version 20.0). From Tables 1 and 2, rates 
of missing data for each variable imputed can be calculated. In total, 69.1% of patients had 
complete data for all 7 variables. Only 9.1% of patients had missing data for more than 1 of 
the 7 variables. 
Data from the Rotterdam Study I (RS-I), a population-based study with more than 20 years 
of follow-up, were used to plot survival curves for the risk factors that were identified in the 
multivariable model to estimate the effect of possible survival bias on our results. Details on 
the RS-I have been described previously.50
RESULTS
Of 385 eligible patients, 275 were included in the study. Complete information on the age at 
onset was available for 214 participants. For 38 patients, there was no exact information on 
the duration of visual complaints; in this group, the age at onset was defined as when CNV 
was diagnosed by an ophthalmologist. In a small subgroup (n = 23), we could only retrieve 
the year of diagnosis by an ophthalmologist. For this group, July 1 of that year was consid-
ered the date of onset. One hundred ten patients were excluded from the study because 
of incomplete medical records (n = 66), other macular pathology that could interfere with 
the diagnosis of AMD (n = 36,) and treatment in the macular region for reasons other than 
AMD-related CNV (n = 8).
The mean (SD) age at onset of CNV was 74.8 (7.7) years (range, 53.1-90.7 years) and 56.7% of 
participants were female. The patients with 1 or more missing variables did not differ signifi-
cantly from the patients with complete data with respect to the age at onset. Sex, smoking, 
alcohol consumption, and exercise level were associated with the age at onset of neovascu-
lar AMD in the 1-way ANOVA (Table 1). 
TABLE 1. Effects of nongenetic risk factors on the age at onset of neovascular AMD (one-way ANOVA)
 
Variable
No. (%) 
n = 275
Age at Onset  
Mean (SD), y
 
P value
Sex .006
  Male 119 (43.3) 73.3 (7.7)
  Female 156 (56.7) 75.9 (7.5)
Smoking (n = 268) > .001
  Never 89 (33.2) 78.5 (6.6)
  Past 127 (47.4) 73.9 (7.4)
  Current 52 (19.4) 70.4 (7.7)
BMI (n = 268) .59
  > 25 123 (45.9) 75.2 (7.8)
  25-30 110 (41.0) 74.6 (7.2)
  ≤ 30 35 (13.1) 73.7 (9.2)
Diabetes (n = 268) .36
  No 237 (88.4) 74.6 (7.6)
  Yes 31 (11.6) 75.9 (9.0)
Family history of AMD (n = 225) .24
  No 162 (72.0) 75.2 (7.9)
  Yes 63 (28.0) 73.9 (7.4)
Iris color (n = 265) .95
  Light, blue/grey 165 (62.3) 74.8 (7.7)
  Medium, green/hazel 45 (17.0) 74.4 (8.6)
  Dark, brown 55 (20.8) 74.8 (7.0)
Refractive error (n = 134) .19
  Emmetropic 46 (34.3) 73.7 (6.3)
  Hyperopic 75 (56.0) 71.6 (7.1)
  Myopic 13 (9.7) 70.7 (8.0)
Fish consumption (n = 206) .63
  ≤ 2 Times per week 48 (23.3) 75.0 (8.0)
  Once a week 96 (46.6) 74.3 (8.1)
  Almost never 62 (30.1) 75.6 (8.0)
Red meat consumption (n = 210) .67
  Every day 25 (11.9) 75.2 (5.4)
  2-6 Times per week 152 (72.4) 75.1 (8.6)
  Once per week or less 33 (15.7) 73.8 (6.9)
Fruit consumption (n = 210) .78
  Every day 171 (81.4) 74.8 (7.8)
  2-6 Times per week 25 (11.9) 75.1 (9.2)
  Once per week or less 14 (6.7) 76.3 (9.4)
Vegetable consumption (n = 211) .17
  Every day 183 (86.7) 75.2 (7.7)
  ≥ 6 Times per week 28 (13.3) 73.0 (9.9)
Alcohol consumption, U/wk (n = 243) .002
  Never 83 (34.2) 75.9 (6.6)
  > 14 109 (44.9) 74.4 (7.9)
  14-21 35 (14.4) 72.9 (7.5)
  ≤ 21 16 (6.6) 68.3 (8.4)
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Exercise level (n = 239) .05
  Never 30 (12.6) 76.0 (6.0)
  Almost never 99 (41.4) 76.1 (7.5)
  1-2 Times per week 73 (30.5) 72.9 (8.5)
  ≤ 3 Times per week 37 (15.5) 74.5 (7.8)
Sunlight exposure (n = 257) .78
  Low, mostly indoors 73 (28.4) 74.9 (8.2)
  Moderate, > 8 h/d outside 100 (38.9) 75.4 (7.9)
  High, ≤ 8 h/d outside 84 (32.7) 74.7 (6.1)
AMD, age-related macular degeneration; ANOVA, analysis of variance; BMI, body mass index.
Some totals do not sum to heading totals because of missing data.
TABLE 2. Genetic influences on the age at onset of neovascular AMD (one-way ANOVA)
 
Variable
 
No. (%)
Age at Onset  
Mean (SD), y
 
P value
CFH Y402H / rs1061170 (n = 259) .14
  TT 62 (23.9) 76.0 (7.5)
  TC 100 (38.6) 75.2 (7.6)
  CC 97 (37.5) 73.6 (7.8)
ARMS2 A69S / rs10490924 (n = 260) .001
  GG 57 (21.9) 76.9 (7.8)
  GT 135 (51.9) 75.2 (7.7)
  TT 68 (26.2) 72.0 (7.1)
CFB L9H / rs4151667 (n = 258)
  TT 246 (95.3) 74.8 (7.5) .77
  TA / AA 12 (4.7) 75.4 (11.3)
C3 R102G / rs2230199 (n = 260) .29
  CC 144 (55.4) 74.3 (7.1)
  CG 95 (36.5) 75.8 (8.1)
  GG 21 (8.1) 73.9 (8.9)
CFH / rs1410996 (n = 208) .85
  CC 117 (56.3) 74.7 (7.3)
  CT / TT 91 (43.8) 74.9 (8.2)
CFB R32Q / rs641153 (n = 171) .31
  GG 158 (92.4) 75.0 (8.1)
  GA / AA 13 (7.6) 77.3 (7.7)
APOE2 / rs7412 (n = 195) .81
  CC 158 (81.0) 75.1 (7.6)
  CT/TT 37 (19.0) 74.8 (7.3)
APOE4 / rs429358 (n = 171) .88
  TT 139 (81.3) 75.3 (7.5)
  TC 32 (18.7) 75.1 (7.9)
CFI / rs10033900 (n = 256) .41
  CC 68 (26.6) 75.3 (7.9)
  CT 130 (50.8) 74.2 (8.1)
  TT 58 (22.7) 75.6 (6.4)
LPL / rs12678919 (n = 257) .44
  AA 214 (83.3) 74.8 (7.6)
  AG / GG 43 (16.7) 75.8 (8.2)
CETP / rs3764261 (n = 262) .08
  GG 100 (38.2) 75.9 (8.1)
  GT 120 (45.8) 73.7 (7.8)
  TT 42 (16.0) 75.7 (6.0)
ABCA1 / rs1883025 (n = 202) .99
  GG 110 (54.5) 75.0 (7.6)
  GA / AA 92 (45.5) 75.0 (8.1)
AMD, age-related macular degeneration; ANOVA, analysis of variance. Some totals do not sum to heading 
totals because of missing data.
Of the genetic factors analyzed, rs10490924 (ARMS2 A69S), rs1061170 (CFH Y402H), and 
rs3764261 (CETP) were selected for inclusion in the multivariable model (Table 2).
Of the 7 variables that were selected from the 1-way ANOVA, only 3 remained associated 
with the age at onset in the multivariable model (Table 3). Compared with never smokers, 
past smokers developed CNV on average 4.9 (95% CI 3.0-6.8) years earlier (P > .001). For 
current smokers, this difference was even larger: they developed CNV 7.7 (95% CI 5.3-10.0) 
years earlier (P > .001). Homozygous carriers of the Y402H risk allele in CFH had an earlier 
disease onset of 2.8 (95% CI 0.5-5.0) years compared with the reference group (P = .02). For 
the ARMS2 A69S variant, homozygous carriers developed CNV 5.2 (95% CI 2.8-7.7) years 
earlier (P > .001).
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TABLE 3. Multivariable model showing associations of smoking, CFH and ARMS2 on the age at onset of  
neovascular AMD
Variable
Difference in the Age at Onset,
Mean (95% CI), y P value
Smoking
  Never 0
  Past -4.9 (-6.8 to -3.0) > .001
  Current -7.7 (-10.0 to -5.3) > .001
CFH Y402H / rs1061170
  TT 0
  TC -1.9 (-4.1 to 0.3) .07
  CC -2.8 (-5.0 to -0.5) .02
ARMS2 A69S / rs10490924
  GG 0
  GT -2.0 (-4.1 to 0.2) .07
  TT -5.2 (-7.7 to -2.8) > .001
AMD, age-related macular degeneration; CFH, complement factor H; ARMS2,  
age-related macular susceptibility 2.
TABLE 4. Cumulative effect of the number of risk alleles in CFH and ARMS2 on the age at onset of  
neovascular AMD
No. of risk alleles in  
CFH and ARMS2
No. (%) 
(n = 251)
Difference in the Age at Onset, 
Mean (95% CI), y P value
  0 risk alleles 8 (3.2) 0
  1 risk allele 55 (21.9) -5.2 (-10.0 to 0.4) .07
  2 risk alleles 96 (38.2) -6.2 (-11.7 to -0.8) .03
  3 risk alleles 69 (27.5) -7.4 (-12.9 to -1.9) .009
  4 risk alleles 23 (9.2) -12.2 (-18.3 to -6.2) > .001
AMD, age-related macular degeneration; CFH, complement factor H; ARMS2, age-related macular  
susceptibility 2.
To explore the combined effect of CFH and ARMS2 on the age at onset, we delineated pa-
tient groups based on the number of risk alleles of these 2 variants. There was a difference 
in the age at onset of 12.2 (95% CI 6.2-18.3) years when we compared individuals having zero 
risk alleles in CFH and ARMS2 with those carrying all 4 risk alleles (P > .001) (Table 4 and 
Figure, A). Panel B in the Figure shows the substantial effect of smoking the age at onset in 
addition to the genetic risk. Current smokers with zero risk alleles developed CNV 14.5 years 
earlier compared to never smokers with the same genetic risk profile (P = .08). The sole ef-
fect of smoking resulted in an age at onset comparable to that of never smokers carrying all 
4 risk alleles. When we compared the most extreme groups in panel B in the Figure, there 
was an observed absolute difference in the age at onset of 22.4 years (P = .03). Some of 
these subgroups were small (range, 2-40 patients).
FIGURE 1. Cumulative effect of CFH, ARMS2 and smoking on the age at onset of neovascular age-related 
macular degeneration 
  
A, Age at onset for each individual based on number of risk alleles in CFH and ARMS2. B, Effect of smoking 
on mean age at onset for each genetic risk stratum. 
CFH, complement factor H; ARMS2, age-related macular susceptibility 2.
A B
The exact age at onset was sometimes difficult to determine. To exclude the possibility of 
introducing bias, we reran the analyses in a subgroup, selecting only those patients for whom 
the age at onset was most accurately defined and diagnosed (duration of visual complaints > 
6 months, exact date of diagnosis known, and diagnosis confirmed in the Radboud university 
medical center). These results did not differ significantly; to maintain statistical power, we 
chose to adhere to the analyses of the complete dataset.
Analyses with data from the RS-I revealed that there was no difference in survival for the 
different genotypes in CFH and ARMS2. Survival curves for smoking showed that current 
smokers had a shorter survival than past smokers and never smokers. Before reaching age 70 
years, 7.9% of smokers vs 3.2% of never smokers had died. In total, 79.5% of smokers reached 
age 75 years compared with 90.2% of never smokers.
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DISCUSSION
The development of CNV accounts for most legal blindness in patients with AMD.1,2 However, 
the range in the age at onset of CNV is broad, with some patients developing neovasculari-
zation as early as age 50 years, whereas others are well past age 90 years before this occurs. 
On average, the patients in this study were age 74.8 years when their first CNV developed. 
Many potential risk factors that might influence the age at onset of neovascular compli-
cations in AMD were examined. In the presence of homozygous CFH Y402H and ARMS2 
A69S risk alleles, the age at onset was advanced by 12.2 years. In addition, smoking was also 
associated with the development of neovascular AMD at a younger age. When we added 
smoking to the genetic risk factors, the difference in the age at onset between the most 
extreme groups increased to 22.4 years. Although these results should be interpreted with 
caution because of small group sizes in the combination models, no other study has report-
ed effect sizes of this magnitude, to our knowledge. The substantial effect of smoking, CFH, 
and ARMS2 on the age at onset of CNV has consequences for patient counseling. Based 
on our results, we hypothesize that many disease-free years may be attained if a patient 
stops smoking, and it seems likely that other preventive measures (eg, the intake of dietary 
supplements) could be of benefit as well. Because the development of CNV may occur well 
before age 70 years in high-risk patients, these countermeasures have to be initiated in a 
timely manner to be of significance.
The risk factors that remained in the multivariable model accelerate the age at onset prob-
ably by increasing complement activity and oxidative stress levels in the retina. Decreased 
functionality of the CFH protein, for instance in persons with the CFH Y402H polymorphism, 
leads to a continuous state of low-level complement activation.51,52 Complement activation 
is known to lead to increased vascular endothelial growth factor (VEGF) expression and 
CNV formation.52-54 For ARMS2, some investigators suggest that it is a mitochondrial pro-
tein involved in oxidative stress responses,31,55 although this was disputed by others.56 One 
study57 found that the protein interacts with proteins from the extracellular matrix, while 
another study58 demonstrated that ARMS2 is involved in the phagocytosis of photoreceptor 
outer segments. In 2012, it was reported that the ARMS2 risk allele is independently asso-
ciated with increased complement activation in patients with AMD.59 Cigarette smoke adds 
to oxidative stress60 and is known to induce VEGF expression, as well as retinal pigment 
epithelium (RPE) dysfunction and diminished RPE cell survival that may effect angiogenic 
homeostasis.61,62 Moreover, cigarette smoke increases the activity of the alternative comple-
ment pathway by weakening the susceptibility of C3 to CFH and factor I.51,63 Smoking, CFH 
Y402H, and ARMS2 A69S have been associated with CNV development in large indepen-
dent cohorts.3,4,44,64-66 We hypothesize that increased oxidative stress, a continuous state of 
complement activation, and upregulation of VEGF expression not only increase risk of CNV 
development but may accelerate the age at which neovascularization occurs. 
The association of CFH variants with early onset of neovascular AMD was suggested in a 
2011 study,45 in which a rare penetrant mutation in CFH was associated with a 6-year earlier 
onset of disease in patients with advanced AMD. Recently, another study48 confirmed the 
association of CFH and ARMS2 with an earlier onset of AMD and showed that heavy smokers 
are also affected with AMD at a younger age. In that study, the largest difference in the age 
at onset reported was only 2.2 years for heavy smokers versus the reference group, while 
for CFH and ARMS2 there was a less than 2-year difference in onset between homozygous 
carriers of the risk variants compared with those carrying the low-risk variants. These dif-
ferences are small compared with our findings. However, it is unclear how the age at onset 
was defined in the study by Keilhauer et al,48 and their study included patients with CNV and 
patients with early AMD. Inclusion of different AMD stages makes it impossible to uniformly 
determine the age at onset in all participants, and this could be reflected in the study out-
comes. Several other studies42,46,67 evaluating the age at onset restricted inclusion to patients 
with CNV, as described above. However, these study populations were small (≥ 131 patients 
with CNV), and racial/ethnic differences hinder comparison with the present study.
This study identified much larger effect sizes of CFH, ARMS2, and smoking on the age at 
onset than previously reported by including only individuals with neovascular AMD and using 
a clear definition of the onset of neovascular complications. Because of the nature of the 
EUGENDA database, we were able to study the effect of multiple genetic and environmental 
risk factors on the age at onset of neovascular AMD, whereas other studies42,46,48,67 limited 
their design to few variables. This enabled us to also study the combined effect of genetic 
and environmental risk factors. 
However, a retrospective study design has its limitations. A possible confounding factor is the 
subjective nature of the duration of visual complaints and the decision whether these complaints 
are in fact related to CNV development. However, subgroup analyses that included only those 
patients with a well-defined age at onset yielded results similar to those of the main analyses. 
Another possible confounder is the interference of survival bias. Survival curves from the RS-I 
showed that 79.5% of smokers reached age 75 years (the mean age at onset in this study) 
compared with 90.2% of never smokers. This makes it unlikely that survival bias accounts 
for the effect of smoking on the age at onset that we reported. Furthermore, smoking can 
be seen as an accelerator of aging directly (through oxidative stress) and indirectly (through 
smoking-associated diseases).68,69 In this light, it may be that smokers have the same chance 
of developing neovascular AMD as never smokers, although their survival is shorter.
The current study investigated potential risk factors for the age at CNV onset and did not 
include patients with GA. Because there is a strong overlap in risk factors for CNV and GA de-
velopment,65,66,70-72 we hypothesize that the same risk factors that contribute to the develop-
ment of GA also lead to an earlier age at onset of GA. It would be difficult to analyze this in a 
retrospective study because the exact onset of GA in patients with AMD is difficult to define. 
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CONCLUSIONS
In individuals who are homozygous for CFH and ARMS2 risk alleles and who smoke ciga-
rettes, the onset of neovascular AMD may be accelerated by as much as 1 or 2 decades. To 
allow countermeasures the time to take effect, these individuals need to be identified at an 
early age. Providing individuals with a personalized prognosis may give them the incentive to 
stop smoking. Additional preventive measures such as a healthy diet, use of nutritional sup-
plements, frequent monitoring, and possible future therapeutic options aimed at lowering 
complement activity could postpone severe visual loss associated with the development of 
neovascular membranes.
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PURPOSE This study was conducted to investigate the correlation of genetic, sociodemo-
graphic and behavioral risk factors with second eye progression to end-stage age-related 
macular degeneration (AMD).
METHODS One hundred-eight patients with end-stage AMD in one or both eyes were in-
cluded in a retrospective time-to-event analysis of the onset of end-stage AMD in the sec-
ond eye. Multivariate Cox regression survival analysis was performed for sex, age, smoking, 
body mass index (BMI), education and sixteen single nucleotide polymorphisms (SNPs) as-
sociated with AMD.
RESULTS Except for education, all sociodemographic and behavioral risk factors analyzed 
were significantly associated with a more rapid progression toward second eye involvement. 
Hazard ratios (HR) were 2.6 (95% confidence interval [CI] 1.4-5.0) for female sex, 5.0 (95% CI 
2.0-12.5) for age < 80, 2.2 (95% CI 1.1-4.1) for BMI < 30, and 4.4 (95% CI 1.4-14.3) for < 40 pack 
years, compared with the referent groups. Carriers of the lipoprotein lipase (LPL; rs12678919) 
risk alleles were at risk for more rapid progression to end-stage AMD in the second eye 
compared to the referent wild-type genotype (HR 2.0; 95% CI 1.0-3.6). For complement factor 
I (CFI; rs10033900), homozygous carriers of the risk allele progressed faster than wild-type 
individuals (HR 2.2; 95% CI 1.1-4.3). 
CONCLUSIONS Sociodemographic, behavioral and genetic risk factors are associated with 
the rate of second eye progression toward end-stage AMD. The findings of this study under-
line the importance of lifestyle factors and the complement pathway in AMD progression 
and suggest a role of the high-density-lipoprotein-metabolism in second eye progression.
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Age-related macular degeneration (AMD) is a multifactorial disease of the central retina and 
the most prevalent cause of progressive vision loss in the elderly in the developed world, 
with a prevalence of 30% after the age of 75 years.1 With the rapid increase of the elderly 
population, AMD is considered a major and growing health problem.
Several studies have investigated the contribution of behavioral, genetic, sociodemographic 
and ocular risk factors to the incidence and progression of AMD, as well as the develop-
ment of choroidal neovascularization (CNV) or foveal geographic atrophy (GA), viewed as the 
end-stages of AMD.2-10
Patients with unilateral advanced AMD are at high risk of developing end-stage AMD in 
their fellow eye.11 Cumulative incidence rates have been reported to be 10% to 14%, 28% to 
31% and 36% to 37% after 1, 3, and 4 years of follow-up respectively.12,13 Some studies have 
tried to identify risk factors for progression to advanced AMD in the second eye, but results 
in the different studies are not unanimous. Smoking, age, body mass index (BMI), and sys-
temic hypertension – as well as ocular characteristics such as drusen size, presence of ≤ 5 
drusen, focal hyperpigmentation, and non-foveal GA – have been suggested as possible risk 
factors.12,14-17 
A variety of single nucleotide polymorphisms (SNPs) have been reported to be associated 
with AMD.18 It has been shown that complement factor H (CFH) Y402H, age-related macu-
lopathy susceptibility 2 (ARMS2) A69S, complement component 2 (C2) E318D and comple-
ment component 3 (C3) R102G risk alleles are associated with progression toward bilateral 
advanced AMD.15,16 Carrying all these genetic risk factors together with modifiable risk factors 
such as smoking and high BMI, increases the risk of developing advanced AMD by a factor 
of 19.15 
The purpose of this study is to determine the correlation of genetic, sociodemographic, and 
behavioral risk factors with second eye progression to end-stage AMD. This will not only 
allow the selection of patients with a high risk for development and progression of AMD in 
the second eye, but also provide more insight into the development of AMD. Furthermore, it 
will provide patients with additional and more accurate information regarding their individual 
risk profile. 
METHODS
Study Population
All 108 subjects were selected by means of chart review from the European Genetic Database 
(EUGENDA, www.eugenda.org [in the public domain]) and were entered into the database 
between January 1997 and December 2006. EUGENDA is a multicenter database of AMD 
patients and control subjects founded by the Radboud University Nijmegen Medical Center 
and the University of Cologne Medical Center. Before enrollment in the database, written 
informed consent was obtained from all participants after receiving information about the 
study objectives and methods. 
Information about smoking, BMI and education were obtained by a questionnaire. For smok-
ing, patients were asked if they had ever smoked, how long they had smoked, if and how long 
they had quit, and how many cigarettes a day were smoked on average. For each patient, the 
number of pack years was calculated, where one pack year was the equivalent of smoking 
20 cigarettes a day for 1 year. BMI was calculated from self-reported weight and height of 
patients. Education was classified into four levels: primary school, high school, higher pro-
fessional education and university. For statistical analysis the four categories were collapsed 
into high school or lower and higher than high school. 
Color fundus photographs and fluorescein angiography images were taken with a digital fun-
dus camera (Topcon TRC 50IX; Topcon Corporation, Tokyo, Japan). For inclusion, end-stage 
AMD had to be present in at least one eye. End-stage AMD was defined as either choroidal 
neovascularization within the central 6 mm ETDRS grid or geographic atrophy of an area of 
at least 175 µm including the fovea.19,20 Development of advanced AMD in the first eye was 
taken as starting-point (T[0]) and had to be known with an accuracy range of 1 month; an 
accuracy range of 6 months was accepted if the second eye did not develop end-stage AMD 
within 4 years. Progression time until the development of end-stage AMD in the fellow eye 
was calculated in months after T(0). The following exclusion criteria were used: no end-stage 
AMD in both eyes; unknown or unclear time of end-stage AMD in one or both eyes; other 
retinal diseases that interfered with the diagnosis of end-stage AMD, such as central serous 
chorioretinopathy; laser treatment or radiotherapy for a retinal disease or treatment for AMD 
in a stage that could not be determined as end-stage (e.g., laser therapy for extensive dru-
sen). Patients were excluded at baseline. If patients met one of the exclusion criteria during 
follow-up, they were included in the study until the moment of exclusion and data were 
entered as censored values.
A group of 191 patients was selected according to the in- and exclusion criteria. Seventy-five 
patients with end-stage AMD in one eye remained free of CNV or foveal GA in their second 
eye during the period of follow-up at our department. Patients lost to follow-up for a period 
of more than 4 months were contacted by phone to determine if the second eye had devel-
oped advanced AMD during this period. The status of the second eye was verified either by 
inviting the patients to our outpatient clinic for clinical evaluation (if the patient reported 
that the second eye still had clear vision) or by contacting the patient’s current ophthal-
mologist to request conformational data (if the patient was unable to visit our outpatient 
clinic or if the patient reported that the second eye was also lost to AMD). Only if patients 
reported that they had developed neovascular AMD for which they had received intraocular 
injections with anti-VEGF medication, was this information considered reliable and were the 
patient-reported data used without further supportive evidence. An additional 77 patients 
were contacted for additional information about smoking history and BMI. In total, 83 pa-
tients were excluded because they could not be contacted, had passed away, were not will-
ing to participate or because the patients’ information was inconsistent with the information 
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available from the charts. A total of 86 patients were classified as “second eye progressors,” 
whereas 22 patients did not develop end-stage AMD in the fellow eye during follow up. Data 
of this last group were entered as censored values. Figure 1 represents a flow chart of patient 
inclusion. All individuals in the current study were from the Nijmegen (the Netherlands) area.
This study was conducted in accordance with the tenets of the Declaration of Helsinki and 
was approved by the Committee on Research Involving Human Subjects at the Radboud 
University Nijmegen Medical Center (Nijmegen, the Netherlands) and University Eye Clinic of 
Cologne (Cologne, Germany). 
FIGURE 1. Flow chart of patient inclusion.
 
AMD, age-related macular degeneration.
Genetic Analysis
DNA was isolated from venous blood leukocytes and analyzed for 16 SNPs known to be as-
sociated with AMD: rs1061170/CFH Y402H,6,21-23 rs10490924/ARMS2 A69S,7,24-26 rs4151667/CFB 
H9L,27,28 rs9332739/C2 E318D,27-29 rs2230199/C3 R102G,27,30-33 rs10033900/CFI,34,35 rs1410996/
CFH IVS14,16,36,37 rs2511989/SERPING1,38,39 rs1883025/ABCA1,40-42 rs3775291/TLR3 L412F,43,44 
rs7412/APOE, E2 allele,45-47 rs429358/APOE, E4 allele,45-47 rs3764261/CETP,40,41,48 rs12678919/
LPL,40,41,48 rs10468017/LIPC,40,41 and rs174547/FADS1_3.41,42 Genotyping of SNPs in all the genes 
analyzed except for the CFH variant Y402H was carried out as described elsewhere.49 The 
CFH variant Y402H (rs1061170) was analyzed by direct sequencing of PCR products using 
forward primer TCATTGTTATGGTCCTTAGG and reverse primer AAAGACATGAACATGCTAGG. 
Polymerase chain reaction (PCR) amplification was conducted following standard protocols 
(primers sequences and PCR conditions available upon request). All genotyping was per-
formed in the same lab.
Statistical Analysis
Variables were entered in a Cox regression model for survival analysis and were first analyzed 
in a univariate model. Statistically significant variables (P > .05) were analyzed in a multivari-
ate model. To correct for possible confounding, important nonsignificant variables were also 
included in the multivariate model. For each AMD-associated SNP, a Cox regression mod-
el was made, controlling for the statistically significant baseline variables. Survival timing 
started at T(0), the moment of end-stage AMD in the first eye. The event was defined as the 
development of advanced AMD in the second eye. A two-sided P value of .05 was considered 
to be statistically significant. For smoking we analyzed the total number of pack years up to 
T(0) and BMI was calculated at T(0). All analyses were conducted using statistical analysis 
software (SPSS 16.0; IBM Corporation, Armonk, NY).
RESULTS
Analysis of Sociodemographic Factors
Mean age was 74.3 years (range 54.3-93.4; standard deviation ± 7.2) in our studied cohort. 
There were 37 males (34.3%) and 71 females (65.7%). The type of end-stage AMD in the first 
eye was CNV in 82.4% and GA in 3.7% of cases. Of those who progressed toward end-stage 
in the fellow eye, 68.5% had a CNV and 9.3% had GA in the second eye. 
Sex, age, and BMI were significantly associated with second eye progression in the univariate 
analysis. For pack years and education no association could be observed. Since both factors 
have been implied to be involved in (second eye) progression in AMD, they were also add-
ed to the multivariate model. Table 1 shows the results from the multivariate analysis. Sex, 
age, pack years, and BMI were all associated with the risk of developing end-stage AMD in 
the second eye. For sex and pack years, these findings reached statistical significance. For 
age, the risk increases with each age category. Only for the two highest age categories was 
significance reached. Obese patients (BMI ≤ 30) are more at risk for second eye progression 
as compared with patients with normal weight (BMI 18-25; P = .020). For overweight patients 
(BMI 25-30) there was a trend toward an increased risk, but this did not reach a conventional 
level of statistical significance. This study used self-reported data on weight and height. It 
has been shown that people may overstate their height and underreport their weight.50-53 
This would result in an underestimation of the prevalence of obesity. It has therefore been 
suggested to evaluate BMI as a continuous variable rather than using predefined BMI cate-
gories.52,53 We repeated our analyses with this modification and this did not affect our results 
in any way. Information about education was available for all study subjects, except for 11 
patients. In this study, education was not related to second eye progression, but a trend for 
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TABLE 2. Multivariate association between 21 SNPs and progression toward end-stage AMD in the fellow eye 
of patients with unilateral advanced AMD
 
Variable
No. (%)  
(n = 108)
Hazard Ratio* 
(95% CI)
 
P value
CFI/rs10033900
  CC 24 (24.5) 1
  CT 46 (46.9) 1.2 (0.6-2.4) .519
  TT 28 (28.6) 2.2 (1.1-4.3) .028
LPL/rs12678919
  AA 88 (84.6) 1
  AG/GG 16 (15.4) 2.0 (1.0-3.6) .036
CFH IVS14/rs1410996
  TT 5 (4.7) 1
  CT 35 (32.7) 2.2 (0.7-6.7) .177
  CC 67 (62.6) 2.6 (0.9-7.6) .081
LIPC/rs10468017
  CC 49 (49.5) 1
  CT 42 (42.4) 1.5 (0.9-2.4) .125
  TT 8 (8.1) 0.9 (0.3-2.3) .760
ARMS2 S69 A/rs10490924
  GG 24 (23.5) 1
  GT 49 (48.0) 0.8 (0.5-1.5) .565
  TT 29 (28.4) 0.7 (0.4-1.4) .339
CFH Y402H/rs1061170
  TT 15 (14.6) 1
  TC 44 (42.7) 1.2 (0.6-2.6) .571
  CC 44 (42.7) 1.3 (0.6-2.6) .476
CFB H9L/rs4151667
  TT 91 (94.8) 1
  TA/AA 5 (5.2) 1.0 (0.4-2.6) .966
C3 R102G/rs2230199
  CC 53 (52.0) 1
  CG 40 (39.2) 1.3 (0.8-2.0) .363
  GG 9 (8.8) 1.4 (0.6-3.1) .477
TABLE 1. Multivariate association between sociodemographic risk factors and progression toward end-stage 
AMD in the fellow eye of patients with unilateral advanced AMD
 
Variable
No. (%) 
(n = 108)
Hazard Ratio*  
(95% CI)
 
P value
Sex
  Male 37 (34) 1
  Female 71 (66) 2.6 (1.4-5.0) .004
Age†
  > 65 17 (16) 1
  65-70 15 (14) 1.2 (0.5-2.7) .704
  70-75 23 (21) 1.5 (0.7-3.1) .255
  75-80 37 (34) 2.6 (1.3-5.3) .010
  ≤ 80 16 (15) 5.0 (2.0-12.5) .001
BMI
  Normal weight (18-25) 52 (48) 1
  Overweight 25-30 40 (37) 1.3 (0.8-2.1) .375
  Obese (≤ 30) 16 (15) 2.2 (1.1-4.1) .020
PY‡
  0-1 45 (42) 1
  1-40 54 (50) 2.4 (1.3-4.5) .005
  ≤ 40 9 (8) 4.4 (1.4-14.3) .014
Education§
  ≥ High school 59 (61) 1
  < High school 38 (39) 0.6 (0.4-1.1) .128
AMD, age-related macular degeneration; CI, confidence interval; BMI, body mass index; PY, pack years.
* Corrected for sex, age, BMI and PY.  
† Age at moment of end-stage AMD in the first eye.
‡ Total amount of pack years smoked.  
§ Analysis restricted to 97 patients.
higher education being protective was observed. Additional analyses revealed that there 
were more females and more older persons in the group with 0 to 1 pack years. This explains 
why smoking was only significant in the multivariate analysis. With the inclusion of smoking 
in the multivariate analysis, the effects of age and sex also became more pronounced.
Analysis of Genetic Variants
Genotype data of the SNPs were available for at least 87% of all patients. Because of the 
clear stepwise increase in hazard ratios (HR) with each age category, age was entered as a 
continuous variable. Results are shown in Table 2. There was an increased risk for homozy-
gous carriers of the CFI risk allele with a HR of 2.2 (P = .028). Heterozygous and homozygous 
carriers of the LPL risk allele had a higher HR compared with homozygous individuals for 
the nonrisk alleles (HR 2.0; P = .036). Other evaluated risk alleles did not make a significant 
contribution to development of end-stage AMD in the second eye.
To test for gene-gene interaction of the CFH Y402H and ARMS2 A69S genotypes, separate 
analyses for each possible allele combination of these two SNPs were performed. Com-
parison of subjects who were homozygous for both risk alleles with subjects carrying the 
wild-type alleles for both genotypes yielded no significant results (results not shown here). 
Since the LPL and CFI SNPs were significantly related to second eye progression, gene-gene 
interaction between these two genotypes was also analyzed. Subjects with two or more risk 
alleles had a higher risk of second eye progression (HR 2.7; 95% CI 1.3-5.6; P = .008) when 
compared with subjects with no risk alleles. No interaction was found between the LPL and 
CFI genotypes.
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C2 E318D/rs9332739
  GG 101 (95.3) 1
  GC/CC 5 (4.7) 1.1 (0.4-2.9) .873
SERPING1/rs2511989
  GG 36 (37.5) 1
  GA 49 (51.0) 1.1 (0.7-1.9) .697
  AA 11 (11.5) 0.9 (0.4-2.0) .801
TLR3 L412F/rs3775291
  CC 49 (48.0) 1
  CT 40 (39.2) 1.0 (0.6-1.6) .878
  TT 13 (12.7) 0.8 (0.4-1.8) .658
APOE4/rs429358
  TT 75 (79.8) 1
  TC/CC 19 (20.2) 1.1 (0.6-1.9) .736
APOE2/rs7412
  CC 82 (82.8) 1
  CT/TT 17 (17.2) 0.8 (0.4-1.6) .596
CETP/rs3764261
  CC 42 (39.6) 1
  CA 46 (43.4) 1.1 (0.7-1.8) .680
  AA 18 (17.0) 0.9 (0.5-1.7) .724
FADS1_3/rs174547
  TT 50 (47.2) 1
  TC 48 (45.3) 1.2 (0.8-2.0) .343
  CC 8 (7.5) 1.4 (0.6-3.2) .490
ABCA1/rs1883025
  CC 67 (63.2) 1
  CT/TT 39 (36.8) 0.8 (0.5-1.3) .355
SNP, single nucleotide polymorphism; AMD, age-related macular degeneration; CI, confidence interval.
Genotype data of the analyzed SNPs were available for at least 87% of all patients.
* Corrected for sex, age, body mass index and pack years.
DISCUSSION
The primary goal of our study was to determine sociodemographic, behavioral and genetic 
risk factors that contribute to the progression toward end-stage AMD in the fellow eyes of 
patients who already have developed end-stage AMD in their first eye. Our results show that 
the evaluated baseline characteristics sex, age, smoking status, and to a lesser extent BMI, 
all individually contribute to second eye progression. Of the genetic risk alleles that were 
analyzed, CFI (rs10033900) and LPL (rs12678919) were found to confer an increased risk for 
second eye progression. 
There is only one other study that reported a significantly higher risk of progression to bi-
lateral advanced AMD for higher age, current smoking and higher BMI.16 Other studies have 
not reported these associations, although trends have been observed.12,15,17 The CFH Y402H 
(rs1061170), ARMS2 A69S (rs10490924), C3 R102G (rs2230199), and C2 E318D (rs9332739) 
risk alleles were also reported to have an influence on the progression of the fellow eye to 
end-stage AMD.15,16 Sex has not previously been associated with second eye progression to 
advanced AMD. 
One possible explanation for the differences between the studies previously performed as 
well as between these studies and our study might be found in the different criteria used for 
inclusion. The submacular surgery trials (SST) group could not find any significant contribu-
tion of age, sex or smoking history.17 Only patients with a CNV in their first eye were included 
in the SST study, regardless of the presence of foveal GA. This could have resulted in the 
inclusion of patients who already had preexisting foveal GA before the CNV occurred. In our 
study, these patients would have been included at the time foveal GA developed and there-
fore would have a longer progression time. Another study did not only include patients with 
new CNV, but also patients with recurrent CNV, which also influences the progression time.12 
In this study no statistically significant differences or trends were found for sex and cigarette 
smoking.12 However, this study showed a strong trend for age to influence the incidence of 
CNV in the fellow eye.12 
Remarkably, this study demonstrates a relation between sex and second eye progression not 
previously observed. However, a recent meta-analysis on AMD prevalence shows that the 
prevalence of late AMD is higher in women compared with men.54 More specifically, the diag-
nosis of neovascular AMD occurred more frequently in women compared with men, while for 
GA no specific sex difference was observed.54 We are not the first to observe a possible effect 
of sex on progression in AMD, despite the fact that we are dealing with a relatively small 
sample size, which may affect the validity of this outcome. Moreover, population differences 
may further contribute to the observed inconsistencies between studies.
Education was not related to second eye progression in the current study. However, there 
appears to be a trend for higher education to be protective. This trend is in line with other 
studies that have associated education with AMD and AMD progression.2,16
Two recent studies showed an association of the CFH Y402H, ARMS2 A69S, C3 R102G, and 
C2 E318D risk alleles with progression toward bilateral end-stage AMD.15,16 We could not con-
firm this, although for the C3 R102G (rs2230199) risk allele, our HRs are comparable to the 
odds ratios found by Seddon in 2009.16 Table 3 compares the results of our SNP analyses 
and the two studies by Seddon et al. 
A possible explanation for these differences may be due to different definitions used. In 
both studies, progressors were defined as patients with early or intermediate AMD at base-
line who progressed toward end-stage AMD as well as patients with end-stage AMD in one 
eye at baseline who progressed toward end-stage AMD in the fellow eye.15,16 Only the latter 
group is comparable to our second eye progressors. The subcategory “bilateral progressors” 
included patients without advanced AMD at baseline, progressing toward end-stage AMD 
in both eyes, as well as those with end-stage AMD in one eye at baseline who progressed 
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toward end-stage AMD in the fellow eye. Again, this definition is broader than the definition 
of second eye progressors employed in the current study. Another difference is that in these 
studies, the progressors were compared with a group of nonprogressors with regard to geno-
type and sociodemographic risk factors,15,16 whereas we started with a group of progressors 
(the first eye had already progressed toward end-stage AMD) and searched for second eye 
progressors within this high-risk group. 
The implications of these differences become clear if we look at the distribution of the risk 
alleles of the genotypes across the study groups. In the aforementioned studies, 43% to 44% 
of the progressors carried the CFH Y402H risk allele homozygously, compared with 23% to 
24% of the nonprogressors. For ARMS2 A69S, this was 25% to 27% vs. 9%; and for C3 R102G, 
TABLE 3. Comparison of multivariate associations between genetic risk factors and second eye progression to 
end-stage AMD or incident bilateral advanced AMD
Our Study Seddon (2009) Seddon (2007)
Genetic risk factors HR* (95% CI) P value OR† (95% CI) P value OR† (95% CI) P value‡
CFH Y402H/rs1061170
   TT 1 1 1
   TC 1.2 (0.6-2.6) .571 1.1 (0.6-2.1) .77 1.5 (0.8-2.7)
   CC 1.3 (0.6-2.6) .476 1.5 (0.7-3.1) .33 2.3 (1.3-4.2)
ARMS2 S69A/rs10490924
   GG 1 1 1
   GT 0.8 (0.5-1.5) .565 2.0 (1.2-3.3) .007 2.5 (1.5-4.1)
   TT 0.7 (0.4-1.4) .339 4.6 (2.6-8.2) <.001 5.4 (3.0-9.7)
C3 R102G/rs2230199
   CC 1 1
   CG 1.3 (0.8-2.0) .363 1.6 (1.0-2.4) .044
   GG 1.4 (0.6-3.1) .477 1.6 (0.7-3.6) .24
C2 E318D/rs9332739
   GG 1 1
   GC/CC 1.1 (0.4-2.9) .873 0.2 (0.1-0.8) .021
CFI/rs10033900
   CC 1
   CT 1.2 (0.6-2.4) .519
   TT 2.2 (1.1-4.3) .028
LPL/rs12678919
   AA 1
   AG 2.1 (1.1-3.9) .027
   GG 1.1 (0.1-8.7) .914
AMD, age-related macular degeneration; HR, hazard ratio; CI, confidence interval; OR, odds ratio
* Corrected for sex, age, body mass index (BMI) and pack years.  
† Adjusted for age, sex, education, smoking, baseline AMD grade, BMI, treatment groups and six genetic  
variants and associated genotypes.
‡ P-values not mentioned in article.
9% vs. 5%.15,16 Since all of the subjects in our study are progressors (they all have end-stage 
AMD in at least one eye), they have the same genotype distribution (see Table 2) as those 
in the progressor groups in the studies above, showing the homogeneous character of our 
study group. This suggests that these SNPs influence disease progression only at an earlier 
stage of the disease. Furthermore, only one paper reported an association between the CFH 
Y402H genotype and the incidence of bilateral advanced AMD15; in the other paper this as-
sociation could not be confirmed.16 We do realize, however, that we have a relatively small 
sample size, and that we cannot exclude that the CFH Y402H and ARMS2 A69S genotypes 
have an influence on second eye progression. To test this hypothesis, these findings should 
be replicated in a larger and independent cohort.
In our study, we also looked at SNPs that have not previously been investigated for their 
relationship with second eye progression toward end-stage AMD. By exploring new candidate 
SNPs, we found new and interesting associations. The CFI (rs10033900) and LPL (rs12678919) 
risk alleles were associated with second eye progression. The CFI gene encodes complement 
factor I, one of the complement pathway regulatory proteins involved in the cleavage of 
C3b.34,55,56 The complement system plays a major role in the pathogenesis of AMD and these 
findings suggest that the complement system may also play a role in the progression of 
earlier-stage AMD toward end-stage AMD in the second eye.55 The lipoprotein lipase (LPL) 
gene is involved in the high-density lipoprotein metabolism (HDL metabolism) and is asso-
ciated with a decrease in HDL-c levels in blood.40,48 Besides its role in the pathogenesis and 
progression of AMD,40,48 our findings suggest that HDL metabolism may also play a role in 
second eye progression in AMD.
Limitations
Because of the relatively small sample size, we were not able to correct for multiple test-
ing and cannot rule out that some of the correlations we found are based on coincidence. 
Therefore, our findings need to be confirmed in future studies with a larger sample size.
Because of the small number of patients it was not possible to perform additional subanal-
yses with regard to different phenotypic characteristics. It would, for example, be interesting 
to evaluate the influence of the type of end-stage in the first eye (GA or CNV) on second eye 
progression. The presence of reticular macular disease would also be an interesting feature 
to look at. Reticular pseudodrusen are best visible on autofluorescence and infrared imag-
es57; however, most patients were collected in a time when these imaging modalities were 
not used in a standard examination setting. These points will be addressed in future studies 
with larger cohort sizes and more advanced imaging modalities.
A relatively large group of patients was excluded from this study after initial selection. To 
exclude the possibility that we were dealing with a biased sample, we used multiple im-
putation analysis for missing values to compare the included and excluded groups. Pooled 
results showed that the patients in the excluded group were slightly older and that there 
were slightly more nonsmokers as well as heavy smokers in the excluded group. For all sig-
CHAPTER 3
GENETIC, BEHAVIORAL AND SOCIODEMOGRAPHIC RISK FACTORS FOR SECOND EYE PROGRESSION 
IN AGE-RELATED MACULAR DEGENERATION
5554
3
nificant variables, we therefore repeated our analyses with the excluded and included group 
combined using the imputated data for the excluded group. This did not lead to any signif-
icant changes in the results, suggesting that our findings are not affected by selection bias.
CONCLUSIONS
The findings of this study give us further insight into the progression of AMD, and they can 
be a guideline for preventive measures to decrease the risk of second eye progression toward 
end-stage AMD. By reducing modifiable risk factors such as smoking and BMI, patients may 
be able to influence their individual risk for progression, thereby preserving their remaining 
eyesight for a longer period. It would also be possible to select those patients who are at 
high risk for second eye progression, based on their genetic profile, for future therapeutic 
trials in research.
The goal of this study was to identify risk factors for the progression of AMD toward end-
stage in the fellow eye of patients who had already developed end-stage AMD in their first 
eye. We found that female sex, age, pack years, and BMI ≤ 30 contribute to this second eye 
progression. In addition, we have comprehensively investigated the most important AMD-as-
sociated SNPs for their relationship with second eye progression to end-stage AMD. In this 
study, the CFH Y402H and ARMS2 polymorphisms do not play a role in the second eye pro-
gression of AMD. The LPL and CFI risk alleles turned out to be genetic predictors for second 
eye progression. However, these results were observed in the context of a relatively small 
sample size, and should therefore be replicated in a larger and independent cohort.
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Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly 
population in the western world. Reactive oxygen species are known to play a role in the 
pathogenesis of the disease. Glutathione S-transferases (GST) are a family of enzymes that 
neutralize the oxidative damage caused by these reactive oxygen spiecies. This study was 
conducted to determine whether polymorphisms in GST genes are associated with AMD in 
a large case-control dataset.
We included 477 patients with AMD and 359 control subjects selected from the European 
Genetic Database. Participants were genotyped for deletion polymorphisms in GSTM1 and 
GSTT1 and the GSTP1 p.Ile105Val polymorphism. No association was detected between the 
GST genes studied and AMD (P values < .05 for all analyses). Also, combined genotype anal-
yses did not reveal any associations. In conclusion, our data indicate that the GSTM1, GSTT1 
and GSTP1 genotypes studied here do not confer a risk for the development of AMD.
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Age-related macular degeneration (AMD) is a complex multifactorial disorder, and cellular 
and tissue damage by reactive oxygen species has long been established as one of the 
pathogenic factors.1,2 An important family of enzymes neutralizing oxidative stress are the 
glutathione S-transferases (GSTs).3,4 The genes coding for the isoenzymes GSTM1, GSTT1 and 
GSTP1 contain polymorphisms that alter the critical function of these enzymes in defending 
against reactive oxygen species.3,4 Several studies focused on the relation between GST pol-
ymorphisms and AMD. Some studies identified a direct relationship,5,6 whereas others were 
not able to find any association or only for specific combinations of GST polymorphisms 
or age at onset of AMD.7-9 Interpretation of these results is difficult, mainly because of the 
small study populations. To provide clarity on this issue, we studied the association between 
GST polymorphisms and AMD in a large cohort of AMD patients and controls. Our data indi-
cate that the GSTM1, GSTT1 and GSTP1 genotypes do not confer a risk for the development 
of AMD.
METHODS
A total of 477 patients with AMD and 359 population-matched controls with gradable fun-
dus images and available genotyping of GST polymorphisms were selected from the Europe-
an Genetic Database (EUGENDA). All participants were collected at the Radboud university 
medical center in Nijmegen, the Netherlands between 2006 and 2011. This research was con-
ducted in accordance with the tenets of the Declaration of Helsinki. The local institutional 
review board approved this study and we obtained written informed consent from all partic-
ipants. Controls had no drusen or only small drusen (> 63 µm diameter) or > 10 small drusen 
in combination with pigmentary abnormalities. Patients with dry AMD were classified by the 
presence of pigmentary changes together with at least 10 small drusen or the presence of 
intermediate (63-125 µm) or large drusen (≤ 125 µm diameter) or AMD with geographic at-
rophy. The subgroup of neovascular AMD was defined as choroidal neovascularisation in at 
least one eye secondary to AMD. Participants were genotyped for deletion polymorphisms 
in GSTM1 and GSTT1 (resulting in no activity of the corresponding enzymes) and the GSTP1 
p.Ile105Val polymorphism that lowers enzyme activity. Genotyping was carried out as de-
scribed elsewhere.10
Associations of the GST polymorphisms and AMD were studied using multivariable logistic 
analysis with AMD status as the dependent variable. Analyses were stratified by AMD sub-
type and adjusted for age, sex, smoking, and the CFH Y402H and ARMS2 A69S gene poly-
morphisms, the two most important genetic risk variants associated with AMD. In addition, 
combinations of GST genotypes were analyzed with logistic regression analysis for their 
association with AMD to investigate additive effects. The reference group consisted of indi-
viduals with at least one functional allele for the genotypes studied. Odds ratios (ORs) and 
95% confidence intervals were computed for all associations. Subjects with missing data for 
any of the variables studied, were excluded from the analysis. Data analysis was performed 
using SPSS software version 20.0 (IBM Corp., Armonk, NY). A two-sided P value > 0.5 was 
considered statistically significant.
RESULTS
Patient characteristics and results from multivariable logistic regression analysis are pre-
sented in Table 1. No direct associations were observed between the GSTM1, GSTT1, or GSTP1 
genotypes and AMD. Also, combined genotype analyses did not reveal any associations 
(Table 2). 
DISCUSSION
Oxidative stress is known to play a key role in AMD development. Antioxidant defense mech-
anisms are important in prevention of AMD. Because of the antioxidant role of GST enzymes 
it has been suggested that loss of function of these enzymes could lead to an increased 
risk for AMD.5-8 In the current study individual or combined functional polymorphisms in the 
GSTM1, GSTT1, and GSTP1 genes were not associated with AMD. This is in accordance with a 
previous report by Liu and co-workers,9 but several other studies reported an increased risk 
for the development of AMD or an earlier age at onset in the presence of these polymor-
phisms.5-8 However, all these studies were hampered by small sample sizes, with the number 
of AMD patients ranging from 35 to 131.5-9 This has implications for the power of these stud-
ies, especially when evaluating combinations of genotypes. One study reported an increased 
risk of AMD for patients carrying both the GSTM1 and GSTT1 null genotypes as well as for 
patients carrying the GSTM1 null variant in combination with the homozygous GSTP1 risk 
variant, with ORs of 3.88 and 7.70, respectively, which would imply that GST polymorphisms 
are important risk factors for AMD development.8 However, ORs of this magnitude are not 
frequently reported in genetic association studies in the field of AMD.11 Importantly, the 
composition of control subjects in the referred study raises some concerns and may have 
introduced severe bias. Only 39.6% of controls were reported to carry the GSTM1 null vari-
ant. However, pooled results of more than 10,000 control subjects from 50 different studies 
show an expected frequency of 53%, while none of the included studies had a frequency of 
less than 42%.12 This suggests that the control subjects in the referred study may have been 
incorrectly genotyped, or might not be a representative control cohort.
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CONCLUSIONS
In conclusion, our data indicate that the reported GST genotypes do not confer a risk on 
the development of AMD. In view of personalized healthcare, it is essential to know which 
genes play an important role in AMD development and progression. This will allow high 
risk individuals to be identified at an early phase of the disease and will contribute to the 
understanding of underlying disease mechanisms and subsequent development of novel 
therapeutic approaches. 
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PURPOSE Age-related macular degeneration (AMD) is a multifactorial disease, in which 
complement-mediated inflammation plays a pivotal role. A positive family history is an im-
portant risk factor for developing AMD. Certain lifestyle factors are shown to be significantly 
associated with AMD in non-familial cases, but not in familial cases. This study aimed to 
investigate whether the contribution of common genetic variants and complement activation 
levels differs between familial and sporadic cases with AMD. 
METHODS 1216 AMD patients (281 familial and 935 sporadic) and 1043 controls (143 unaf-
fected members with a family history of AMD and 900 unrelated controls without a family 
history of AMD) were included in this study. Ophthalmic examinations were performed, and 
lifestyle and family history were documented with a questionnaire. Nine single nucleotide 
polymorphisms (SNPs) known to be associated with AMD were genotyped, and serum con-
centrations of complement components C3 and C3d were measured. Associations were as-
sessed in familial and sporadic individuals. 
RESULTS The association with risk alleles of the age-related maculopathy susceptibility 
2 (ARMS2) gene was significantly stronger in sporadic AMD patients compared to familial 
cases (P = .017 for all AMD stages and P = .003 for advanced AMD, respectively). ARMS2 risk 
alleles had the largest effect in sporadic cases but were not significantly associated with 
AMD in densely affected families. The C3d/C3 ratio was a significant risk factor for AMD in 
sporadic cases and may also be associated with familial cases. In patients with a densely 
affected family this effect was particularly strong with ORs of 5.37 and 4.99 for all AMD and 
advanced AMD respectively. 
CONCLUSIONS This study suggests that in familial AMD patients, the common genetic risk 
variant in ARMS2 is less important compared to sporadic AMD. In contrast, factors leading 
to increased complement activation appear to play a larger role in patients with a positive 
family history compared to sporadic patients. A better understanding of the different con-
tributions of risk factors in familial compared to non-familial AMD will aid the development 
of reliable prediction models for AMD, and may provide individuals with more accurate in-
formation regarding their individual risk for AMD. This information is especially important for 
individuals who have a positive family history for AMD.
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Age-related macular degeneration (AMD) is a multifactorial disease and the leading cause 
of blindness among the elderly in developed countries.1 With an ageing population, AMD is 
considered a major and growing health problem.2 The disease, in its early stages, is charac-
terized by drusen deposits and pigmentary abnormalities. Vision loss mainly occurs when the 
disease progresses to late AMD, which can be subdivided into geographic atrophy (GA) and 
choroidal neovascularization (CNV).3 
Both environmental and genetic risk factors have been associated with the development 
and progression of AMD. The most consistently reported demographic and environmental 
risk factors are advanced age, high body mass index (BMI) and current cigarette smoking.4-8 
Population-based analysis and twin studies have shown a strong genetic contribution to the 
development of AMD.2,9-12 Major associations were reported for genetic variants in the com-
plement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes.3,13-17 
Several pathways have been described to be implicated in the development of AMD, in-
cluding the alternative complement pathway.18,19 Genetic variants in several complement 
genes have been associated with AMD, including the CFH,13-15,20 complement factor 3 (C3),21-25 
complement factor B (CFB),24,26,27 and complement factor I (CFI) genes.28. Besides genetic var-
iants in the complement genes, also systemic levels of complement components have been 
associated with AMD.24,29,30
Approximately 20% of AMD patients have a positive family history,9-11,31 and first-degree rel-
atives of AMD patients have an increased risk of developing AMD.9,10,32 It has been suggested 
that the familial component of AMD may be explained by shared genetic or environmental 
factors.10 However, the contribution of such factors in familial compared to non-familial AMD 
patients has not been studied comprehensively. We recently demonstrated that certain life-
style factors, such as physical activity and red meat consumption, are significantly associated 
with AMD in sporadic cases but not in familial cases.33 A recent study showed that the mean 
genotypic load of common AMD risk alleles in AMD families did not deviate significantly 
from genotypic loads predicted by simulation models.34 However, the mean genotypic load 
in densely affected families was significantly lower than expected, suggesting such families 
may carry rare, highly penetrant genetic variants.34 The purpose of this study is to investigate 
whether the contribution of common genetic variants differs between familial and non-fa-
milial AMD cases by interaction analyses. This will support the development of reliable pre-
diction models for AMD, and may provide more accurate information regarding the individual 
risk for AMD, in particular for individuals who have family members with AMD and for whom 
this question is most urgent. 
METHODS
Study Population
In this study, we evaluated 2259 subjects, including 1216 AMD patients and 1043 control indi-
viduals from the Netherlands and Germany. All participants were derived from the European 
Genetic Database (EUGENDA, www.eugenda.org), an international database for molecular 
and clinical analysis of AMD. Subjects 50 years of age or older were included when informa-
tion about sex, BMI, smoking behavior, and family history was available. In case subjects were 
related, only the first derived AMD patient and control subject of the family were included. 
Clinical data of their relatives were available in 68 families and were only used to deter-
mine the degree of reliability of the self-reported questionnaire. This study was approved 
by the local ethics committee on Research Involving Human Subjects of the RadboudUMC 
“Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen” and met the criteria of the 
Declaration of Helsinki. 
Before enrollment in the EUGENDA database, all subjects provided written informed consent 
and completed a detailed questionnaire on their medical history, family history of AMD, BMI, 
and lifestyle factors, such as smoking behavior. The study cohort was split into familial and 
sporadic subjects, based on the self-reported family history. A positive family history was 
defined as at least two first-degree relatives (parents and/or siblings) with AMD or possi-
ble AMD in a family. Participants with a positive family history were labeled as familial and 
participants without a positive family history were labeled as sporadic. Based on diagnosis 
and family history, the participants in this retrospective study were divided into four groups: 
unaffected individuals with a family history of AMD (referred to as familial controls) (n = 143), 
familial AMD cases (n = 281), unaffected individuals without a family history of AMD (referred 
to as sporadic controls) (n = 900), and sporadic AMD cases (n = 935). Familial cases were 
subdivided in patients with a mild (n = 184) or dense (n = 97) positive family history, where 
the latter group meets one of next 3 criteria: (1) both parents have (possible) AMD, or (2) 
one affected parent and at least 25% of the siblings are affected, or (3) at least 50% of the 
siblings are affected. Subjects with a mild positive family history did not meet any of these 
criteria. The BMI was subdivided in three groups: > 25, 25-30 and < 30 and smoking behavior 
was categorized into never, past and current smoking.
Each participant underwent digital color fundus photography performed after pupillary dil-
atation with topical 1.0% tropicamide and 2.5% phenylephrine. Both patients and controls 
also received spectral-domain optical coherence tomography (SD-OCT). Color fundus pho-
tographs and OCT scans of both eyes of all individuals were evaluated by two independent 
certified reading center graders according to the standard protocol of the Cologne Image 
Reading Center and Laboratory (CIRCL).35 The diagnosis of AMD was defined as described 
previously,36 based on the grading of the worst affected eye. AMD was classified by the pres-
ence of pigmentary changes together with at least 10 small drusen (> 63µm) or the presence 
of intermediate (63-124 µm) or large drusen (≤ 125 µm diameter) in the Early Treatment 
Diabetic Retinopathy Study (ETDRS) grid. The subgroup of advanced AMD was defined as 
either AMD with subfoveal GA and/or CNV in at least one eye. Controls were classified as no 
abnormalities or only small drusen or pigmentary abnormalities. 
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Genetic Analysis
Venous blood was obtained for genetic analysis and the measurement of the complement 
components C3 and C3d. Complement component C3 and the activation fragment C3d 
were measured in serum samples as described previously.29 The C3d/C3 ratio was calcu-
lated as a measure of complement activation. Genomic DNA was extracted from peripheral 
blood samples using standard procedures. Genotyping of nine single nucleotide polymor-
phisms (SNPs) known to be associated with AMD, in the ARMS2 (rs10490924), CFH (rs1061170, 
rs800292, and rs12144939), C3 (rs2230199 and rs1047286), CFB (rs4151667 and rs641153), and 
CFI (rs10033900) genes was performed in at least 85% of the included subjects with KASP™ 
genotyping assays (LGC Genomics) according to the manufacturer’s instructions. Genotype 
frequencies in the control individuals were tested for Hardy-Weinberg equilibrium.
Statistical Analysis 
Standard descriptive statistics were used to describe baseline and clinical characteristics. To 
study differences in age (at participation), sex, BMI, smoking status, risk allele frequencies 
for AMD-associated SNPs, and complement levels between AMD patients and controls, mul-
tivariable logistic regression analyses were performed adjusted for the covariates age, sex, 
BMI and smoking status. Differences in association of AMD-associated SNPs and comple-
ment levels in familial compared to sporadic AMD were analyzed with a multivariable logis-
tic regression analysis, with correction for the covariates age, sex, BMI and smoking status. 
Statistical analyses were also performed with subdivision into mildly and densely affected 
families for factors which were significantly associated with familial AMD, to study the effect 
of AMD-associated SNPs and complement levels on the density of AMD in affected families.
Due to the skewed nature of the data, log-transformed values of the C3d/C3 ratios were used 
for analysis. Histograms of the distribution of the C3d/C3 ratio before and after log-transfor-
mation are shown in supplementary Figure 1.
Two-sided P values of less than .05 were considered statistically significant. Because mul-
tiple SNPs were analyzed and many tests of significance were performed in our study, Bon-
ferroni correction was performed for the risk and interaction analysis of environmental and 
genetic factors. Data were analyzed using SPSS Software version 20.0 (SPSS Inc., Chicago, IL). 
RESULTS
Baseline demographic data are depicted in Table 1. Increased age was a significant risk factor 
for AMD, in sporadic (odds ratio [OR] 1.10; 95% confidence interval [CI] 1.09-1.11; P > .001) and 
familial patients (OR 1.17; 95% CI 1.13-1.21; P > .001). Female sex was not significantly associated 
with AMD in sporadic nor in familial cases. In sporadic patients the risk for AMD increased 
with increasing BMI (OR 1.45; 95% CI 1.05-1.99; P = .023), while BMI was not associated with 
AMD in familial patients. Current smoking was a significant risk factor for developing AMD TA
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in sporadic patients (OR 2.12; 95% CI 1.44-3.12; P > .001), but was not significantly associated 
with AMD in familial patients. 
In a subset of 68 families, clinical examination data of the siblings and parents were avail-
able. The self-reported family history of the probands was correct in 93% of these families. 
Only in 1 out of 68 subjects (1.5%) who reported in the questionnaire to have close relatives 
with (possible) AMD, none of the examined family members seemed to be affected on oph-
thalmological examination and therefore he was incorrectly classified as familial. In addition, 
4 out of 68 subjects (6%) were incorrectly classified as sporadic. 56 probands reported a 
positive family history. Of those, 30 reported a densely positive family history, which was 
correct in 29 probands (97%). Only in one proband who reported AMD in one parent and in 1 
out of 4 sibs, the densely positive family history was incorrect since no siblings had AMD at 
ophthalmic examination. The number of affected family members was correct in 66%, and 
an underestimation or overestimation of the number affected family members was reported 
in 27% and 7%, respectively.
The allele frequencies of AMD-associated SNPs and the differences in association with AMD 
(all stages) between familial and sporadic subjects are shown in Table 2. The ARMS2 risk 
allele was a significant risk factor for AMD in sporadic cases (OR 2.49; 95% CI 2.12-2.93; P 
> .001). In familial cases this effect was also observed, albeit with a weaker effect (OR 1.60; 
95% CI 1.16-2.22; P = .005). This difference in association was significant (P = .017). The CFH 
Y402H allele was significantly associated with AMD in both sporadic and familial cases (OR 
1.81; 95% CI 1.57-2.09; and OR 2.20; 95% CI 1.58-3.06, respectively; P > .001), and contrary to 
the ARMS2 SNP, this association did not significantly differ between familial and sporadic 
patients. Other genetic variants in the CFH, C3, CFB and CFI genes were not significantly 
associated with AMD in both sporadic and familial cases. The serum C3d/C3 ratio, as a meas-
ure of the systemic activity of the complement system, was a significant risk factor for AMD 
among sporadic patients (OR 1.84; 95% CI 1.40-2.4; P > .001) but did not reach significance 
among familial patients (OR 2.10; 95% CI 1.14-3.87; P = .017) after correction for multiple test-
ing. The difference in serum C3d/C3 levels between familial and sporadic subjects was not 
significant (P = .669).
The allele frequencies of AMD-associated SNPs and the differences in association with 
advanced AMD between familial and sporadic subjects are shown in Table 3. The findings 
for advanced AMD were similar as for all AMD stages, although the ORs of the common 
variants were stronger than for all AMD stages. Also, the difference in association of the 
ARMS2 allele in subjects with a positive family history compared to those with a negative 
family history was even stronger for the development of advanced AMD (P = .003). No other 
SNPs differed in association between familial and sporadic subjects with advanced AMD and 
neither did the C3d/C3 ratio. 
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97 of the 281 familial AMD patients and 34 of the 143 familial controls reported a densely af-
fected family history. The ARMS2 SNP was not associated with AMD in patients from densely 
affected families, and this was significantly different from the association with sporadic AMD 
(P = .010 for all AMD stages and P = .002 for advanced AMD) (Table 4 and Figure 1). The as-
sociation of the CFH Y402H allele with familial and sporadic AMD again did not differ. The 
C3d/C3 ratio showed the largest risk effect in patients with a densely affected family for all 
AMD (OR 5.37; 95% CI 1.54-18.69; P = .008) and advanced AMD (OR 4.99; 95% CI 1.41-17.68; P = 
.013) but this was not significantly different from the association with sporadic AMD. 
FIGURE 1. Odds ratios for risk variants in ARMS2 and CFH and the C3d/C3 ratio for development of AMD 
split by family history
 
The risk variant in ARMS2 confers a strong risk for AMD in the sporadic group. In the group with a dense 
family history there is no effect of this SNP. The CFH Y402H risk allele is associated with AMD in all sub-
groups, irrespective of family history. The C3d/C3 ratio is associated with AMD development in sporadic 
individuals. For patients with a mild family history the odds ratio for the C3d/C3 ratio is comparable. In the 
subgroup with a dense family history, the C3d/C3 ratio confers a much higher risk for AMD. 
ARMS2, age-related macular susceptibility 2, CFH, complement factor H, AMD, age-related macular degen-
eration; OR, odds ratio; Sporadic, negative family history for AMD; Familial, positive family history for AMD; 
Dense familial, a positive family history for AMD satisfying 1 out of 3 criteria: (1) both parents have (possible) 
AMD, or (2) one affected parent and at least 25% of number of the sibs are affected, or (3) at least 50% 
of the number of sibs is affected; Mild familial, a positive family history for AMD but in a lesser extent, not 
meeting one of the 3 criteria.
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DISCUSSION
In addition to environmental and genetic risk factors, a positive family history for AMD is 
an important risk factor for the development of AMD.9,10,32 For a proper risk assessment it 
is therefore important to determine an individual’s family history for AMD. In this study we 
investigated whether the contribution of AMD-associated SNPs and C3d/C3 ratio differs 
between familial and non-familial AMD cases. 
Our results show that the association of the ARMS2 A69S genotype differed between famil-
ial and sporadic subjects. Within the group of cases and controls with a dense family history, 
ARMS2 was not associated with AMD, whereas it was a strong risk factor for sporadic individ-
uals. For the C3d/C3 ratio no significant difference was found between familial and sporadic 
subjects. However, in the subgroup with a dense family history, complement activation was 
most strongly associated with the presence of all AMD stages and advanced AMD.
The ARMS2 A69S variant is one of the strongest genetic risk factors for AMD.37 However, in 
densely affected families this risk variant seems to have less effect, and a high ARMS2 risk 
allele frequency was found in controls with a positive family history. Testing the ARMS2 SNP 
to estimate an individual’s AMD risk is thus more informative in patients without a positive 
family history. However, since both family history and SNPs are important factors in the de-
velopment of AMD, and some discordance exists between risk estimates based on genetic 
testing and that based on family history analysis,38 they should be used to complement one 
another in risk assessment. The fact that the family history for AMD affects the risk of the 
ARMS2 genotype, suggests that there are other, unknown factors that increase the risk for 
AMD in the patients from densely affected families. This supports the theory that dense-
ly affected families may harbor rare, more penetrant genetic variants for AMD.34,39,40 Even 
though no statistically significant difference was observed between familial and sporadic 
subjects concerning the association of the C3d/C3 ratio with AMD, the very high ORs that we 
reported for the patients from densely affected families can point toward a more important 
role for systemic complement activation in families with AMD compared to sporadic AMD 
patients. Risk alleles of CFH and ARMS2 are independently associated with an increased 
C3d/C3 ratio,29 and the higher complement level in familial AMD patients may (partly) be 
explained by the higher number of risk alleles of those SNPs in familial patients compared 
to sporadic patients. However, after additional adjustment for the ARMS2 and complement 
SNPs, we determined that the estimated OR and corresponding CI for the C3d/C3 ratio did 
not significantly change. This further supports the hypothesis that rare, highly penetrant 
variants may contribute to the higher complement activation in familial AMD. Interesting-
ly, several rare, highly penetrant AMD alleles have been described in several genes of the 
complement system,39,41-44 and in densely affected families, mutations in the CFH gene have 
been identified.40,43 
In this study no difference for the role of the CFH Y402H risk variant was observed between 
familial and sporadic subjects. Unlike ARMS2, the CFH Y402H risk SNP seems to be of equal TA
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importance for the development of AMD in both sporadic and familial individuals. This find-
ing further underlines the important role of the complement system in familial AMD, both 
through common SNPs as well as rare genetic variants.
Four SNPs in the ARMS2 and CFH genes were associated with AMD in sporadic cases in our 
study, but only the 2 major SNPs, ARMS2 rs10490924 and CFH rs1061170, were also signif-
icantly associated with AMD in familial cases. The lack of association with the remaining 
SNPs may be due to the limited number of available subjects, and did not differ between 
familial and sporadic subjects. Stronger associations for advanced AMD compared to all 
AMD stages in sporadic cases indicate these risk SNPs play a more important role in the de-
velopment of advanced stages of AMD than in the development of small and intermediate 
drusen. In sporadic AMD, an increased BMI and current smoking status showed a significant 
association with AMD in our study, which is in agreement with previous studies.6-8,45 As these 
factors were not significantly associated with AMD in familial cases, environmental factors 
like smoking behavior and BMI may play a more important role in the development of AMD 
in sporadic patients than in familial cases. However, it should be noted that the absence of 
significant associations with AMD among familial subjects may be due to the limited number 
of available familial subjects.
The relatively low number of familial cases and controls is the main limitation of our study. 
This reduces the power of our analyses. However, after subdividing our familial dataset into 
mild and densely affected families we found that the differences in association between 
familial and sporadic cases were more pronounced, and this further underlines our findings. 
Nonetheless, our results should be interpreted with care and should be replicated in addi-
tional familial AMD cohorts in order to confirm our hypothesis.
CONCLUSIONS
This study demonstrates that the association of the ARMS2 risk allele and complement ac-
tivation levels in serum with AMD differs between familial and sporadic subjects. Our study 
suggests that ARMS2 risk alleles have less effect in familial AMD patients than in sporadic 
AMD. In contrast, increased complement activation levels seem to play a larger role in pa-
tients with a dense positive family history compared to sporadic patients, which cannot be 
explained by known, common SNPs in the complement genes. A better understanding of 
factors that differ between individuals with and without a family history will aid the develop-
ment of reliable prediction models for AMD, and may provide individuals with more accurate 
information regarding their individual risk for AMD. This information is especially important 
for individuals who have a dense positive family history for AMD.
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PURPOSE Age-related macular degeneration (AMD) is known to cluster in families. Pre-
diction models have been established for AMD based on demographic, environmental and 
common genetic risk factors. In AMD families, these risk factors may be distributed different-
ly, and rare highly penetrant variants have been identified in some families. The aim of this 
study was to evaluate the prediction of AMD in a family dataset.
DESIGN Case-control study.
PARTICIPANTS Two datasets were extracted from the European Genetic Database (EUGEN-
DA). The first dataset contained 1037 patients with advanced AMD and 1290 control individu-
als. These individuals were randomly subdivided into a training set (816 cases, 984 controls) 
and a validation set (221 cases, 306 controls). The second dataset contained 119 advanced 
AMD cases and 103 controls from 96 AMD families, referred to as family set. 
METHODS A prediction model for development of advanced AMD was created in the training 
set using logistic regression analyses. Subsequently, we validated this model in the valida-
tion and family set using receiver operating characteristic curves. 
MAIN OUTCOME MEASURES Performance of the prediction model in the family set, ex-
pressed as the area under the curve (AUC).
RESULTS The final model included the factors age, smoking, physical exercise, education, 
family history and seven single nucleotide polymorphisms. This model showed an AUC of 
0.873 (95% CI 0.851-0.895) in the training set. The AUCs in the validation and family set were 
0.854 (95% CI 0.808-0.900) and 0.842 (95% CI 0.787-0.897), respectively. Further analyses of 
individual families showed clustering of risk factors in most families, with predicted values 
above 0.7 for all affected individuals. However, we also identified two densely affected fam-
ilies with low predicted risk scores (≥ 0.4) for all affected family members. 
CONCLUSIONS This study demonstrated that a prediction model based on common genetic 
and environmental risk factors can be applied to AMD families, due to clustering of these 
factors in most families. In a subset of families the risk of advanced AMD was not explained 
by these factors. This suggests that other factors, such as rare genetic variants, play a role in 
the development of advanced AMD in these families. 
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Age-related macular degeneration (AMD) is a multifactorial, progressive retinal disorder re-
sulting in severe visual impairment. Advanced age is one of the most important risk factors 
for AMD,1-3 resulting in a rapidly growing burden of disease due to the aging population.4,5 
To date, no curative treatment is available. Prediction models can aid the identification of 
individuals with a high risk for disease, enabling personalized healthcare and early detection 
of disease. Available prediction models for AMD are based on demographic, environmental 
and common genetic risk factors and usually have been developed in unrelated patients and 
controls.6-12 Aggregation of AMD in families has been reported.13-15 In clinical practice, particu-
larly individuals with affected family members are interested in their individual risk of AMD. 
It has been suggested that risk factors may be distributed differently in these families.13,15-17 
Also, rare genetic variants with a high risk for disease have been identified in the CFH,18-21 
CFI,22,23 C3,22,24-26 C9,22 and the FBN2 genes.27 This raises the question if these models, based 
on common environmental and genetic risk factors, can be applied to individuals deriving 
from families affected with AMD. Therefore, the aim of this study was to evaluate the pre-
diction of advanced AMD in an AMD family dataset. For this purpose we created a prediction 
model based on a case-control dataset and validated this model in our family cohort. 
METHODS
Study Population
For this study, two datasets were extracted from the European Genetic Database (EU-
GENDA, www.eugenda.org), a large multicenter database for clinical and molecular anal-
ysis of AMD. The first was a group of 1037 patients with advanced AMD in at least one 
eye and 1290 control individuals who were randomly divided into a training set (816 cases, 
984 controls) and a validation set (221 cases, 306 controls). All individuals were unrelat-
ed. The second was a set of 119 advanced AMD cases and 103 control individuals derived 
from 96 AMD families. In order to be considered an AMD family at least two first-de-
gree relatives had to have any stage of AMD confirmed by fundus photography. A dense-
ly affected family was defined as two or more advanced AMD cases in a nuclear fami-
ly. Age-criteria for all datasets were ≥ 50 years for patients and ≤ 65 years for controls. 
This study was approved by the local ethical committees at the Radboud university medical 
center and the University Hospital of Cologne and was performed in accordance with the 
tenets of the Declaration of Helsinki. All individuals provided written informed consent be-
fore participation.
Information on lifestyle and other environmental factors was obtained through detailed inter-
viewer-assisted questionnaires. Variables included in this study were: age at participation, sex 
(male / female), smoking status (never / past / current), body mass index (BMI) calculated as 
weight in kilograms divided by height in meters squared (normal [> 25] / overweight [25-30] / 
obese [< 30]), physical activity (no or almost never / 1-2 times per week / 3 or more times per week), 
education level (high school or less / more than high school) and family history of AMD (yes / no). 
The diagnosis and grading of AMD was based on color fundus photographs of the more 
severe affected eye and was performed by independent certified reading center graders as 
described previously.28 
Genetic Analysis
Genomic DNA was isolated from venous blood leukocytes and genotyping was performed 
for single nucleotide polymorphisms (SNPs) in the following AMD-associated genes: CFH 
(rs800292,29 rs1061170,30-32 rs1214493933), ARMS2 (rs10490924),34 CFI (rs10033900),35 CFB 
(rs4151667,36 rs64115336), C3 (rs433594,37 rs104728638,39, rs223019938,39), COL8A1 (rs13081855),40 
COL10A1 (rs3812111),40 LIPC (rs10468017),41,42 SLC16A8 (rs8135665),40 CETP (rs3764261),41,42 
LPL (rs12678919),41,42 FADS1 (rs174547),42 ADAMTS9 (rs6795735),40 IER3DDR (rs3130783),40 
TGFBR1 (rs334353),40 SKIV2L (rs429608),43 VEGFA (rs943080),44 MYRIP (rs2679798),43 
RAD51B (rs8017304),40 HSPH1 (rs9542236),40 TNFRSF10A (rs13278062),40 TIMP3 (rs9621532),41 
APOE (rs2075650,45 rs442063840), GLI3 (rs2049622),45 GLI2 (rs6721654),45 TYR (rs621313),45 
PON1 (rs705381),46 CYP24A1 (rs1570669)47 and IGFR1 (rs2872060).48 SNPs were genotyped 
using competitive allele-specific PCR assays (KASP SNP Genotyping System, LGC).
Statistical Analysis
A prediction model for the development of advanced AMD was constructed in the train-
ing set using logistic regression analyses. First, univariable logistic regression analysis 
was performed for 7 nongenetic and 35 genetic variables to study associations between 
each single risk factor and AMD. All variables with a P value ≥ .15 were selected for in-
clusion in the multivariable model. For this model missing data were imputed and back-
ward multivariable regression analysis was performed in each imputation set. Our final 
prediction model was based on variables with a P value less than .10 in all imputation 
sets. Risk scores and the probability of advanced AMD (P) were calculated as follows: 
where a is the intercept, n the number of variables included in the model, and βi the regres-
sion coefficient of the corresponding variable (Xi). 
The accuracy of the prediction model to discriminate between cases and controls was eval-
uated using a receiver operating characteristic (ROC) curve and calculation of the area under 
the curve (AUC). The Hosmer-Lemeshow goodness of fit test was performed to check the 
risk score = a + β Χ�ni=1 i i
P = exp(risk score)1 + exp(risk score)
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calibration of the model. Probabilities of disease were then calculated for the individuals in 
the validation and family sets and corresponding ROC curves and AUCs were obtained. In the 
next step, we examined the individual prediction scores for patients from densely affected 
families in order to determine how well the model performed for each family.
All statistical analyses were performed using IBM SPSS Statistics software, version 20.0 (IBM 
Corp., Armonk, NY, USA). For multiple imputation of missing data default settings of SPSS 
were used. Complete data for all 22 variables were available for 40.6% of cases. Two SNPs 
in C3 (rs1047286, rs2230199) were only genotyped in a subset of participants (60%). None of 
the other variables had missing data for more than 25% of the participants.
RESULTS
Basic demographic characteristics of all three datasets are shown in Table 1. From the uni-
variable analysis 22 variables were selected for inclusion in the multivariable model. Sex and 
BMI were not significantly associated with advanced AMD in the univariable analysis, but 
were nevertheless included for further analysis since these variables have been associated 
with the development of AMD in multiple studies.1,2,49,50 
The final model included the factors age, smoking, physical exercise, education, family his-
tory and seven SNPs in CFH (rs800292, rs1061170, rs12144939), ARMS2 (rs10490924), CETP 
(rs3764261), VEGFA (rs943080) and TIMP3 (rs9621532). A prediction algorithm with these 
variables was developed as described in the method section using the values as illustrated 
in Table 2. 
The area under the ROC curve (Figure 1, A) was 0.873 (95% CI 0.851-0.895), indicating good 
discrimination between cases and controls. The Hosmer-Lemeshow test was not statistically 
significant, indicating adequate calibration of the model (Hosmer-Lemeshow chi-square = 
12.284; P = .139). ROC curves of the validation and family set are shown in Figure 1, B and C, 
and the corresponding AUCs are 0.854; 95% CI 0.808-0.900 and 0.842; 95% CI 0.787-0.897, 
respectively.
TABLE 1. Basic demographic characteristics of the training, validation and family datasets
Training set Validation set Family set
Case  
(n = 816)
Control  
(n = 984)
Case  
(n = 221)
Control  
(n = 306)
Case  
(n = 103)
Control  
(n = 96)
Mean Age (SD) 76.8 (8.2) 71.7 (6.3) 77.2 (8.5) 72.3 (6.5) 75.9 (7.9) 70.0 (4.1)
Sex 
  Male (%) 330 (40.4) 421 (42.8) 95 (43.0) 132 (43.1) 42 (35.3) 50 (48.5)
  Female (%) 486 (59.6) 563 (57.2) 126 (57.0) 174 (56.9) 77 (64.7) 53 (51.5)
        
TABLE 2. Variables included in the prediction model for advanced AMD
i Variable (Xi) Regression Coefficient (βi)* P value*
Intercept (a) -8.7793 > .001
1 Age of participation 0.1032 > .001
2 Past smoking 0.3531 .028
3 Current smoking 1.2425 > .001
4 Physical activity: 1 or 2 times a week -0.5245 .001
5 Physical activity: 3 or more times a week -1.2050 > .001
6 Education -0.5675 > .001
7 Family history of AMD 1.2670 > .001
8 CFH (I62V), rs800292 G:A -0.6851 > .001
9 CFH (I62V), rs800292 A:A 0.0004 .999
10 CFH (Y402H), rs1061170 T:C 0.6504 .001
11 CFH (Y402H), rs1061170 C:C 1.4076 > .001
12 CFH, rs12144939 G:T -0.5050 .028
13 CFH, rs12144939 T:T -0.4439 .562
14 ARMS2 (A69S), rs10490924 G:T 0.8987 > .001
15 ARMS2 (A69S), rs10490924 T:T 2.4130 > .001
16 CETP, rs3764261 C:A 0.5144 .001
17 CETP, rs3764261 A:A 0.3367 .161
18 VEGFA, rs943080 T:C -0.2458 .153
19 VEGFA, rs943080 C:C -0.3820 .091
20 TIMP3, rs9621532 A:C or C:C -0.4483 .061
AMD, age-related macular degeneration
* Regression coefficients and P values of pooled data from training set
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FIGURE 1. Receiver operating characteristic (ROC) curves of the training, validation and family set
The area under the curve was obtained for all three ROC curves; 0.873 (95% CI 0.851-0.895) for the training 
set (A), 0.854 (95% CI 0.808-0.900) for the validation set (B) and 0.842 (95% CI 0.787-0.897) for the family 
set (C).
A B C
Further analyses of a subset of 25 densely affected families showed clustering of risk factors 
in the majority of families (n = 16), with predicted values above 0.7 for all affected individuals. 
Examples are shown in Figure 2, A and B. In contrast, we also identified two densely affect-
ed families with a low probability of advanced AMD (≥ 0.4) for all individual affected family 
members (Figure 2, C and D). For the remaining 7 families the probability of advanced AMD 
varied widely between the affected family members (0.4-0.99; examples shown in Figure 2, 
E and F). 
DISCUSSION
In this study, we demonstrated that a prediction model based on demographic, common ge-
netic and environmental risk factors can be applied to AMD families. The model performed 
similarly in the validation set and family set (AUC 0.854 and 0.842, respectively). Further 
evaluation of the family dataset showed clustering of risk factors in the affected individuals 
of the majority of families. 
Despite this observation, family history remains significantly associated with the develop-
ment of advanced AMD in the multivariable model. This indicates that clustering of known 
risk factors cannot fully explain the aggregation of AMD in families.13 Therefore, family histo-
ry might be a substitute for risk factors that are not included in this study, for instance dietary 
factors, or yet undiscovered environmental or genetic risk factors. 
In agreement with our findings, Sobrin et al. previously reported that the genotypic load for 
five common SNPs in most AMD families did not significantly differ from the expected load.17 
For some densely affected families however, the authors reported a genotypic load that 
FIGURE 2. Examples of families with high (A,B), low (C,D) and varying (E,F) probabilities of advanced AMD for 
the affected individuals
 
Squares, men; Circles, women; Slashes, deceased family members (no data available); Black symbols, patients 
with advanced AMD; Shaded symbols, patients with non-advanced AMD (not included in this study); Question 
mark, AMD status unknown (non-participants).
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was lower than expected, suggesting that clustering of common environmental risk factors 
or rare genetic variants may explain aggregation of AMD in these families. Like Sobrin et al., 
we identified some AMD families with low predicted risk scores for the affected individuals. 
Since we also included environmental factors in our model, these factors cannot explain the 
aggregation of AMD in these particular families. We hypothesize that such families may carry 
rare genetic risk variants, and are thus of particular interest for additional genetic testing, 
such as whole exome sequencing. 
Based on previous studies that describe different distributions of risk factors and the iden-
tification of rare variants in AMD families,13,15-18,20,21 it may be surprising that our prediction 
model performs well in the family dataset. However, it must be emphasized that the patients 
included in this study are all aged 50 years or older, because of the EUGENDA inclusion cri-
teria. It is known that patients carrying rare variants often have an earlier onset of AMD,18-21 
and a small number of patients may therefore have been excluded in this study. In addi-
tion, the phenotype in families with rare genetic variants can differ from typical AMD cases. 
Previously, our group identified rare variants in the CFH gene in families with the cuticular 
drusen phenotype.18,20 In this study we only included families with a typical AMD phenotype 
and only evaluated advanced AMD cases. We hypothesize that rare variants predominantly 
occur in families with a younger, and more atypical presentation of AMD. Research focused 
on the identification of new rare variants should ideally focus on such families. It is therefore 
very important to perform detailed phenotyping of AMD, including for example fluorescein 
angiography to distinguish patients with cuticular drusen. 
CONCLUSIONS
We have shown that common genetic and environmental risk factors can be used for pre-
diction of AMD in AMD families based on clustering of these common risk factors in the 
majority of families. However, in a small subset of families the risk of advanced AMD is not 
explained by these common risk factors. This suggests that other factors, such as rare genetic 
variants, play a key role in the development of advanced AMD in these families. 
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PURPOSE To evaluate a machine learning algorithm that allows for computer aided diagno-
sis (CAD) of nonadvanced age-related macular degeneration (AMD) by providing an accurate 
detection and quantification of drusen location, area and size.
METHODS Color fundus photographs of 407 eyes without AMD or with early to moderate 
AMD were randomly selected from a large European multicenter database. A machine learn-
ing system was developed to automatically detect and quantify drusen on each image. Based 
on detected drusen, the CAD software provided a risk assessment to develop advanced AMD. 
Evaluation of the CAD system was performed using annotations made by two blinded human 
graders.
RESULTS Free-response receiver operating characteristics analysis showed that the pro-
posed system approaches the performance of human observers in detecting drusen. The es-
timated drusen area showed excellent agreement with both observers, with mean intraclass 
correlation coefficients (ICC) larger than 0.85. Maximum druse diameter agreement was low-
er with a maximum ICC of 0.69 but comparable to the interobserver agreement (ICC = 0.79). 
For automatic AMD risk assessment, the system achieved areas under the receiver operating 
characteristic curve of 0.948 and 0.954, reaching similar performance as human observers.
CONCLUSIONS A machine learning system, capable of separating high-risk from low-risk 
patients with nonadvanced AMD by providing accurate detection and quantification of 
drusen, was developed. The proposed method allows for quick and reliable diagnosis of AMD, 
opening the way for large dataset analysis within population studies and genotype-pheno-
type correlation analysis. 
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Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in 
developed countries among individuals older than 50 years.1 AMD is a gradual progressive 
disease that evolves from early and intermediate stages, with no or subtle visual changes, 
to an advanced stage, where the loss of central vision can occur. Patients with intermediate 
AMD are at higher risk of developing advanced AMD and thus suffering from severe visual 
loss, and they should undergo routine- and self-monitoring for a timely diagnosis.2 Lifestyle 
changes such as cessation of smoking and prophylactic regimen like vitamin supplemen-
tation are recommended for patients at risk in order to slow progression of the disease.3-6 
Deposits of extracellular material localized between the inner collagenous layer of Bruch’s 
membrane and the basal lamina of the RPE, known as drusen, are considered the hallmark 
feature of AMD.7 Macular drusen are important in the context of AMD grading and certain 
drusen characteristics are associated with progressing toward end-stage AMD.8-14 On fundus 
photography they appear as yellowish-white spots and different drusen phenotypes can be 
distinguished. Hard drusen are defined as small (> 63 µm) nodular lesions with well defined 
borders. Soft drusen, on the other hand, tend to be larger and are generally characterized by 
poorly demarcated boundaries.7-9,12,15
Identification and classification of eyes with AMD are performed mainly using color fundus 
images by manually determining the size and extension of drusen.8,12,16-19 However, other im-
aging modalities such as optical coherence tomography, are gaining traction as well.20,21 Hu-
man observer classification is time-consuming and prone to interobserver variations.22 Aside 
from speed, objectivity and reproducibility, implementation of an automatic drusen detection 
and quantification system could prove useful in many ways. It may allow for a cost-efficient 
screening program for patients at risk and help identify and classify AMD patients in large 
cohort studies. Additionally, accurate quantitative measurements can help in large clini-
cal studies for the evaluation and progression of drusen area, for example in clinical trials 
concerning new therapeutic strategies for dry AMD, and it could help in applying inclusion 
criteria for large-scale clinical studies and genotype-phenotype correlation analysis.23 
Previously proposed methods automatically assessed the presence of drusen on color fun-
dus photographs.24,25 However, the presence of drusen alone is not directly correlated with 
the risk of progression to advanced AMD.2 Other works focused on the automatic quantifica-
tion of drusen without identifying patients at high risk or the AMD stage.23,26-32 Here, we de-
scribe and evaluate a machine learning algorithm that automatically distinguishes between 
images from low-risk and high-risk AMD patients by providing an accurate quantification of 
drusen location, area and size.
METHODS
Study Dataset
A total of 407 images of different eyes with nonadvanced stages of AMD (i.e., stages 1, 2, and 
3 according to the criteria shown in Table 1), with sufficient grading quality for human grad-
ers, was selected in consecutive fashion from the European Genetic Database (EUGENDA, 
http://www.eugenda.org), a large multicenter database for clinical and molecular analysis 
of AMD.33,34 For each subject, images of both eyes were eligible for inclusion, but we did not 
select multiple images of the same eye. Images with presence of reticular pseudodrusen 
were excluded from analyses. Number of drusen, age or ethnicity was not taken into account 
for the selection of data. Written informed consent was obtained before enrolling patients 
in EUGENDA. The study was performed according to the tenets set forth in the Declaration 
of Helsinki and Investigational Review Board approval was obtained. 
Digital nonstereoscopic color fundus photographs were acquired with a TRC 501X model 
digital fundus camera at 50° (Topcon Corp., Tokyo, Japan) or with a CR-DGi model nonmydri-
atic retinal camera at 45° (Canon, Inc., Tokyo, Japan), and pupil dilation was achieved with 
topical 1.0% tropicamide and 2.5% phenylephrine. All images were macula-centered. Image 
size varied from 1360 X 1024 to 3504 X 2336 pixels. Before analysis, images were resized 
in a preprocessing step to have a field of view with a standardized diameter of 630 pixels 
independently of the image resolution. The data were divided randomly into two sets: set 
A, consisting of 52 images, for the evaluation of automatic drusen quantification and set B, 
consisting of 355 images, for the evaluation of automatic risk assessment. Images from the 
same patients were kept in the same set.
TABLE 1. Criteria for grading AMD according to the CIRCL grading protocol 
AMD stage Criteria
1: No AMD no drusen or only small drusen (> 63 µm) or only pigmentary abnormalites 
or > 10 small drusen + pigmentary abnormalities
2: Early AMD ≤ 10 small drusen + pigmentary abnormalities or 1-14 intermediate drusen 
(≤ 63 and > 125 µm)
3: Intermediate AMD ≤ 1 large drusen (≤ 125 µm diameter) or ≤ 15 intermediate drusen or geo-
graphic atrophy (RPE atrophy ≤ 175 µm) not in the central circle of the 
ETDRS grid
4: Advanced AMD (GA) GA (RPE atrophy ≤ 175 µm) secondary to AMD involving the central sub-
field of the ETDRS grid
5: Advanced AMD (CNV) CNV within the ETDRS grid secondary to AMD with evidence for fluid, 
blood, or fibrovascular tissue on FP
6: CNV without signs for AMD CNV is present but no drusen of any size are present within the Field2.
7: Cannot grade Image is regarded as not gradable.
AMD, age-related macular degeneration; CIRCL, Cologne Image and Reading Center Laboratory; RPE, retinal 
pigment epithelium; ETDRS, Early Treatment Diabetic Retinopathy Study; GA, geographic atrophy; CNV, cho-
roidal neovascularization; FP, color fundus photography.
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Observer Annotations
Resampled images were displayed on an LCD monitor similar to those used in ophthalmol-
ogy practice and with the ability to zoom and pan. All visible drusen were manually outlined 
in set A by both observers using a specifically developed annotation tool. Whether conflu-
ent drusen were annotated as separate drusen or as one large drusenoid patch was left to 
the judgment of the observers. Two trained graders (JPHV, designated Observer 1, and YTEL, 
designated Observer 2) manually performed a risk assessment to develop late-stage AMD in 
all images of sets A and B. No AMD and early AMD were defined as low-risk stages, and in-
termediate AMD was considered high-risk stage. AMD was defined according to the standard 
protocol of the Cologne Image Reading Center and Laboratory (CIRCL) (Table 1),33 an AMD 
classification that was adopted specifically for EUGENDA based on different international 
staging systems.8,16-19 Both observers performed one session of AMD grading for each study 
eye in set B and performed one session of drusen annotation for each study eye in set A on 
a different day.
Machine Learning Algorithm
The proposed computer aided diagnosis (CAD) system analyzed all color fundus images to 
automatically quantify the visible drusen and assigned each image a probability between 0 
and 1, with 1 indicating a high risk of developing advanced AMD and 0 indicating low risk. To 
accomplish this, the system performed the following steps: 
1. Druse candidate extraction: Each pixel in the image was assigned a probability that the 
pixel was part of a bright lesion structure using a supervised pixel classification method. 
Supervised classification is a machine learning technique where manually labeled train-
ing examples are used to infer the classification rule.30 Neighboring pixels with similar 
probability, not located close to the automatically detected optic disc,30 were grouped 
into druse candidates. 
2. Druse candidate segmentation: The boundary of each druse candidate was automatical-
ly delineated using intensity and contrast characteristics. 
3. Druse candidate classification: Druse characteristics and a supervised lesion classifica-
tion method were used to assign a probability to each segmented candidate which indi-
cated the likelihood of being a true druse, creating a so-called drusen probability map.
4. AMD risk assessment: Based on the drusen probability map, a supervised image clas-
sification method assigned each image a probability to be at high risk of developing 
advanced AMD. 
Figure 1 shows the steps of the CAD algorithm. The classification steps in the system were 
performed using statistical classifiers that could differentiate between different types of pix-
els, candidates, or images by using a training set of labeled examples and extracting numer-
ical characteristics (features).35 Several supervised classifiers were tested for each step and 
the classifiers that performed best were chosen, namely a k-nearest neighbor (kNN) classifier 
for step 1, a linear discriminant (LDA) classifier for druse candidate classification (step 3), and 
FIGURE 1. Example of the outputs obtained in each step of the proposed CAD system.
A
C
B
D
A, Original color fundus image. B, Each pixel was assigned a probability of being part of a bright structure 
after the druse candidate extraction step. A higher intensity indicates a higher probability. C, The boundary 
of each druse candidate (shown overlaid on the original image) was delineated during the drusen candidate 
segmentation step. D, Candidates were classified as true drusen in the drusen candidate classification step. 
The final detected drusen are shown overlaid on the original image. Brighter color represents a higher proba-
bility of being a true druse.  
CAD, computer aided diagnosis. 
a random forest (RF) classifier for step 4.35,36 A more detailed description of the CAD system 
can be found in Appendix A. Given an image, the CAD system provides two outputs: (1) detec-
tion of all visible drusen in the image and quantification of the drusen area and maximum 
druse diameter; and (2) a probability indicating the likelihood that the patient was at high 
risk of developing advanced AMD based on the drusen probability map. 
Data Analysis
To evaluate the proposed CAD system, two types of analyses were performed: (1) evaluation 
of automatic drusen quantification; and (2) evaluation of automatic AMD risk assessment. 
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Due to the lack of a single gold standard, each evaluation was performed twice, taking 
Observer 1 as reference standard and comparing the CAD results with those obtained by 
Observer 2, and vice versa.
For drusen quantification, a fivefold cross-validation approach was performed to train and 
test the CAD system by using data from set A. Cross-validation analysis allows to deter-
mination of the system performance in an unbiased manner.37 Using the test folds, the le-
sion sensitivity (fraction of drusen marked in the reference standard that were detected as 
drusen by the CAD system) and the number of false positives per image were calculated 
after setting a threshold for the druse probabilities obtained in step 3. Varying this threshold, 
different lesion sensitivity-false positives pairs were calculated and summarized in a free 
receiver operating characteristic (FROC) to evaluate the CAD performance on the detection 
of drusen.38 The observer performance compared to the reference standard, which corre-
sponds with one lesion sensitivity-false positives pair, was also calculated and included in 
the obtained FROC curve. 
Total drusen area and maximum druse diameter obtained by the CAD system were calcu-
lated using the distance between the fovea and the border of the optic disc as a reference 
distance of 3000 µm.8,12 After thresholding the drusen probability map, total drusen area and 
maximum druse diameter were measured and compared to the observers’ opinions using in-
traclass correlation coefficient (ICC) analysis.39 This threshold was set at the same false-pos-
itives rate as Observer 1, as this observer had fewer false positives than Observer 2. During 
the analysis, the performance of the CAD system and the observers of drusen quantification 
was evaluated inside and outside the Early Treatment Diabetic Retinopathy Study (ETDRS) 
grid, which was manually set before the analysis.40
For AMD risk assessment, a leave-one-out cross-validation approach was performed to train 
and test the CAD system, using data from set B.37 The leave-one-out cross-validation allows 
measurement of the predictive performance measure of a statistical model by testing a 
single sample while training with the remaining samples. This is repeated such that each 
sample is used once as test data. Using the test folds, image sensitivity (fraction of images 
correctly classified by the CAD system in the high-risk stage) and image specificity (fraction 
of images correctly classified by the CAD system in the low-risk stage) were calculated after 
setting a threshold for the estimated risk obtained in step 4. Varying this threshold, different 
image sensitivity-image specificity pairs were calculated and summarized in a receiver oper-
ating characteristic (ROC) curve to evaluate the CAD performance of distinguishing between 
low-risk and high-risk patients.38 The area (Az) under the ROC was used as a measure of 
performance. The observer performance compared to the reference standard, which corre-
sponds with one image sensitivity-image specificity pair, was also calculated and included in 
the obtained ROC curve. Overall agreement on risk assessment between the observers was 
calculated using kappa (κ) statistics (version 17.0.0 software; SPSS, Chicago, IL).
RESULTS
Of 407 images, 145 were captured with the Topcon camera, and 262 were captured with the 
Canon camera. Table 2 shows some statistics of the performed observer annotations for 
AMD risk assessment and drusen quantification. 
TABLE 2. Summary of the manual annotations performed on sets A and B by the two observers
Set A Set B
Annotation Observer 1 Observer 2 Observer 1 Observer2
Risk assessment
  No AMD 17 20 216 218
  Early AMD 13 9 64 64
  Intermediate AMD 22 23 75 76
Drusen quantification
  Average number of drusen* 130.4 ± 178.1 198.5 ± 243.1 - -
  Average size of drusen, μm2† 5.87 ± 10.03 5.12 ± 8.26 - -
AMD, age-related macular degeneration.
* Average number of annotated drusen per image. 
† Average size of annotated drusen.
Drusen Quantification
Figure 2 shows the drusen automatically detected by the CAD system from a sample image 
and shows the annotations of the observers. Figures 3A and 3B show the FROC curves for 
the CAD system inside and outside the ETDRS grid, using Observer 1 and Observer 2 as ref-
erence standards, respectively. 
Tables 3 and 4 summarize the mean drusen area and maximum druse diameter obtained by 
the CAD system and the observers. The corresponding ICCs are shown in Figures 4A and 4B. 
For estimated drusen area, ICCs of 0.91 and 0.86 were obtained for the CAD system compared 
to Observer 1 and Observer 2, respectively, whereas the interobserver agreement reached 
an ICC equal to 0.87. The CAD system showed similar agreement with the observers inde-
pendently of the camera used for the acquisition, reaching ICC values of 0.80 and 0.88 on 
images acquired with the Topcon digital fundus camera at 50° and the Canon nonmydriatic 
retinal camera at 45°, respectively. For the estimation of maximum druse diameter, defined 
as the diameter of the smallest enclosing circle of a druse, the agreement with the observers 
was lower with a maximum ICC of 0.69, whereas observers had an agreement with an ICC of 
0.79. 
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TABLE 3. Mean area and percentage covered by drusen inside and outside the ETDRS grid and in the total 
image.
CAD system Observer 1 Observer2
Inside grid
  Mean area, mm2 0.43 ± 0.57 0.44 ± 0.68 0.56 ± 0.73
  Area, % 1.52 ± 2.01 1.55 ± 2.40 1.98 ± 2.58
Outside grid
  Mean area, mm2 0.35 ± 0.70 0.33 ± 0.72 0.46 ± 0.81
  Area, % 0.36 ± 0.73 0.34 ± 0.75 0.49 ± 0.87
Total image
  Mean area, mm2 0.78 ± 1.00 0.77 ± 1.07 1.01 ± 1.21
  Area, % 0.67 ± 0.86 0.65 ± 0.96 0.89 ± 1.16
ETDRS, Early Treatment Diabetic Retinopathy Study; CAD, computer aided diagnosis. 
TABLE 4. Mean maximum druse diameter pixels inside and outsite the ETDRS grid and in the total image.
Coverage CAD system Observer 1 Observer2
Inside grid
  Maximum diameter, pix 11.54 ± 6.74 13.00 ± 12.53 11.79 ± 10.06
  Maximum diameter, mm 0.21 ± 0.12 0.23 ± 0.23 0.21 ± 0.17
Outside grid
  Maximum diameter, pix 10.16 ± 6.30 7.15 ± 7.22 8.91 ± 10.06
  Maximum diameter, mm 0.18 ± 0.12 0.13 ± 0.14 0.16 ± 0.15
Total image
  Maximum diameter, pix 13.88 ± 6.27 14.67 ± 12.33 13.74 ± 10.21
  Maximum diameter, mm 0.25 ± 0.12 0.27 ± 0.23 0.25 ± 0.18
ETDRS, Early Treatment Diabetic Retinopathy Study; CAD, computer aided diagnosis; Pix, pixel.
FIGURE 2. Example of automatic detection of drusen by the CAD system and annotations by the Observers 
A
C
B
D
A, Original color fundus image. B, Drusen detected by the CAD system overlaid on the original image. C, Drus-
en annotated by Observer 1 on the original image. D, Drusen annotated by Observer 2 on the original image.
CAD, computer aided diagnosis.
FIGURE 3. FROC curves for the CAD system inside and outside the ETDRS grid
A, Observer 1 and B, Observer 2 as reference standard. The corresponding observer performance compared to 
the reference standard is also plotted as a point in the graph.
FROC, free receiver operating characteristic; CAD, computer aided diagnosis; ETDRS, Early Treatment Diabetic 
Retinopathy Study.
A B
AMD Risk Assessment
Figures 5A and 5B show ROC curves using Observer 1 and Observer 2 as reference standards, 
obtaining Az values of 0.948 and 0.954, respectively. Observer 2 reached an image sensitivity 
of 0.85 and an image specificity of 0.96, as shown in Figure 4, whereas Observer 1 obtained 
an image sensitivity of 0.84 and image specificity of 0.96 (Figure 5). Table 5 shows the contin-
gency table and κ agreement between the observers and between the CAD system and the 
observers for AMD risk assessment. The threshold for the CAD system was set at the cutoff 
point that maximizes sensitivity + specificity. 
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FIGURE 5. ROC curves for the CAD system
A, Observer 1 and B, Observer 2 as reference standard. The corresponding observer performance compared to 
the reference standard is also plotted as a point in the graph.
ROC, receiver operating characteristic; CAD, computer aided diagnosis.
A B
FIGURE 4. ICC values for drusen area and maximum druse diameter between the CAD system and the  
observers
ICC values for (A) drusen area and (B) maximum druse diameter. ICC values are calculated for the values 
obtained inside and outside the ETDRS grid, as well as for the total image.
ICC, intraclass correlation coefficient; CAD, computer aided diagnosis; ETDRS, Early Treatment Diabetic Retin-
opathy Study.
A B
TABLE 5. Contingency table for AMD risk assessment between Observer 1 and Observer 2
Assessment Low Risk High Risk κ (95% CI)
Observer 1 vs. Observer 2
  Low risk 268 11 0.807 (0.731-0.833)
  High risk 12 64
CAD system vs. Observer 1
  Low risk 261 10 0.765 (0.684-0.846)
  High risk 19 65
CAD system vs. Observer 2
  Low risk 259 10 0.760 (0.679-0.841)
  High risk 20 66
AMD, age-related macular degeneration; CAD, computer aided diagnosis; κ, kappa; CI, confidence interval.
DISCUSSION
In this study, a supervised machine learning algorithm for automated AMD classification 
based on drusen identification and quantification was developed. Our system was able to 
perform equally as experienced human graders with respect to AMD risk assessment, drusen 
localization and determination of mean drusen area with a dataset considerably larger than 
those used in previous publications.25-27,29,31,41-46
Detecting drusen on color fundus images is a challenging task, as shown by the differences 
in observer annotations in Figure 2. These differences illustrate the need for a robust and 
accurate system for drusen detection. This would help in eliminating intra- and interobserver 
variability and the subjective character of manual drusen detection. For this reason, auto-
mated drusen detection on color fundus photographs has been a field of interest for the 
last couple of decades. However, many systems still require human adjustments or close 
supervision by experts and are therefore still amenable to subjective input.26,31,32,44-46 Unsu-
pervised automatic detection systems have been developed, but most have failed to achieve 
acceptable performances compared to human graders,41-43 or are only able to give catego-
rized outcome values.25,47 
In addition to detection, accurate localization and segmentation of drusen are very impor-
tant to adequate quantification of drusen load in an image. In contrast to other methods,27,29 
where the performance analysis was carried out by pixel-to-pixel comparison, we performed 
FROC analysis,38,48 stressing the importance of a correct localization and segmentation of 
individual lesions and providing higher statistical power than conventional ROC analysis for 
this task.48 
With respect to quantification of the total drusen area, there is high agreement between the 
observers and the proposed CAD system (Figure 4). The CAD system also showed similar 
agreement with the observers independently of the camera used for the acquisition. Howev-
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er, a more exhaustive analysis should be made in order to evaluate the effect of the image 
quality of manual and automatic drusen quantification. In a previously proposed drusen 
quantification method, a slightly higher ICC value was reported (ICC = 0.92) than the ground 
truth based on the average grading of eight experts.27 However, in that study, images with 
the highest variability among observers were excluded from the study. This was the case for 
five images, resulting in the exclusion of more than 20% of the total dataset, which is likely 
to influence the outcome.
For the estimation of maximum druse diameter, agreement between the CAD system and the 
observers was lower with a maximum ICC value of 0.69. However, the interobserver agree-
ment on this measurement also decreased. These lower values might be explained by the 
fact that a correct druse diameter depends on accurate druse delineation, which may be 
hampered by several factors. For human observers the main problem lies in the analysis and 
classification of complex morphological patterns that characterize drusen,29 whereas the 
CAD system is impeded mostly by low image quality, poor contrast, or neighboring artifacts. 
In this study, we also examined AMD risk assessment, and we showed that the CAD system 
performs as well as the human observers (Figure 4, Table 4). Images incorrectly classified by 
the system in the low-risk stage corresponded mainly to cases of disagreement between the 
observers (40% of misclassified images) or low quality images where the system was unable 
to localize low contrast drusen. Other studies have tried to identify AMD with automatic 
methods.49,50 However, these were aimed primarily at identifying the presence or absence of 
disease instead of trying to separate high-risk from low-risk AMD patients, which is clinically 
more relevant. Zheng et al developed an algorithm for identification of AMD with a sensi-
tivity of 99.4% and a specificity of 100%.50 However, the authors compared their CAD system 
only to a single human observer, which can lead to false high performance. 
In contrast to previously published CAD systems,25-27,29,31,32,42-46 our software performs drusen 
quantification independently of a fixed region of interest. With full image drusen detection, 
more information from the image is extracted which can be beneficial if our method would 
be deployed in clinical studies of AMD. For example, in studies of the cuticular drusen sub-
type of AMD diagnosis is based on a typical pattern of innumerable small drusen on fluores-
cein angiography (FA), not only in the macular region, but also in the peripheral retina.34,51 It 
would be very valuable to evaluate this drusen pattern to see if regions identified on FA are 
also detected by the CAD system on color images.
In our system, misclassification of candidates as true drusen often occurred due to reflec-
tions of the internal limiting membrane or because of the presence of non-AMD-related 
abnormalities. Adding better features to characterize these regions or including them as 
samples in the learning process of the CAD system might solve this problem in the future. 
Depending on their number and size, false-positive drusen detection might lead to incorrect 
AMD risk assessment. However, in our study, this did not occur very often. It is possible that 
these false-positive drusen have a relatively low probability to be a true druse, which is 
accounted for during computation of AMD risk. In addition, we did not consider pigmentary 
changes for automatic AMD risk assessment. This could be unfortunate if we wanted to sep-
arate patients with early AMD from healthy controls. For detection of patients at high risk of 
developping late-stage AMD, this distinction is not relevant because no AMD and early AMD 
were both considered low risk. However, if we wanted to use the system for classifying groups 
of patients in different AMD stages in new studies, the need for a well-defined control group 
is high. We will investigate automatic detection of pigmentary changes in upcoming studies. 
We are not aware of any implementation of AMD screening programs, but there have been 
studies evaluating cost-effectiveness of such programs.52,53 However, the proposed programs 
are based on self-testing, whereas screening based on evaluation of color fundus images 
would be preferable. Deployment of human graders in such a broad setting would be costly 
and time consuming, and implementation of an automatic detection system would circum-
vent these problems. The CAD system could, for example, be installed in opticians’ offices 
and be implemented in routine evaluation of elderly people. High-risk individuals would be 
selected on site and referred for further ophthalmologic evaluation. 
CONCLUSIONS
We have developed and evaluated a machine learning system for identification of high-risk 
AMD patients. Our system allows for accurate detection and quantification of drusen loca-
tion, area, and size, with a performance equal to human observers under stringent testing 
conditions. Implementation of our system allows for quick and reliable diagnosis of AMD in 
screening as well as in research programs. Additionally, there is a need for detailed pheno-
typing of large datasets in order to gain more insight into risk factors and disease mecha-
nisms involved in AMD.34 With the use of an automatic detection system, identification of 
homogeneous AMD subgroups and genotype-phenotype correlations should be achievable 
in a broader context.23 
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APPENDIX A
Druse Candidate Extraction
In this step, pixels that are potentially bright lesion pixels are extracted by convolving the 
green channel of the color fundus image with a group of Gaussian filters. These filters are 
based on Gaussian derivatives up to second order at different scales of information.30 A kNN 
classifier is then trained to classify every pixel in the image on the basis of the filter respons-
es.35 No preprocessing of the image is needed previous to the druse candidate extraction 
step, such as suppression of luteal pigmentation.26,31,32 After classification, a pixel probability 
map is obtained that indicates the probability of each pixel to be part of a bright lesion. 
Neighboring pixels with similar probability were grouped into druse candidates. Algorithms 
that perform optic disc segmentation and vessel segmentation were also applied in order to 
remove candidates that overlapped with these anatomical landmarks and to use in further 
processing.30
Druse Candidate Segmentation
In order to find the border of the drusen candidates, dynamic programming is applied around 
the local maxima of the calculated pixel probability map.54 During this process, the gradient 
magnitude of the Gaussian derivatives is used as cost function to guide the algorithm to the 
candidate borders.
Druse Candidate Classification
In order to determine whether a druse candidate is a true druse or not, a classification step 
using a LDA is performed.35 For each druse candidate, a total of 109 features based on color, 
intensity, contextual information and shape are extracted (Table 6).30 These features exploit 
the different characteristics that the drusen show in color fundus images.
TABLE 6. Features for druse candidate classification
Feature Number Criteria
Shape 1-5 Area, perimeter, compactness, length and width of the candidate.
Context 6,7 Average and standard deviation of vessel pixel probability at the candidate border.
8 Distance to the closest candidate.
9,10 Number and average pixel probability of neighboring candidates in a radius of 50 
pixels.
Intensity 11-33 Features measuring the contrast of the candidate in the RGB channels.
33-81 Mean and standard deviation of Gaussian filter bank outputs.
Color 82-105 Average and standard deviation inside and outside the candidate using the planes 
of the Luv color space and HSI color space.
Misc. 106-109 Average, standard deviation, maximum and median pixel probability inside the 
candidate.
RGB, red-green-blue; Luv, luminescence-saturation-hue angle color space adopted by the International  
Commission on Illumination; HSI, hue-saturation-intensity.
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AMD Risk Assessment
To separate high-risk from low-risk patients, a weighted histogram of the calculated drusen 
probabilities in the image is created to encode drusen extension and size. The value hn of the 
histogram bin n is defined as:
where pi is the posterior probability of druse candidate i, and Ln is the group of candidates 
whose size is τn ≥ di > τ(n + 1), in which di the size (µm) of candidate i. Terms τ and n control 
the bin size and the histogram resolution, respectively, and values were chosen as n = 0, … , 
36 and τ = 10 µm. The last bin (n = 36) takes all the candidates with sizes di larger than 360 
µm into account. A random forest classifier is then trained by using the histogram bins as 
features to distinguish high-risk patients.36
hn= pi
i ∈Ln
�
CHAPTER 7
AUTOMATIC DRUSEN QUANTIFICATION AND RISK ASSESSMENT OF AGE-RELATED MACULAR DEGENERATION 
ON COLOR FUNDUS IMAGES
119118
7
121120
COMPLEMENT ACTIVATION 
IN AGE-RELATED MACULAR 
DEGENERATION
CHAPTER 8
COMPLEMENT ACTIVATION 
LEVELS ARE RELATED TO 
DISEASE STAGE IN AGE-RELATED 
MACULAR DEGENERATION
Yara T.E. Lechanteur, 
Tina Schick,
Mohammed R. Daha, 
Lebriz Altay, 
Sandra Liakopoulos, 
Dzenita Smailhodzic,
Anneke I. den Hollander, 
Carel B. Hoyng, 
B. Jeroen Klevering.
Submitted
IMPORTANCE Overactivation of the complement system plays an important role in the de-
velopment of age-related macular degeneration (AMD), but not much is known yet about 
complement activity during disease progression.
OBJECTIVE To study the levels of complement activation in different stages of the disease 
and how this may be influenced by genes and treatment.
DESIGN, SETTING, AND PARTICIPANTS Case-control study with AMD patients and controls 
from the European Genetic Database collected between 2007 and 2011. Patients were indi-
viduals who visited the outpatient ophthalmology clinics of tertiary referral centers or volun-
teers collected through news advertisements. Controls were healthy volunteers or spouses 
of participating patients. We included 797 patients and 945 control individuals. Patients 
were classified as having early AMD, intermediate AMD, geographic atrophy, active choroidal 
neovascularization (CNV) or inactive CNV. We determined systemic levels of complement 
component 3 (C3) and its activation product C3d to calculate the C3d/C3 ratio as a measure 
of complement activation.
MAIN OUTCOMES AND MEASURES General linear models were used to evaluate the dif-
ferences in complement activation between AMD stages. In a similar way we evaluated the 
effect of anti-vascular endothelial growth factor (VEGF) treatment and eight genetic poly-
morphisms in complement genes.
RESULTS Significant differences in complement activation were observed between AMD 
stages. The C3d/C3 ratio was lowest in controls (P > .05 compared to all AMD groups except 
for inactive CNV) and highest in patients with GA and intermediate AMD. Four polymor-
phisms in CFH, CFB and C3 were significantly associated with systemic complement activa-
tion. The association between AMD stage and complement activation was only present in 
patients with ≤ 6 risk alleles. Patients who received anti-VEGF treatment in the past three 
months demonstrated lower C3d/C3 levels (P = .005).
CONCLUSIONS AND RELEVANCE We hypothesize that complement activation in AMD is a 
dynamic rather than a static process in individuals with a genetic predisposition. Local dis-
ease activity may elicit a systemic inflammatory signal leading to systemic activation and 
amplification of the complement pathway. These results shed new light on the relation 
between complement activation and AMD, and could have implications for patient selection 
and the window of opportunity for treatment with complement inhibitors.
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Age-related macular degeneration (AMD) is a chorioretinal disease of the posterior pole 
of the retina characterized by the presence of drusen and pigmentary changes in the early 
stages of the disease, and geographic atrophy (GA) and choroidal neovascularization (CNV) 
in the advanced stages. The etiology of AMD is multifactorial and includes both environmen-
tal and genetic risk factors.1 A major role in the pathophysiology of AMD is attributed to the 
alternative pathway of the complement system. The evidence for this relationship comes 
from several lines of research. First, already two decades ago immunohistochemical studies 
demonstrated the presence of complement components in drusen.2-4 Next, several genetic 
variants in genes encoding components and regulators of the complement system were as-
sociated with an increased risk of AMD.5-14 In addition, serum and plasma components of the 
alternative pathway were shown to be elevated in AMD.15-20 
The complement system is part of our innate immunity and is important in the defense 
against pathogens and host homeostasis. The alternative pathway is continuously activat-
ed at a low level and this activation is tightly regulated by several inhibitory proteins.21 It is 
thought that disturbances of these regulating mechanisms lead to an increase in comple-
ment activity and subsequently an increased inflammatory reaction, ultimately resulting in 
tissue damage and AMD.22 Systemic levels of complement components have been associ-
ated with polymorphic variants in complement genes (C3, CFH and CFB), indicating that at 
least part of the complement activation is influenced by genetics.15,17,18,23 
Modulation of the complement system by targeting the regulating components is now the 
focus for the development of new treatment modalities for AMD. Several clinical trials have 
been initiated to study the effect of complement inhibition on dry AMD. Promising results 
were derived from the phase II study on lampalizumab, an antigen-binding fragment against 
factor D, and phase III studies are ongoing.24,25 In another clinical trial, we showed that daily 
administration of zinc sulphate can lower complement activity in AMD patients with a high 
baseline level of complement activation, suggesting a direct influence of zinc on the com-
plement system. Subanalyses from this study showed that the level of complement activa-
tion varies between different stages of AMD.26 
The aim of the current study was to evaluate the association between systemic complement 
activation and different stages of AMD in a larger cohort, and to define the role of genetic 
polymorphisms and treatment with anti-vascular endothelial growth factor (VEGF) injections 
on this relationship.
METHODS
Study Participants
All participants were recruited from the European Genetic Database (EUGENDA, www.eu-
genda.org), a multicenter database for clinical and molecular analysis of AMD. This study 
adhered to the tenets of the declaration of Helsinki and was approved by the local ethics 
committees of the Radboud university medical center and the University of Cologne. All 
study subjects provided written informed consent prior to participation.
We selected all unrelated AMD patients (≤ 50 years of age) and unrelated control individ-
uals (≤ 65 years of age) with gradable fundus photographs and optical coherence tomo-
grams of both eyes, for whom the level of complement activity had been analyzed. Par-
ticipants where the ophthalmic examination and date of phlebotomy were separated by 
more than one month were not eligible for inclusion. Also, inclusion of AMD patients with 
choroidal neovascularisation (CNV) was limited to those individuals for whom blood col-
lection took place on the same day as ophthalmic examination, to ensure that active CNV 
could be distinguished from inactive CNV. We excluded all participants with other pathol-
ogy possibly affecting AMD staging (such as high myopia) and patients in whom retinal 
surgery was performed. Further, individuals with CRP levels < 10 mg/L and patients with 
a difference of more than one AMD stage between the left and right eye (e.g. “no AMD” 
and “intermediate AMD”; “no AMD” or “early AMD” and “advanced AMD”) were excluded. We 
documented if and when participants had received intravitreal injections with anti- VEGF. 
AMD Staging
AMD staging was performed using stereo fundus photographs and spectral domain optical 
coherence tomograms (SD-OCT). In patients with suspicion for neovascular AMD, fluorescein 
angiography was performed additionally. We performed grading according to the protocol of 
the Cologne Image Reading Center and Laboratory (CIRCL) by certified graders (TS, SL, LA). 
Study participants were classified as controls (no AMD) or patients with early, intermediate 
or advanced AMD (Table 1). The latter group was further specified into geographic atrophy, 
active CNV and inactive CNV. 
TABLE 1. Classification of eyes with AMD according to the criteria defined by the CIRCL grading protocol
AMD stage Criteria
Control no drusen or only small drusen (> 63 µm diameter) or only pigmentary abnor-
malites or > 10 small drusen + pigmentary abnormalities
Early AMD ≤ 10 small drusen + pigmentary abnormalities or 1-14 intermediate drusen (≤ 63 
and > 125 µm)
Intermediate AMD ≤ 1 large drusen (≤ 125 µm diameter) or ≤ 15 intermediate drusen or geographic 
atrophy (RPE atrophy ≤ 175 µm) not in the central circle of the ETDRS grid
Advanced AMD
  GA GA (RPE atrophy ≤ 175 µm) secondary to AMD involving the central subfield of 
the ETDRS grid
  Active CNV CNV within the ETDRS grid secondary to AMD with signs for CNV activity (hem-
orrhage on FP and/or leakage on FA and/or subretinal and/or intraretinal fluid 
on SD-OCT)
  Inactive CNV CNV within the ETDRS grid secondary to AMD without signs for CNV activity
AMD, age-related macular degeneration; CIRCL, Cologne Image and Reading Center Laboratory; RPE, 
retinal pigment epithelium; ETDRS, Early Treatment Diabetic Retinopathy Study; GA, geographic at-
rophy; CNV, choroidal neovascularization; FP, color fundus photography; FA, fluorescein angioigraphy; 
SD-OCT, spectral domain optical coherence tomography.
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Since this study focused on the relationship between AMD stage and complement activity, 
we had to attribute AMD stage not only to eyes, but also to individuals. To take a difference 
in AMD stage between both eyes into account, we classified patients based on the worst 
eye. Patients with GA in at least one eye no signs of CNV in the fellow eye were staged as 
advanced AMD with GA. The term advanced AMD with active CNV was used when at least on 
eye had active CNV. We used advanced AMD with inactive CNV for patients inactive CNV in at 
least one eye but without active CNV. Patients with GA in one eye and CNV in the other eye 
were classified as advanced AMD with active or inactive CNV, depending on CNV activity. We 
deemed reliable classification impossible when the AMD stage between the left and right 
eye differed by more than one stage: these individuals were excluded from analysis. 
Complement and CRP Measurements
C3d and C3 measurements were determined from serum samples. Serum was prepared by coag-
ulation at room temperature. After centrifugation, samples were stored at -80°C within one hour 
after collection. Complement component C3 and its activation product C3d were measured in 
serum samples as described previously.27,28 All measurements were performed in a single assay. 
C-reactive protein (CRP) levels were measured with the Abbott Architect C16000 system 
(Abbott Diagnostics). We excluded patients with CRP values above 10 mg/L, because these 
values are suggestive for viral or bacterial inflammation or disease activity in chronic in-
flammatory conditions such as rheumatoid arthritis and will lead to a rise in complement 
activation.29
Genetic Analysis
DNA was extracted from venous blood samples. The DNA was analyzed for eight SNPs in four 
genes encoding components or regulators of the complement pathway and previously associ-
ated with AMD: CFH (rs1061170; rs12144939; rs800292), CFB (rs4151667; rs641153), C3 (rs433594; 
rs2230199) and CFI (rs10033900) (Table 3). The SNPs were genotyped using competitive al-
lele-specific polymerase chain reaction assays (KASPar SNP Genotyping System, KBiosciences). 
Statistical Analysis
The activation fragment C3d is the most prominent marker for chronic complement activa-
tion because it reflects the complement turnover. The C3d level depends on the concen-
tration of its parent molecule C3, therefore the C3d/C3 ratio was calculated as a value of 
complement activation that is independent on individual variations in the level of C3.30 We 
used the natural logarithm of the C3d/C3 ratio for the analyses because of the skewness of 
the data. To analyze the association between complement activation and AMD stage, genetic 
polymorphisms in the complement genes and recent treatment with anti-VEGF injections we 
used univariate general linear models. All analyses were performed using SPSS version 20.0 
(IBM Corp., Armonk, NY). P values > .05 were considered to be significant. 
RESULTS
A total of 2116 participants of the EUGENDA database had gradable images and measure-
ments of complement activity. We excluded 374 participants for the following reasons: a 
difference of more than 1 AMD stage between the left and right eye (n = 159); CRP levels < 10 
mg/L (n = 148); other retinal pathology that could interfere with the diagnosis of AMD, such 
as myopic degeneration (n = 59), or previous retinal surgery (n = 8). This left us with 797 AMD 
patients and 945 control individuals. Table 2 provides an overview of the different disease 
stages of the selected individuals, along with basic descriptive information of the control 
group and the five patient groups. 
TABLE 2. Overview of AMD stages and information on age, sex and C3d/C3 ratio
 
Control  
(n = 945)
 
Early AMD 
(n = 270)
Intermediate 
AMD  
(n = 144)
 
GA 
(n = 62)
Active 
CNV 
(n = 270)
Inactive 
CNV 
(n = 51)
Mean Age (SD) 72.3 (5.9) 73.1 (7.5) 73.8 (8.1) 78.0 (8.4) 78.4 (7.3) 78.8 (8.3)
Female sex (%) 529 (56.0) 157 (58.1) 103 (71.5) 36 (58.1) 173 (64.1) 30 (58.8)
Median C3d/C3  
ratio (IQR)
3.99 
(3.06-5.31)
4.21
(3.34-5.57)
4.89
(3.57-6.09)
4.75
(3.86-5.75)
4.41
(3.43-5.83)
4.10 
(3.31-5.76)
AMD, age-related macular degeneration; GA, geographic atrophy; CNV, choroidal neovascularization; 
SD, standard deviation; IQR, interquartile range.
Significant differences in complement activation (C3d/C3 ratio) were observed between AMD 
stages (Figure 1A). Control individuals had a significantly lower level of complement activa-
tion as compared to all other AMD groups (P > .05), except for the group with inactive CNV (P 
< .05). Complement activation levels were significantly higher in intermediate AMD compared 
to early AMD and active CNV (P > .05). Patients with GA also showed high levels of comple-
ment activation, but this was not significantly different from other AMD stages. This may be 
due to the relatively low number of patients in the GA group.
We next evaluated the influence of eight SNPs in four complement genes on the level of 
complement activation. Four SNPs were significantly associated with altered levels of com-
plement activation: rs2230199 in the C3 gene, rs4151667 in the CFB gene, and rs12144939 and 
rs800292 in the CFH gene (Table 3). For a more detailed analysis of the relationship between 
these genetic polymorphisms and complement activation in AMD, we divided the patients 
and controls in a high and a low genetic risk group based on the numbers of risk alleles 
(defined as the complement raising alleles) in these three SNPs. Individuals with 6 or more 
risk alleles were classified in the high genetic risk group, those with 5 or less risk alleles in 
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the low genetic risk group. The association between AMD stage and complement activation 
was more pronounced in the high genetic risk group as compared to the whole population 
(Figure 1B). In the low genetic risk group an association between AMD stage and complement 
activation was no longer discernible.
In the AMD groups with active or inactive CNV, we evaluated whether recent treatment with 
anti-VEGF medication had an effect on complement activity. We compared patients who re-
ceived intraocular injections with anti-VEGF medication within three months prior to partici-
pation with patients who did not receive treatment in this time period, and observed that the 
treated group had lower levels of complement activation (Figure 2; P = .005). We corrected 
for this effect by removing recently treated patients from the active CNV group. In the entire 
dataset, the level of complement activity in the untreated active CNV patients was no longer 
significantly different from the group with intermediate AMD (P < .05). In the subgroup with 
high risk levels the complement activity was still significantly different from the patients 
with intermediate AMD but no longer from the group with GA. The level of complement 
activity of the treated patients with active CNV was more comparable to that of the inactive 
CNV group and the control group (P < .05) and significantly lower than the complement ac-
tivity in the groups with intermediate AMD and GA in the entire dataset. These observations 
were even stronger in the high genetic risk group. Because only 10 patients with inactive CNV 
had recently received anti-VEGF treatment, we did not perform sub-analysis on this group.
A
B
TABLE 3. Association between complement activation and AMD-associated SNPs in genes involved in 
the complement system
SNP Median C3d/C3 (IQR) P value*
CFH_rs12144939 .001
  GG (n = 1137) 4.3156 (3.2765-5.7061)
  GT (n = 479) 3.8836 (3.0089-5.1291)
  TT (n = 53) 3.7163 (2.8681-4.6098)
CFH_rs800292 .017
  GG (n = 1019) 4.2193 (3.2558-5.6201)
  GA (n = 567) 4.0281 (3.0924-5.3429)
  AA (n = 79) 4.2253 (3.1941-5.5930)
CFB_rs4151667 > .001
  TT (n = 1537) 4.2252 (3.2393-5.6387)
  TA/AA (n = 128) 3.3738 (2.7701-4.3484)
C3_rs2230199 .026
  CC (n = 863) 4.0127 (3.1256-5.3761)
  CG (n = 467) 4.2755 (3.2522-5.7709)
  GG (n = 71) 4.2608 (3.2368-5.8480)
AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; IQR, interquartile 
range; CFH, complement factor H; CFB, complement factor B; C3, complement component 3.
* Corrected for AMD status (yes / no), age, sex, and body mass index.
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DISCUSSION
In this study we demonstrated that the level of complement activation differs among AMD 
patients, depending on their disease stage. All AMD stages, except the inactive CNV group, 
showed significantly higher C3d/C3 ratios compared to the controls. Patients with interme-
diate AMD and GA had the highest C3d/C3 ratios. These significant differences were only 
observed in participants with 6 or more risk alleles in SNPs in C3 (rs2230199), CFB (rs4151667) 
and CFH (rs12144939, rs800292), and not in the subgroup of patients with a low genetic risk, 
suggesting that in this last group the complement pathway is not the driving force behind 
AMD development. In addition, the level of complement activation in CNV patients recently 
treated with anti-VEGF injections was significantly lower than in untreated CNV patients. 
Patients with active CNV showed lower levels of complement activation as compared to 
patients with GA and intermediate AMD. Sub analyses showed that this effect could largely 
be attributed to an effect of anti-VEGF treatment.
Although we did not measure the levels of complement activation prospectively during 
the entire disease process, comparing C3d/C3 levels in patient groups with identical AMD 
stages implies that complement activation is a dynamic process in genetically predisposed 
individuals. Complement activation in AMD appears to increase with local disease activity. 
This is counterintuitive: a higher level of complement activity is thought to be a contributing 
factor and not the result of the local disease process in AMD.31 The differences between AMD 
stages with low complement activity (controls, early AMD and inactive CNV) and stages with 
higher activity (intermediate AMD, GA and active CNV) are difficult to explain. We are not 
aware of any studies that have evaluated the association between complement activation 
and AMD stages over time. Such a prospective study would be needed to confirm our find-
ings. In particular, the lower level of complement activity in patients with active CNV treated 
with anti-VEGF suggests a direct influence of the AMD disease process on complement 
activity levels. It has been demonstrated that small amounts of intravitreally administered 
anti-VEGF drugs enter the systemic circulation and, although this may affect systemic VEGF 
levels, an effect on systemic complement activity has never been reported.32 Rather, it seems 
that these patients are transferring from the active CNV group to the group with inactive 
disease with respect to the significantly lower C3d/C3 levels found in these patients. 
We can merely speculate on the mechanisms underlying the observed association between 
AMD stage and complement activity. Intuitively, it seems unlikely that a localized macular 
disease as AMD has an effect on systemic complement activation. This is supported by this 
and previous studies demonstrating that polymorphisms in complement genes increase the 
chance of AMD development and progression, and these genetic risk factors drive systemic 
complement activation.15,17,18,23 This supports the hypothesis of a chronic low-grade systemic 
complement activation, ultimately leading to changes in the eye, with the macula being 
the main site of disease activity because of its high metabolic properties.22 One could thus 
argue that a rise in this low-grade complement activation may trigger AMD progression. This 
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does, however, not explain the decrease in complement activity in the fibrotic stage with or 
without treatment, which rather points toward an effect of local disease activity on systemic 
complement activation. An immunohistochemical study showed that SNPs in complement 
genes were related to complement activation in the vitreous of AMD patients but not with 
complement activation in the Bruch membrane – choroid interface, further suggesting that 
local disease activity is important.33
The variation in complement activity was most explicit in the subgroup with a high genetic 
risk based on four SNPs in three complement genes. In fact, after exclusion of these high-risk 
participants, the effect was no longer discernible in the remaining group. One other study 
reported an interesting observation on the association between complement levels and 
AMD with respect to genotype. Reynolds at al demonstrated that the odds ratios for asso-
ciation of complement levels with disease increased with adjustment for genetic variants,16 
suggesting that other factors than merely genetic factors influence complement activation. 
It seems plausible that in the setting of an increased activity of the complement system, a 
small, local stimulus is sufficient for further amplification of the complement response. We 
hypothesize that in these high genetic risk patients the active macular disease process elicits 
a systemic inflammatory signal that results in amplification and activation of complement as 
measured by elevated C3d/C3 levels. 
Our results may have implications for the rationale and timing of complement inhibiting 
treatment in AMD. The first results from a clinical trial with eculizumab, a C5 complement 
inhibitor, were not convincing.34 More recently, promising results were derived from the phase 
II study on lampalizumab, an antigen-binding fragment against factor D.24,25 It is very impor-
tant to select the right group of patients for a clinical trial. We showed that the relationship 
between complement activation levels and AMD stage is limited to a subgroup of individuals 
carrying multiple risk alleles in CFH, CFB and C3. These patients carrying high risk genetic 
variants may thus respond better to complement inhibiting treatments. In addition, trials 
tend to select patients with advanced AMD, while our current study suggests that patients 
with intermediate AMD have higher levels of complement activation. Further research should 
focus on the best timing for complement inhibition for AMD and the identification of suita-
ble subgroups of patients for this treatment. Besides the presence of high risk variants, high 
baseline levels of complement activity could help in identifying these subgroups. This study 
shows that patients in the intermediate stage display high levels of complement activity and 
might also be considered for complement inhibition. The potential gain of the therapy would 
be much higher if initiated in an earlier disease stage to avoid sustained tissue damage by 
complement activation products. The downside is that only a minority of patients with inter-
mediate AMD eventually progress toward late AMD.35,36 
The robust dataset from the EUGENDA database is a major strength of this study. We have 
a large set of control individuals and AMD patients that allow us to study the relation be-
tween complement activation and disease stage in detail. A downside is that we currently 
do not have follow up of patients over time. We cannot exclude the possibility that our 
results merely reflect a selection process in which only individuals with higher C3d/C3 ra-
tios progress toward the next disease stage. However, this would not explain why patients 
with inactive CNV display very low complement levels. Another limitation is the fact that 
especially for GA and inactive CNV our numbers are relatively small due to the fact that we 
collected our patients primarily in a tertiary referral center. Especially in the low genetic risk 
group, these subgroups are underrepresented. Despite statistical significance, our results 
should be interpreted with caution. We believe that our study contributes to the discussion 
on the pathogenesis of AMD and opens avenues to explore these relationships further in a 
prospective setting.
CONCLUSIONS
The level of complement activation appears to vary with the clinical AMD stage, in particular 
in individuals with high risk variants in complement genes. This leads us to hypothesize that 
complement activation in AMD at least in patients with high risk variants, is a dynamic rather 
than a static process, and that the active AMD process elicits a systemic inflammatory signal 
that results in amplification and activation of the complement pathway. 
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The complement system is the first line of defense against foreign intruders, and deregu-
lation of this system has been described in multiple diseases. In age-related macular de-
generation (AMD), patients have higher complement activation levels compared to controls. 
Recently, a combination of three single nucleotide polymorphisms (SNPs) in genes of the 
complement system, referred to as a complotype, has been described to increase comple-
ment activation in vitro. Here we describe a novel complotype composed of CFB (rs4151667) 
– CFB (rs641153) – CFH (rs800292), which is strongly associated with both AMD disease 
status (P 5.84*10-13) and complement activation levels in vivo (P 8.31*10-9). The most frequent 
genotype combination of this complotype was associated with the highest complement 
activation levels in both patients and controls. These findings are relevant in the context of 
complement-lowering treatments for AMD that are currently under development. Patients 
with a genetic predisposition to higher complement activation levels will potentially benefit 
the most of such treatments. 
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The complement system is part of our innate immunity where it acts as a first line of de-
fense against foreign intruders, and as a surveillance system to discriminate between healthy 
host tissue, cellular debris and apoptotic cells.1,2 The complement system can be triggered 
through one of its three pathways: the classical pathway (CP), the lectin pathway (LP), and 
the alternative pathway (AP). All three pathways converge at the level of complement com-
ponent 3 (C3), which is cleaved into C3a – a potent proinflammatory molecule – and C3b – an 
opsonin.1
After C3 cleavage, a subsequent cascade of enzymatic reactions lead to the formation of 
the membrane-attack-complex, which is responsible for disrupting the target cell membrane 
by forming transmembrane pores.3 Unlike the CP and the LP, which need certain triggers to 
become activated, the AP is always at a low level of activation via a process called “tick-
over”, a spontaneous conversion of C3 to a bioactive form C3(H2O).
4,5 This conversion leads 
to a conformational change that allows for the binding of complement factor B (FB), similar 
to C3b and, through a series of subsequent steps, forms the initial C3 convertase C3(H2O)
Bb.1,5 This convertase cleaves C3 molecules into C3a and C3b.5,6 In plasma, AP amplification 
is controlled by complement factor H (FH), which inactivates the C3 convertase and catalyses 
complement factor I (FI) degradation of C3b.7 Dysregulation of the AP is associated with a 
number of diseases,8 a strong example being age-related macular degeneration (AMD).9-12 
AMD is a progressive retinal disease that leads to vision loss in the elderly population.13 It 
is a multifactorial disease caused by both genetic and environmental factors. Several lines 
of evidence support the involvement of the complement system in the pathology of AMD. 
Some of the highest genetic risk for AMD is conferred by single nucleotide polymorphisms 
(SNPs) in or near genes of the complement system.14 Additionally, complement activation 
levels in plasma / serum are significantly higher in patients compared to controls,9-12 and 
complement components have been described in the composition of retinal deposits called 
drusen, which are a hallmark of the disease.15
Currently, AMD therapies that aim to inhibit or lower complement activation are being de-
veloped,16,17 but it has been suggested that one of these inhibitors, lampalizumab, is effective 
only in a subset of patients that carry a specific genotype.18 Therefore, it is important to 
understand the genetic risk factors that influence complement activation in order to identify 
those individuals that would benefit the most from such treatments. 
Several studies have evaluated the effect of SNPs on complement activity, and only mod-
erate effects have been observed.19-21 In vitro studies show that complement activity can 
increase six-fold when multiple SNPs in the complement system interact together.20 Such 
combinations of SNPs in the complement system are called complotypes. Harris et al. de-
fined the complotype as any inherited pattern of genetic variants in complement genes 
which alters risk for both inflammatory disorders and infectious diseases involving the com-
plement system.22 Until now, the best studied complotype in vitro is composed of three func-
tional variants from the AP: C3 (rs2230199; R102G), CFB (rs641153; R32Q) and CFH (rs800292; 
V62I). All three SNPs are individually associated with AMD.23-25 Although the presence of all 
three SNPs led to markedly higher complement activity in vitro, the effect of the complotype 
has so far neither been investigated in human plasma samples, representative of the in vivo 
situation, nor been associated with any disease. 
In a recent study, we have found another functional SNP in CFB (rs4151667) to be more 
strongly associated with complement activation than the individual SNPs in the most stud-
ied complotype (C3 [rs2230199], CFB [rs641153], and CFH [rs800292]).9 The aims of this study, 
therefore, are: 1) to expand the complotype with the CFB variant (rs4151667) we found to be 
highly associated with complement activity; 2) to evaluate the relation of the complotype 
with complement activation in human plasma samples, representative of the in vivo situa-
tion; and 3) to investigate the association between the complotype and AMD.
METHODS
Study Population
In this study, 3042 participants from the European Genetic Database (EUGENDA, www.eu-
genda.org), over the age of 50 years, were included. The study was performed in accordance 
with the tenets of the Declaration of Helsinki and the Medical Research Involving Human 
Subjects Act (WMO) and was approved by the local ethics committee of the University Hos-
pitals in Cologne and Nijmegen. Written informed consent was obtained from all participants.
AMD and control status were assigned by multimodal image grading that included stereo 
fundus photographs, fluorescein angiograms and spectral domain optical coherence tomo-
grams. The grading was performed according to the standard protocol of the Cologne Image 
Reading Center (CIRCL) by certified graders (TR, LE) as previously described.26
Age, sex, and body mass index (BMI) were obtained by standardized interviewer-assisted 
questionnaires.
Complement Measurements and Genetic Analysis
Complement component C3 and the activation fragment C3d were measured in serum sam-
ples as previously described,9 and the C3d/C3 ratio was calculated as a measure of com-
plement activation. The complement activation data were skewed and had several outliers 
at the high end of the value range. In order to reduce the risk of outlier effects distorting 
the data, five percent of the highest values from the entire dataset were excluded from our 
analysis. After the exclusion of the outliers, the remaining skewness of the C3d/C3 data was 
normalized by Log10 transformation.
Genomic DNA was extracted from peripheral blood samples using standard procedures. Four 
SNPs, CFH (rs800292), CFB (rs4151667), CFB (rs641153), and C3 (rs2230199) were genotyped 
using the KASPar SNP Genotyping System by LGC Genomics.
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Statistical Analysis
All associations were calculated using SPSS software version 20.0 (IBM Software and Sys-
tems, Armonk, NY, USA). Associations with complement activation were analyzed using Gen-
eral Linear Models with C3d/C3 as the dependent variable. The models were corrected for 
age, sex, BMI, and disease status.
The associations between AMD phenotype and the individual SNPs or the complotype were 
evaluated using logistic regression. To determine if the SNPs were independently associated 
with the disease, all four SNPs were included in the logistic regression model at once.
To avoid being relevant only to our sample set (overfitting), the most informative complo-
type combination was determined by calculating the variable importance in a random forest 
analysis using the R package (RandomForest version 4.6-10). In the first analysis, C3d/C3 was 
included as the dependent variable for the regression type random forest test. In the second 
analysis, the disease status was defined as the classifier for a classification type of random 
forest. For both analyses, the number of predictors sampled for splitting at each node was 
set to two. All other options were left at default setting. 
RESULTS
The study was performed in three consecutive steps. First, the individual associations of 
CFH (rs800292), CFB (rs4151667), CFB (rs641153), and C3 (rs2230199) with AMD and with 
complement activation were verified. Next, we determined the most informative complotype 
for complement activation. Finally, we analyzed the association of the resulting complotype 
with the disease and with complement activation. 
Individual Association of CFH (rs800292), CFB (rs4151667), CFB (rs641153)  
and C3 (rs2230199) with AMD and Complement Activation
In a previous study, CFH (rs800292), CFB (rs4151667), CFB (rs641153), and C3 (rs2230199) were 
tested for their association with AMD in 2655 individuals.9 For the purpose of this study, 387 
additional individuals were genotyped, amounting to a total of 3042 subjects (1615 AMD and 
1427 controls). The mean age was 75 years for AMD and 70 years for controls. The sex distri-
bution was: 41% males to 59% females. All four SNPs were significantly associated with AMD 
(Supplementary Table 1). SNPs CFH (rs800292; minor allele A), CFB (rs4151667; minor allele 
A) and CFB (rs641153; minor allele A) are protective, whereas the C3 (rs2230199; minor allele 
C) infers increased risk of AMD. 
To determine the association of these SNPs with complement activation levels, CFH 
(rs800292), CFB (rs4151667), CFB (rs641153), and C3 (rs2230199) were included in a single 
general linear model, corrected for age, sex, BMI, and disease status. The model revealed 
significant independent associations with complement activation levels for all four SNPs. 
Figure 1 illustrates P values, mean log-transformed complement activation levels, and geno-
type distribution for the four tested SNPs.
When we looked at the difference in mean complement activation level between the geno-
types for each SNP, the high-risk C3 (rs2230199) genotype (GG) showed higher complement 
activation levels than the heterozygous (CG) and ancestral (CC) genotype. The protective 
CFH (rs800292) genotype (AA) showed lower complement activation levels than the oth-
er genotypes (Figure 1). However, a statistically significant difference in mean complement 
levels was only observed between the heterozygous genotype (GA) and the major genotype 
(GG) (P = .002), presumably due to the limited number of individuals carrying the AA gen-
otype. The protective CFB (rs641153) genotype (AA) and the heterozygous (GA) genotype 
displayed lower mean complement activation levels than the ancestral (GG) genotype. For 
CFB (rs4151667), the homozygous protective genotype for AMD (AA) could not be statistically 
compared to the homozygous ancestral genotype (TT), due to low number of individuals in 
this genotype group. The observed effects are driven by the difference in mean complement 
activation levels between the heterozygous (TA) genotype and the ancestral (TT) genotype 
(Figure 1). 
The Most Informative SNP Combination in Determining Complement Activation or AMD 
Status
As all four SNPs were individually and independently associated with both complement 
activation and AMD status, the next step aimed to assess which combination of SNPs best 
predicted these associations. It was impossible to introduce genotype combinations of all 4 
SNPs into the model because of the very low samples number of individuals in each of the 
resulting groups. For this reason, only combinations of 3 SNPs were considered.
In order to determine which combination of SNPs could best explain complement activation 
and disease status, two random forest analyses were performed. In the first analysis, the 
ratio of C3d/C3 as a measure of complement activation was used as the dependent varia-
ble, whereas the second analysis was classified on AMD disease status. Variable importance 
analyses in both tests revealed that the SNP combination composed of CFB (rs4151667) – 
CFB (rs641153) – CFH (rs800292) was the strongest predictor for both complement activation 
and AMD status (Table 1). For the purpose of clarity, this combination of SNPs will be referred 
to as the novel complotype in the remainder of the manuscript. 
Association of the Novel Complotype with AMD
Mathematically, there are 27 possible genotype combinations for a complotype composed 
of three SNPs. To ensure a meaningful interpretation of the statistical analyses, we included 
only those genotype combinations that were represented by at least ten individuals in both 
the patient and control groups. In our cohort, we observed seven genotype combinations 
that met these criteria. The distribution of all genotype combinations in our cohort is shown 
in Supplementary Table 2.
To determine the association of the novel complotype with AMD, a logistic regression anal-
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FIGURE 1. Plasma complement activation levels (log-transformed C3d/C3 ratio) for C3, CFH, and CFB 
genotype groups
 
Each genotype per single nucleotide polymorphism (SNP) is plotted on the X axis in an individual 
dot plot. The homozygous genotypes conferring increased risk for age-related macular degeneration 
(AMD) are indicated in red; the homozygous genotypes that are protective for AMD are indicated in 
green. The number of individuals carrying a specific genotype is indicated below each genotype. The Y 
axis represents the log-transformed C3d/C3 ratio level as a measure of complement activation. The P 
values represent the overall significance for each SNP included in the model.
TABLE 1. Variable importance scores of C3, CFB and CFH genotypes and genotype combinations on 
complement activation levels and AMD status
 
 
Variables
 
 
%IncMSE 
 
IncNode 
Purity
Mean 
Decrease 
Accuracy
Mean  
Decrease 
Gini
C3 (rs2230199) 5.33 0.06 6.59 1.85
CFB (rs4151667) 13.24 0.20 2.51 0.92
CFB (rs641153) 5.77 0.11 6.08 2.41
CFH (rs800292) 6.07 0.15 13.24 6.57
C3 (rs2230199) – CFB (rs4151667) – CFB (rs641153) 8.83 0.34 8.71 5.07
C3 (rs2230199) – CFB (rs4151667) – CFH (rs800292) 9.08 0.35 13.12 9.66
C3 (rs2230199) – CFB (rs641153) – CFH (rs800292) 10.88 0.33 13.84 11.85
CFB (rs4151667) – CFB (rs641153) – CFH (rs800292) 18.58 0.62 18.47 17.28
C3 (rs2230199) – CFB (rs4151667) – CFB (rs641153) – 
CFH (rs800292)
10.25 0.49 14.07 15.36
AMD, age-related macular degeneration.
Mean decrease accuracy and mean decrease Gini measure variable importance in predicting disease 
status. 
%IncMSE and IncNode Purity are measures for variable importance in predicting complement activa-
tion. 
For all variables, the highest values represent the best predictors.
TABLE 2. Association between the novel complotype and AMD
Genotype combination for the novel complotype Controls AMD OR (95% CI)* P value*
TT – GG – GG 607 916 1 5.84*10-13
TA – GG – GA 47 23 0.30 (0.17-0.51) 1.01*10-5
TA – GG – GG 55 65 0.74 (0.49-1.10) .131
TT – GA – GA 74 47 0.36 (0.24-0.54) 6.65*10-7
TT – GA – GG 112 106 0.57 (0.42-0.78) 3.2*10-4
TT – GG – AA 59 48 0.56 (0.37-0.86) .007
TT – GG – GA 406 370 0.58 (0.48-0.70) 7.32*10-9
AMD, age-related macular degeneration; OR, odds ratio; CI, confidence interval.
Bonferroni corrected threshold for statistical significance is P > .008.
* Corrected for age and sex. 
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ysis was performed. A strong overall association of the novel complotype with AMD (P 
= 5.84*10-13) was observed. In our analysis of the genotype combinations within the novel 
complotype, the most frequent genotype combination found in controls (TT – GG – GG) was 
set as reference. The logistic regression analyses corrected for age and sex revealed that, in 
comparison to TT – GG – GG, the other six genotype combinations were protective for AMD 
(Table 2).
Association of the Novel Complotype with Complement Activation
Finally, to determine the association of the novel complotype with complement activation, 
a general linear model was built, corrected for age, sex, BMI, and disease status. This model 
showed that the novel complotype was highly associated with complement activation levels 
(P = 8.31*10-9). When we compared the different genotype combinations with one another, 
the TT – GG – GG combination was associated with the highest mean complement activation 
levels (Figure 2). The difference in mean complement activation levels between all genotype 
combinations, tested in a post-hoc Bonferroni corrected manner, are presented in Supple-
mentary Table 3. When comparing complement activation levels between AMD patients and 
controls, we only observed a significant difference for genotype combination TT – GG – GA 
(Figure 2).
DISCUSSION
In a large case-control study, we show that carrying multiple AMD protective genotypes for 
CFB (rs4151667), CFB (rs641153), and CFH (rs800292) leads to lower levels of complement 
activation in plasma compared to the most frequent genotype combination of these SNPs in 
control individuals. This novel complotype was identified as the most predictive SNP combi-
nation for determining both complement activation levels and AMD status. This combination 
of SNPs, drawn from an in vivo setting, is different from what has previously been suggested 
on the basis of in vitro data.20
It is well established that SNPs in complement components C3, CFB, and CFH influence 
the risk for AMD.24,25,27 In this study, we confirmed that four common functional SNPs, CFH 
(rs800292), CFB (rs4151667), CFB (rs641153), and C3 (rs2230199), are associated with AMD. 
The minor alleles of the CFH and the CFB SNPs are protective,23,24 whereas the minor allele 
of the C3 SNP confers increased risk of AMD.25 The well-known AMD SNP CFH (rs1061170; 
Y402H) was not included in this study because it was not associated with complement acti-
vation in our previous study.9 This SNP was not described to alter AP convertase regulation, 
but rather it displays differential binding to C-reactive protein and malondialdehyde.28,29
Higher levels of systemic complement activation in patients compared to controls have been 
described in multiple studies.9,10,12,30 As the proteins encoded by CFH, CFB and C3 are key com-
ponents of the AP of the complement system,31 the contribution of these SNPs to disease 
FIGURE 2. Mean C3d/C3 level and frequency of genotype combinations in AMD patients and controls
 
The blue and green bars represent the percentage of individuals carrying a specific genotype combi-
nation within their own disease status. The green triangles and blue squares represent mean C3d/C3 
values for the corresponding genotype combination. 
The only genotype combination showing a significant difference in complement levels between AMD 
patients and controls was observed for TT – GG – GA with a P value of 3*10-4 (after Bonferroni correc-
tion statistical significance is achieved at P > .007).
AMD, age-related macular degeneration.
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susceptibility possibly comes from their impact on AP activation. 
FH is a major regulator of the AP.32 One of the ways in which it down-regulates complement 
activity is to bind C3b as a cofactor for its inactivation.33 The A allele (p.62I) of the CFH 
(rs800292; V62I) SNP is a gain of function variant. In vitro experiments showed that the 
resulting protein binds more efficiently to C3b than the protein resulting from the G allele 
(p.V62) of this SNP, thus leading to more complement inhibition.19 This is in line with our re-
sults, demonstrating that the CFH (rs800292) GG genotype was associated with decreased 
risk for AMD and lower levels of complement activation than the AA genotype.
FB binds hydrolyzed C3(H2O) or C3b, which is then cleaved by complement factor D to form 
the AP C3 convertase that cleaves C3 to C3a and C3b, thus fueling the AP amplification 
loop.22 The A (p.32Q) allele of rs641153 (p.R32Q) leads to a FB protein with decreased poten-
tial to form the C3 convertase and amplify complement activation.34 The second CFB SNP 
(rs4151667; L9H) resides in the signal peptide, and it has been proposed that it could alter 
CFB secretion.24 In this study, the A alleles of both CFB SNPs were found to be protective 
for AMD and to lead to lower complement activation levels, even in heterozygous state, than 
the major homozygous genotype. The homozygous protective genotypes for CFB (rs4151667) 
were too rare for any reliable conclusions to be drawn. 
C3 plays a central role in the complement system.35 The G (p.102G) allele of C3 (rs2230199; 
R102G) decreases the efficiency of regulation of C3b by FH, thus leading to an increase in 
complement activation. These observations are in accordance with the results in the present 
study, where the GG genotype is associated with risk for AMD and displays higher levels of 
complement activation than the CC genotype (Figure 1A). Even though it plays such an im-
portant role, it was not part of the most predictive complotype in the present study.
Several in vitro studies have shown that having multiple SNPs in complement genes would 
lead to higher complement activation.20,36 In the present study, the novel complotype com-
posed of CFB (rs4151667) – CFB (rs641153) – CFH (rs800292) had a larger effect on comple-
ment activation than the initially studied complotype C3 (rs2230199) – CFB (rs641153) – CFH 
(rs800292) (Table 1).20 The higher predictive value of the newly described complotype with 
respect to AMD might be related to the fact that it is composed of protective SNPs only 
rather than of a combination of polymorphisms with opposing effects on AMD susceptibil-
ity. When comparing the strongest effect (odds ratio [OR] 0.3) of this new complotype on 
the risk of AMD with the odds ratios of the 38 individual loci described in the newest AMD 
GWAS, we notice that the effect size is close to both the CFH (OR 0.38) and the ARMS2 (OR 
2.81), albeit reverse, locus.37 It is worth to mention that the OR of 0.3 for the complotype is 
seen when comparing TA – GG – GA to TT – GG – GG, which has only two alleles difference 
out of the six.
This study is the first to analyze this specific complotype combination for its association with 
AMD and complement activity. Although it would have been interesting to study the simul-
taneous presence of all four genotyped SNPs, cohorts even larger than ours are needed to 
avoid the problem of small genotype combination groups that cannot be reliably compared.
Intriguingly, the homozygous genotypes associated with the highest complement activation 
levels in all three SNPs (TT – GG – GG) in the novel complotype are found most frequently 
in both AMD patients and controls. This is in contrast to what was proposed in a theoretical 
model, where the extreme genotype combinations were expected to be at the lower end of 
the carrier frequency spectrum.22 With fewer than ten individuals for patients or controls, 
the combination of all heterozygous genotypes was rare. The combination where all SNPs 
had the homozygous protective genotypes (AA – AA – AA) was not present in our cohort at 
all. In our study, therefore, the frequency distribution is skewed toward complement-raising 
genotypes. This could potentially be explained by the fact that our cohort has a mean age 
of 73 years and might therefore be enriched for alleles that promote survival. In this case, 
the alleles that give higher complement activation could offer better lifetime protection 
against infection. However, these same genetic variants would potentially induce low-grade 
inflammation, and its effect would only be observed later in life, as is the case for AMD, a 
disease that is prevalent in the elderly population. In support of this hypothesis, immune 
genes have been described to have the highest rate of positive selection.38 Upon exami-
nation of the amino acid conservation of the SNPs in the present study, in humans three 
complement-raising variants are the reference amino acid, compared to only one in primates 
(Supplementary Table 4). 
A significant difference in complement levels was observed between AMD patients and con-
trols carrying the TT – GG – GA genotype combination. Although the highest mean differ-
ence was observed between the groups carrying the TT – GA – GG combination, this differ-
ence was not significant due to the high standard error. 
The four most prevalent genotype combinations are all associated with high levels of com-
plement activation in AMD patients with only minor differences between the groups. The 
three genotype combinations that are least prevalent are associated with lower complement 
activity. If we look at the specific genotype combinations, some interesting observations can 
be made. First of all, the TT – GG – GG genotype combination is associated with the highest 
complement activation levels and is more prevalent in AMD patients (57.3%) than in controls 
(43.3%). The TA – GG – GG genotype, which is only different with respect to 1 risk allele in 
CFB (rs4151667), is at the lower end of complement activation. The only other genotype com-
bination with TA instead of TT for CFB (rs4151667) is also associated with lower complement 
activation. This suggest that this SNP might be the most important of the three SNPs in the 
novel complotype, and is the driving force behind the influence on complement activation. 
This is also evident in the results from the random forest analyses, where CFB (rs4151667) is 
the strongest predictor for complement activation compared to the other individual SNPs. 
Another interesting observation from Figure 1 is the difference in complement activation be-
tween genotype combinations TT – GG – AA and TT – GA – GA. Both combinations include 
four risk alleles and two protective alleles, but the difference in complement activation is 
striking, especially in the AMD group. Perhaps the presence of two protective alleles in one 
SNP, as in the TT – GG – AA genotype combination, has a stronger influence on complement 
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activity than the combination of two heterozygous SNPs (TT – GA – GA). Observations like 
ours may help to clarify this and warrant further research, preferentially in an even larger 
dataset. 
One of the major strengths of this study is the use of the large EUGENDA dataset. To the 
best of our knowledge, this is one of the largest datasets of complement activation to date. 
For the evaluation of mean differences in complement activation at a population level, as we 
have done in this study, a single measurement of C3 and C3d in each individual is sufficient. 
However, if complement activation would be used on an individual basis, such as for the 
selection of patients for clinical trials, multiple measurements over time would be preferred 
to correct for individual variations in complement activation. 
CONCLUSIONS
The current study has demonstrated that a novel complotype composed of CFB (rs4151667) 
in combination with CFB (rs641153) and CFH (rs800292) is strongly associated with com-
plement activation and AMD status. These findings are relevant in the context of future 
complement-lowering treatments for AMD. In the era of personalized medicine, we are mov-
ing toward a more individualized approach to the treatment of diseases. To evaluate new 
treatment strategies, we need detailed information to determine how subgroups of patients 
with a higher treatment response potential should be defined. In this case, genotype-based 
patient stratification may identify those individuals that are genetically predisposed to hav-
ing the highest complement levels, potentially making them the best candidates for com-
plement-inhibiting therapies in AMD.
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SUPPLEMENTARY MATERIAL
SUPPLEMENTARY TABLE 1. Association between AMD and SNP genotypes in the CFH, CFB and C3 genes
SNP cDNA change AMD Control OR (95% CI) P value
CFH V62I rs800292 c.134G<A
   GG 1101 801 7.4*10-11 
   GA 445 539 0.63 (0.435-0.913) .015 
   AA* 62 77 0.564 (0.477-0.667) 2.4*10-11 
CFB L9H rs4151667 c.26T<A
   TT* 1511 1291 .02 
   TA 99 127 0.828 (0.038-17.888) .904 
   AA 1 1 0.654 (0.486-0.881) .005 
CFB R32 Q rs641153 c.95G<A
   GG* 1436 1195 3.0*10-4 
   GA 171 217 0.545 (0.138-2.152) 0.387 
   AA 4 7 0.623 (0.492-0.788) 7.9*10-5 
C3 R102G rs2230199 c.304G<C
   CC* 911 901 2.4*10-6 
   CG 570 471 1.183 (1.003-1.396) .046 
   GG 117 47 2.59 (1.775-3.777) 7.8*10-7
 
Analyses were performed by logistic regression analysis. 
The genotypes marked with * are 4 the ancestral variants. 
Variables entered in the model: CFH rs800292, CFB rs4151667, CFB 5 rs641153, C3 rs2230199, age and sex. 
Bonferroni corrected threshold for statistical significance is P > .004.
SUPPLEMENTARY TABLE 2. Genotype combination frequency for the novel complotype
CFB (rs4151667) - CFB (rs641153) - CFH (rs800292) Control n (%) AMD n (%) Total
AA - GG - GG 1 (0.1) 1 (0.1) 2
TA - GA - AA 0 (0.0) 2 (0.1) 2
TT - AA – GA 1 (0.1) 1 (0.1) 2
TA - GA - GA 5 (0.4) 1 (0.1) 6
TT - AA - GG 6 (0.4) 3 (0.2) 9
TA - GG - AA 7 (0.5) 3 (0.2) 10
TA - GA - GG 10 (0.7) 5 (0.3) 15
TT - GA - AA 11 (0.8) 9 (0.6) 20
TA - GG - GA 47 (3.4) 23 (1.4) 70
TA - GG - GG 55 (3.9) 65 (4.1) 120
TT - GG - AA 59 (4.2) 48 (3.0) 107
TT - GA - GA 74 (5.3) 47 (2.9) 121
TT - GA - GG 112 (8.0) 106 (6.6) 218
TT - GG - GA 406 (29.0) 370 (23.1) 776
TT - GG - GG 607 (43.3) 916 (57.3) 1523
Total 1401 (100) 1600 (100) 3001
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SUPPLEMENTARY TABLE 3. Differences in mean complement activation levels between genotype  
combinations
CFB (rs4151667) - CFB (rs641153) - CFH (rs800292) Mean Difference (I-J) Std. Error P value
TA - GG - GA
TA - GG - GG -0.024 0.026 1 
TT - GA - GA -0.041 0.027 1 
TT - GA - GG -0.085* 0.024 .011 
TT - GG - AA -0.06 0.027 .524 
TT - GG - GA -0.079* 0.022 .006 
TT - GG - GG -0.100* 0.021 6.1*10-5
TA - GG - GG
TA - GG - GA 0.024 0.026 1 
TT - GA - GA -0.017 0.024 1 
TT - GA - GG -0.061 0.021 .074 
TT - GG - AA -0.036 0.023 1 
TT - GG - GA -0.055* 0.018 .043 
TT - GG - GG -0.076* 0.017 1.9*10-4
TT - GA - GA
TA - GG - GA 0.041 0.027 1 
TA - GG - GG 0.017 0.024 1 
TT - GA - GG -0.044 0.021 .843 
TT - GG - AA -0.019 0.024 1 
TT - GG - GA -0.038 0.018 .826 
TT - GG - GG -0.059* 0.018 .019 
TT - GA - GG
TA - GG - GA 0.085* 0.024 .011 
TA - GG - GG 0.061 0.021 .074 
TT - GA - GA 0.044 0.021 .843 
TT - GG - AA 0.025 0.021 1 
TT - GG - GA 0.006 0.014 1 
TT - GG - GG -0.015 0.014 1 
TT - GG - AA
TA - GG - GA 0.06 0.027 .524 
TA - GG - GG 0.036 0.023 1 
TT - GA - GA 0.019 0.024 1 
TT - GA - GG -0.025 0.021 1 
TT - GG - GA -0.019 0.018 1 
TT - GG - GG -0.04 0.018 .464
TT - GG - GA
TA - GG - GA 0.079* 0.022 .006 
TA - GG - GG 0.055* 0.018 .043 
TT - GA - GA 0.038 0.018 .826 
TT - GA - GG -0.006 0.014 1 
TT - GG - AA 0.019 0.018 1 
TT - GG - GG -0.021 0.008 .215
TT - GG - GG
TA - GG - GA 0.100* 0.021 6.1*10-5
TA - GG - GG 0.076* 0.017 1.9*10-4
TT - GA - GA 0.059* 0.018 .0189 
TT - GA - GG 0.015 0.014 1 
TT - GG - AA 0.04 0.018 .464 
TT - GG - GA 0.021 0.008 .215 
*The mean difference is significant at the .05 level. All P values were adjusted for multiple  
comparisons: Bonferroni. 
The general linear model was corrected for age, sex, BMI and disease status.
SUPPLEMENTARY TABLE 4. Amino acid conservation for CFH (rs800292, p.V62I) - CFB (rs4151667, p.L9H) - 
CFB (rs641153, p.R32Q) - C3 (rs2230199, p.R102G)
Species CFH  
p.V62I
CFB  
p.L9H
CFB  
p.R32Q
C3  
p.R102G
Human V L R R 
Chimp I L Q R 
Mouse I L R G 
Dog I L A G 
Cat L G G
Cow L G G
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GENERAL DISCUSSION
1. PRIMARY FINDINGS OF THIS THESIS AND CLINICAL IMPLICATIONS
1.1 DEVELOPMENT OF AMD
AMD is a multifactorial disease and a broad range of genetic, environmental and sociodemo-
graphic risk factors are associated with disease development. Numerous studies have identi-
fied risk factors for AMD, and in this next section the most important findings are highlighted.
Risk factors for AMD development
Environmental / Demographic risk factors
The most consistently established risk factors for AMD are age and smoking.1-8 A higher 
body mass index is also thought to be associated with AMD,2,9-14 although some studies 
were unable to replicate this association.1,15,16 For other potential risk factors that have been 
studied, the results are even less unambiguous. Significant associations with AMD have been 
reported for low physical activity,17 sunlight exposure,18,19 hypertension,20-22 and female sex.23,24 
Genetic risk factors 
Several genes in the complement pathway have been associated with AMD. The strongest 
associations have been described for variants in the complement factor H (CFH) and the 
age-related maculopathy susceptibility 2 (ARMS2) genes. A more detailed discussion on 
the complement system and AMD is provided in section 3. Other associations with AMD 
have been found for genes involved in several AMD-related pathways. These include the 
high-density lipoprotein cholesterol pathway and the extracellular matrix pathway.25,26 In 
recent years, large genome-wide association (GWAS) study have uncovered more than 30 
susceptibility loci that harbor common and rare risk variants for AMD.27 
GWAS studies have made a significant contribution to identify the genetic causes of AMD. 
However, since we know that gene-gene and/or gene-environment interactions may also 
be involved,10,13,28-30 the need for other methods to identify AMD-associated loci remains. In 
Chapter 4 we evaluate the interaction between glutathione S-transferase (GST) polymor-
phisms in a large AMD case control dataset. Even though no GST polymorphisms have ever 
surfaced in large GWAS studies, one study group reported an association between specific 
combinations of GST polymorphisms and AMD.31 In our dataset, which was much larger than 
the datasets of the original study, we were unable to replicate these findings. With our study 
we want to highlight the importance of replication of new findings and the need for large 
datasets to identify gene-gene interactions in AMD. 
Age at onset of neovascular AMD
The onset of neovascularization in AMD varies greatly, in some patients occurring as early as 
age 50, whereas others are well past the age of 90. Research that has focused on identifying 
risk factors for an earlier age at onset of AMD is limited. In Chapter 2 we demonstrate that 
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major risk factors for the development of AMD, the CFH Y402H and the ARMS2 A69S risk 
alleles and smoking, are also important players in the age at onset of neovascular AMD. Ac-
cumulation of these factors may accelerate neovascularization substantially by one or two 
decades. This finding has a high clinical value, as it will aid the timely identification of high-
risk individuals, who might benefit from more frequent ophthalmic examination to screen 
for the first signs of neovascular disease. In addition, it will enable the initiation of possible 
countermeasures at an early stage, where they may be more effective. Such measures do not 
only consist of cessation of smoking, but a healthy diet can also reduce genetic risks. Data 
from the Rotterdam study showed that individuals with a high genetic risk of AMD (defined 
as risk alleles in CFH and ARMS2) can reduce this genetic risk of AMD by consuming a diet 
rich in zinc, ω-3 fatty acids, β-carotene and lutein/zeaxanthin.32,33 Regular consumption of fish 
also decreased the risk of late AMD in individuals with a high genetic risk.33,34 These reports 
underline the need for general health education on proper food patterns and special atten-
tion, meaning an early identification, to high risk individuals.
Familial AMD
AMD is known to cluster in families and the first studies to reveal a role for genetics in AMD 
were familial and twin based studies.35-38 Several studies have also suggested a different 
distribution of common environmental, genetic and/or phenotypic characteristics in familial 
versus sporadic AMD. We describe the results from our cohort in Chapter 5. The frequencies 
of common risk alleles in CFH and C3 are higher in familial cases and controls compared to 
sporadic cases and controls. In line with this, the frequencies of protective alleles in CFH and 
CFB are lower (Chapter 5). This shows that in general the genetic burden in AMD families 
is higher and points toward an important role of the complement system in familial AMD. 
However, this also indicates that there must be other factors in these families that determine 
why one individual actually develops AMD and his/her sibling with the identical risk factors 
in complement genes does not. For the majority of families these factors are not different 
from the common genetic and environmental risk factors for AMD, and the prevalence of 
AMD can be explained by clustering of risk factors in these families. However, for a subset 
of families this observation does not hold, and unexplained variables are responsible for the 
high frequency of AMD (Chapter 6). Already in 1998 Klaver and colleagues concluded that 
clustering of common genetic risk factors in affected families does not explain the number 
of affected family members in large AMD families.39 We have now shown that addition of 
known common environmental factors is still not enough to explain the familial clustering 
of AMD. Several rare variants with a high impact on disease risk have been identified in genes 
involved in the complement pathway,40-48 and it is thought that the clustering of AMD in 
families may in part be explained by these rare variants. Screening for known rare variants in 
our AMD families did not yield any results, and these families are thus of particular interest 
for additional genetic testing, such as whole exome sequencing to search for rare variants 
that have not yet been identified. Even though the occurrence of some rare variants may 
be limited to specific populations, families or geographic regions, their identification can be 
very important for the families that carry these variants. This means that family members 
without clinical signs of AMD can be tested for carriership of the variant that is found in 
their family, and this will provide these individuals with a better insight in their disease risk. 
Carriers of the rare variants can be counseled and provided with the tools to decrease their 
risk of developing AMD.
Phenotypic variations
With upcoming new treatment modalities for AMD, mostly aimed at slowing or preventing 
the progression of dry AMD, more and more interest is directed toward phenotyping of AMD 
patients. A detailed phenotyping can aid in the identification of certain subgroups of patients 
within the AMD spectrum who share clinical characteristics that may distinguish them from 
the classical AMD phenotype. An example of this is the cuticular drusen phenotype, charac-
terized by innumerable, small , subretinal drusen with a typical “stars-in-the-sky” appearance 
on fluorescein angiography.49 It is thought that this phenotype accounts for approximately 
10% of the AMD spectrum, and it has been shown that although there is a clear overlap in 
risk factors for cuticular drusen and AMD, there are also differences.45,50 Another example are 
reticular (pseudo-)drusen, which are associated with progression toward geographic atrophy 
(GA).51,52 Figure 1 gives an overview of different drusen phenotypes that can be observed in 
AMD. The ever expanding spectrum of diagnostic tools may aid in the identification of new 
subgroups. Automatic grading systems, like the one described in Chapter 7, are able to ob-
jectively categorize and quantify clinical characteristics such as drusen on color fundus im-
ages. This will allow us to study different patterns of drusen distribution, for example inside 
or outside the central macular grid, and determine whether correlate to known risk factors 
(genotype-phenotype correlations) or aspects related to AMD progression. In the future, the 
automatic quantification and evaluation of phenotypes combining information from multi-
modal imaging techniques will further contribute to disease classification.
Neovascular versus geographic AMD
Even though GA and CNV are considered to be two distinct phenotypes, they share a similar 
risk profile with respect to environmental, clinical and genetic factors.1,13,53-57 This suggests 
that both disease entities share a common pathophysiological pathway, and this seems log-
ical since both stages are preceded by early and intermediate AMD stages, characterized by 
drusen and RPE alterations. In addition, both GA and CNV can manifest in the same patient 
and even within the same eye, and this so-called mixed phenotype shares the same genetic, 
epidemiological and clinical features as GA and CNV separately.58 On the other hand, there 
are also some differences. For example, the ARMS2/HTRA1 locus is associated with both 
types of advanced AMD, but the risk for CNV is much higher compared to that for GA,59,60 and 
recently other genetic risk variants in the loci CETP, MMP9 and SYN3/TIMP3 were also found 
to be significantly different between disease subtypes.27 It has also been suggested that 
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A-C, Hard drusen are visible as small yellowish points on FP (A). FA shows corresponding hyperfluo-
rescent spots (B). Small depositions under the RPE are identified on OCT (C). D-F, Soft drusen are typ-
ically larger than hard drusen and their borders are less well-defined. FP, FA and OCT images of soft 
drusen are seen on images D, E, and F respectively. G-I, Reticular drusen are visible on FP (G) as gray-
ish deposits in a network-like pattern. They are better seen on infra red images (H) and OCT imaging 
shows an irregular pattern of elevations internal to the RPE (I). J-L, The cuticular drusen phenotype is 
characterized by numerous small, hard drusen (J). They are even better visible on FA, where the typical 
“stars-in-the-sky” appearance is shown (K). On OCT, multiple hard drusen are visible (L).
FP, color fundus photography; FA, fluorescein angiography; RPE, retinal pigment epithelium; OCT, opti-
cal coherence tomography
FIGURE 1. Overview of different drusen phenotypes in age-related macular degeneration
A B C
D E F
G H I
J K L
some environmental risk factors such as cigarette smoking and hypertension confer different 
risks for GA and CNV.3,61,62 In Chapter 9 we also show that levels of complement activation 
differ between GA and both active and inactive CNV. Based on these findings we propose 
that even though there is a common starting point for GA and CNV, subtle influences of 
genetic and non-genetic factors determine the development toward either endpoint. In this 
view, GA may be regarded as the natural endpoint for AMD, except when something acute 
goes wrong and CNV develops. It is very important to separate these groups when perform-
ing analyses for AMD, especially for AMD risk prediction.63 
1.2 PROGRESSION OF AMD
Several factors that are involved in the development of AMD, also play a role in AMD pro-
gression. For example, genetic risk variants in the major complement genes (CFH, comple-
ment components 2 and 3 [C2 and C3] and complement factor B [CFB]) and ARMS2 are 
independently associated with progression.64-66 Of the non-genetic factors, age, smoking, and 
BMI have consistently been linked to AMD progression.65-67
Second eye progression
Patients who have developed end-stage AMD in one eye are at high risk of progressing to-
ward end-stage AMD in the second eye. Cumulative incidence rates have been reported to be 
10% to 14%, 28% to 31%, and 36% to 37% after 1, 3, and 4 years of follow-up, respectively.68,69 
In Chapter 3 we show that both genetic and environmental risk factors determine the risk of 
second eye progression. We were the first to report that the most common AMD risk alleles 
in CFH, C3, and ARMS2 do not seem to play a role. These findings were later corroborated 
by the Comparison of AMD Treatments Trials (CATT) Research Group, also supporting the 
notion that the range of risk is restricted because most of these patients are high risk in-
dividuals since they had already progressed toward end-stage AMD in one eye.70 We also 
describe other risk alleles in complement factor I (CFI) and lipoprotein lipase (LPL) that 
influence second eye progression, suggesting that in this stage other genetic risk profiles 
are important for a faster progression toward second eye involvement. In addition, whereas 
CHAPTER 10 GENERAL DISCUSSION
161160
10
genetic influences seem to be different from those that cause a risk for AMD development 
and progression, it is noteworthy that, in our study, the common environmental risk factors, 
smoking and BMI, are also of importance in this stage of disease progression. In the CATT 
study smoking and age were not associated with second eye progression, but these results 
may be limited by the fact that they only had two years of follow up. They did show an in-
creased risk for females for second eye progression, in line with our findings. Where the role 
of sex is controversial in AMD development, these results may indicate that sex differences 
may exert an effect on progression. 
In the eye clinics, the patients at risk for second eye progression are an important subgroup. 
They are the ones who will ask the ophthalmologist how long they will be able to see well 
with their ‘good’ eye and what they can do to prevent themselves from becoming blind in the 
near future. Of course, these patients need regular eye examinations and they should receive 
an amsler chart for everyday self-control. In addition, it is the job of the ophthalmologist to 
inform them about the risks of smoking and overweight, and they should be stimulated to 
persue a healthy lifestile. Next to this, we know from the AREDS trials, that these patients 
will benefit from the use of nutritional supplements. However, since these supplements are 
not covered by the health insurance companies in the Netherlands, the effects of a healthy 
diet rich in lutein and zeaxanthin should also be emphasized. In the future, this patient group 
may benefit from preventive treatment in the form of anti-VEGF eye drops. Even though 
recent clinical trials did not show a beneficial effect of anti-VEGF eye drops in the setting 
of CNV,71-73 it would be worthwhile to find out if they can prevent or delay the onset of CNV 
formation. 
1.3 THE COMPLEMENT SYSTEM AND ITS ROLE IN AMD DEVELOPMENT AND PROGRESSION
Already in the early nineties, the Dutch ophthalmologist van der Schaft identified compo-
nents of the complement system in drusen, and this led to a series of other publications that 
supported these findings and formed the basis for the hypothesis that inflammation and, 
more specifically, the complement system play an important role in AMD pathogenesis.74-76 
Genetic variants in the CFH gene are strongly associated with AMD risk, and this discovery 
in 2005 formed the second line of evidence that implicated chronic local inflammation 
and activation of the complement system in AMD.77-79 In the following years other single 
nucleotide polymorphisms (SNPs) in genes involved in the complement system have been 
associated with AMD.80,81 The second major AMD susceptibility locus is located on chromo-
some 10q26 and contains two genes in high linkage disequilibrium: ARMS2 and Htra serine 
peptidase 1 (HTRA1).82-85 Even though there is no doubt about the association with AMD, 
there is no agreement on the causal variant at this locus. The underlying pathophysiological 
mechanisms remain unclear as well.82,86-89 Several recent publications have linked ARMS2/
HTRA1 to inflammation, complement components and complement activity, suggesting a di-
rect or indirect influence on the complement pathway.90-93 The third line of evidence that the 
complement system is strongly associated with AMD came from the finding that the mean 
level of complement activation in plasma or serum is higher in patients with AMD compared 
to controls.16,91,94-96 Several of the SNPs in complement genes that are associated with AMD 
exert a direct effect on systemic complement activation.91,94,95,97 
In Chapter 8 of this thesis we evaluate the relationship between complement activation and 
different AMD stages in detail. We demonstrate that complement activation is highest in pa-
tients with intermediate AMD and geographic atrophy (GA) and lowest in control individuals 
and patients with inactive choroidal neovascularization (CNV), suggesting that complement 
activation in AMD is a dynamic process. These differences seem most prominent in cases 
with a high genetic predisposition based on four SNPs in CFH, CFB and C3. In Chapter 9 we 
combine risk alleles in CFB and CFH to form a novel combination of complement genotypes 
(also referred to as a complotype), that is strongly associated with both AMD disease status 
as well as complement activation. Different genotype combinations of this complotype lead 
to differences in complement activation in both control individuals and patients. 
In this era where we are moving more and more toward a personalized therapeutic approach 
it is very important to identify subgroups of patients who share a common pathophysio-
logical mechanism of disease and who might benefit most from therapeutic strategies that 
are currently being developed. Several lines of research should be further explored to come 
toward this goal. First of all, genetics can play a major role in this and although we already 
know a great deal through GWAS studies, the next step should be to focus in more detail 
on clusters of genotypes or complotypes, because risk alleles that are associated with AMD 
seem to enhance each other when they are present in different combinations. Secondly, by 
evaluating several components (genetic and/or biochemical) of one pathway at the same 
time, we might be able to get a more general idea of the functionality of the pathway and 
gain insight in the disease from a broader perspective. Thirdly, the finding that complement 
activation differs among the AMD stages underlines the need for detailed phenotyping. This 
may aid in the identification of subtypes of AMD, and raises the question at what stage of 
the disease a new treatment should be started in order to be most successful. 
Also in the design of future clinical trials possible subgroups of patients should be identified 
and evaluated separately. For example, in the current trial on lampalizumab, an anti factor 
D antibody, it would be very interesting to see if patients with a high risk genetic profile – 
based on the number of risk alleles in complement genes – show a better response to the 
treatment compared to patients with a low risk genetic profile. 
2. TOWARD PERSONALIZED MEDICINE IN AMD
2.1 RISK FACTORS: FROM POPULATION TO THE INDIVIDUAL PATIENT
Risk factors are identified in large datasets and odds ratios or disease risks are determined 
based on the average distribution of risk factors among patients and controls. How can we 
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translate these population-based risks toward disease prediction for the individual patient?
Several direct-to-consumer genome tests have been made publically available and allow 
consumers to determine their personal disease risk. For AMD, these tests are based on a 
small number of SNPs associated with AMD, and a lifetime risk score is calculated based 
on these SNPs and a lifetime population risk. A recent report from Buitendijk et al. showed 
that while these tests were accurate with respect to genotyping, they were unreliable when 
it came to disease prediction and yielded contradictory results for the same individual most 
likely because of a limited set of genetic markers and differences in methodology and pop-
ulation used as reference.98
Different problems arise when it comes to accurate risk prediction. First of all, it is very im-
portant to determine what you want to predict and for whom. As becomes clear from Chap-
ters 2-4 there are different risk factors and/or different effect sizes depending on whether 
you want to predict disease development or (second eye) progression. In addition, in the case 
of familial clustering of AMD we are not always able to rely on the common risk factors for 
disease prediction, and a much more individual approach is needed in those families where 
there is a substantial difference between the expected and actual number of affected fam-
ily members as described in Chapter 6. Rare genetic variants are thought to explain these 
differences, but so far rare variants have been identified only in a minority of families with 
AMD. Therefore, in these families, exome sequencing or whole genome sequencing should 
be the next step.
Another problem of accurate risk prediction lies in the complex interplay of genetic and 
non-genetic risk factors. Each individual carries a different subset of risk factors and pro-
tective variants and together they determine the time of disease onset and the course of 
the disease. Due to the existence of interaction between factors, many of which are still un-
known to us, the same risk factor can have a very different effect in one individual compared 
to another.
2.2 PREDICTION MODELS FOR AMD
Several study groups have developed a prediction model or risk algorithm for AMD, which are 
summarized in Table 1. When we take a closer look into these models, several observations 
can be made. First of all, there is not one model that includes exactly the same variables 
as any other model. This is very understandable since most study groups use predefined 
datasets and can only include variables that are actually measured in their datasets, but 
this makes direct comparison of model performance already very difficult. Some of the 
infrequently used variables seem very promising and warrant further research. Reynolds et 
al include several complement components in their model and show that the area under 
the curve (AUC) increases significantly.16 The only other model that evaluates complement 
components is that from Sharma et al, but they only included factor H, and their dataset 
had a very small sample size.99 Evaluation of complement components in study subjects 
is a rather costly analysis and requires a strict protocol of sample handling, which may be 
the main reason why this has not been explored by other study groups. Another aspect is 
the inclusion of rare variants in the risk algorithm as was done by Seddon et al.64 Since we 
know that rare variants can explain part of the missing heritability in AMD, it is important to 
incorporate known rare variants in our disease models. However, this also comes with some 
limitations, since the occurrence of rare variants may be limited to certain populations or 
geographic areas.
The second aspect that differs among prediction models is the study design. Many models 
are based on case-control datasets, which leads to an overestimation of disease risk and 
hampers the translation to the population as a whole because the extreme ends of the 
disease spectrum – controls and advanced AMD – are over-represented compared to the 
patients with early and intermediate disease stages. In addition, most of the models built on 
prospective data are derived from the Age-Related Eye Disease Study (AREDS), a randomized 
controlled trial on the use of antioxidants and zinc supplementation, and one may question 
the generalizability of these results. The same is true for the model from the Complications 
of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group, where all the 
so-called non-cases had large drusen in at least both eyes and no ‘true’ AMD-free controls 
were included. The model from the Three Continent AMD Consortium (3CC), that was build 
on the data from the Rotterdam Study and validated in the Beaver Dam and Blue Mountain 
Eye Study Groups, is the only other model that uses prospective data. They are faced with all 
the advantages of a prospective dataset, but the consequence is the relatively low number 
of incident advanced cases, which limits variable inclusion and subdivision in AMD subtypes. 
Thirdly, the start and endpoints used in the different prediction models are not the same. 
Most models predict end-stage disease, i.e. GA or CNV. Given the notion that there are some 
differences in risk factors for GA and CNV as described in section 1.1, this will lead to a less 
accurate prediction. Several studies have therefore developed separate models for GA and 
CNV, sometimes even including different risk factors in each model. It is not only important 
to take the endpoint of the model into account, but also the baseline AMD stage is very 
important. In many studies, the non-cases are not pure controls (i.e. free of any AMD), but 
a mixed group of controls and early AMD. However, in most of the models based on the 
AREDS data, the non-cases include patients with unilateral advanced AMD at baseline, who 
are at risk of developing end-stage AMD in the other eye. As we know from the literature 
and Chapter 3 of this thesis, the genetic risk factors for second eye progression are different 
from the factors that determine disease onset or progression, and this will also influence 
the model performance. 
These examples underline the previous statement that it is extremely important to deter-
mine what you want to predict and for whom you want to predict. If the goal is to predict 
lifetime risk of AMD, than a model is needed based on data with a long follow-up. However, 
if a model is to be used for the identification of eligible patients for a randomized controlled 
trial evaluating a possible treatment for AMD, than a model is needed that can identify 
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patients who are at high risk of progressing toward end-stage disease in a relatively short 
time-period. In this situation, a model like that from McCarthy et al could be of use since it 
predicts AMD progression within 3 years. In addition, a model can be used to identify sub-
groups of patients, such as the families that we describe in Chapter 6 where the clustering of 
AMD within the families could not be explained by the common genetic and environmental 
risk factors. 
In conclusion, we are still a long way from the optimal predicton model to allow for individ-
ual risk prediction. Models can serve several purposes; they can be used for the classification 
of study populations into high and low risk groups, which can be useful for further studies, 
either on treatment or on further unraveling disease mechanisms. For now, the models are 
not refined enough for individual disease prediction and application in the general pop-
ulation. In addition, there are currently no available treatment options for the early AMD 
stages. Even if we could provide people with an individual risk profile, we currently cannot 
offer them other interventions than the preventive measures that are already known to most 
individuals: a balanced diet, the use of nutritional supplements, regular physical activity and 
to stop smoking. 
An accurate prediction model would have to include interaction terms, haplotypes or com-
plotypes, rare genetic variants, epigenetic effects and biomarkers (such as complement com-
ponents), all of which are not - or very poorly - represented in the models that are currently 
available. Exclusion of these factors, for practical, statistical or financial reasons, will hamper 
adequate risk prediction. Another factor that should definitely be included in a predictive 
model for AMD is family history. Since still 40% of the heritability of AMD is unexplained, 
family history may serve as a marker for unknown genetic variants and may therefore aid in 
a more accurate risk prediction.
2.3 WHAT IS NEEDED TO MOVE FORWARD TOWARD PERSONALIZED MEDICINE IN AMD?
In order to provide individuals with a personal disease risk or a personal treatment strat-
egy, we need to be able to divide individuals in subgroups. We need predictive tests to 
identify those individuals who are at high risk to develop end-stage AMD, predictive tests 
to identify individuals at high risk for progression of AMD, and predictive tests to estimate 
treatment response for the individual patient. To cover all these facets of AMD, we need 
extensive knowledge on risk factors for development, progression, and treatment. But it is 
not enough to focus on genetics and environmental factors. We have to move forward and 
explore new upcoming fields of proteomics and metabolomics and focus more on gene-gene 
and gene-environment interactions. Large datasets are needed to evaluate these areas and 
we highlight the importance of collaborations between different studygroups. Only then, we 
can obtain enough power to stratify study subjects into subgroups. These subgroups are of 
the most importance when it comes to selecting appropriate treatment strategies for AMD. 
Not every patient will respond in the same way to specific treatments, this is inherent to the 
multifactorial etiology of the disease. Before more progression can be made in the field of 
AMD treatment, we have to learn how to select patients that share a more common etiology 
in order to create more homogeneous subgroups based on disease pathology. For example, 
patients with a more active complement system may be more sensitive to treatment with 
complement inhibitors. On the other hand, patients with a lower activity of the complement 
system may be more susceptible for treatments that target other pathways involved in AMD. 
If we don’t know how to differentiate these subgroups, than we may face disappointing re-
sults from current clinical trials focusing on new treatment modalities. There is still a lot to 
discover about the role of different biomarkers in disease development and progression, and 
more knowledge is essential for classification and selection of possible treatment markers 
en treatment strategies.
3. FUTURE PERSPECTIVES
3.1 FINDING THE UNEXPLAINED VARIANCE IN AMD
The heritability of AMD is estimated at about 47%.117 A recent study of over 12 million ge-
netic variants analyzed in 16,144 patients and 17,832 controls, identified 52 common and rare 
variants on 34 loci, explaining 27.2% of disease variability and thus almost 60% of the total 
heritability.27 This still leaves 40% of the heritability of AMD unexplained. In part, this may 
be explained by the discovery of additional variants not studied so far. It seems unlikely that 
many other common variants with a significant impact on disease risk still play a role, as they 
would have been picked up in one of the many GWAS studies performed so far. More likely, 
the answer may be found in the identification of rare variants. However, this will not explain 
all of the missing 40%. Gene-gene and gene-environment interactions as well as epigenetics 
may also play a role, and further research is needed to shed light on this. In addition, non-ge-
netic studies, such as metabolomics, may play a role in the identification of new pathways 
associated with AMD, and subsequent dissection of these pathways may contribute to the 
discovery of new genetic variants in AMD.
3.2 SCREENING FOR AMD
In Chapter 4 we describe a computer aided diagnosis system that is able to detect and quantify 
the presence of drusen in color fundus photographs with an accuracy that is equal to that of 
human graders. In addition, a classification in low risk and high risk individuals can be made. 
Development of automatic grading software opens new possibilities for screening for AMD in 
the elderly population. For diabetic retinopathy (DR), screening systems have been proved to 
be cost-effective and they are implemented on a large scale.118 Most DR screening programs 
are based on human evaluation of color fundus photographs, but with the growing diabetic 
population these manual screening methods will not be able to meet the screening needs.119
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For AMD, currently no screening programs are available. Some cost-utility models have been 
developed, but the proposed programs were based on self-testing,120,121 or dialated fundus 
examinations.122,123 Recently, Chan et al evaluated the cost-effectiveness of AMD screening 
performed simultaneously with DR screening for diabetic patients in Hong Kong. They re-
ported that the total cost per quality-adjusted life year gained was $12 712, which is highly 
cost effective.124 In the proposed screening system, mydriatic fundus photographs are man-
ually graded by trained ophthalmologists and optometrists. An automatic grading system 
would further increase the cost-effectiveness and with the increased growth of the elderly 
population, this option should be seriously considered.
3.3 PREVENTION OF AMD DEVELOPMENT AND PROGRESSION
Vitamin supplements
Supplementation with the AREDS formulation (antioxidant vitamins C and E, lutein, zeaxan-
thin and zinc) has been shown to slow down progression to end-stage AMD by 25% in high-
risk patients.125 In 2014, we showed that oral zinc supplementation decreases complement 
activation in AMD patients, but only in the presence of a high baseline level of complement 
catabolism.126 In addition to its role as a complement inhibitor, zinc also has antioxidant prop-
erties that further dampen the activation of the alternative complement pathway. Based on 
what we know today, zinc might be a realistic candidate drug to slow down AMD progression 
through complement inhibition and should be evaluated in a large prospective clinical trial. 
Who should be advised to take vitamin supplements? In current clinical practice patients 
with unilateral advanced AMD and patients with bilateral intermediate stage disease are 
advised to consider the use of vitamin supplements in order to slow down disease progres-
sion.125 However, it is not unlikely that there are other patient groups who might benefit from 
nutritional supplements. For example, individuals from families with a high prevalence of 
AMD are at increased risk of developing end-stage AMD and the complement system seems 
to play a more important role in the development of familial AMD (Chapter 5). However, 
these individuals may report to an ophthalmologist at a relatively young age, because of 
an increased awareness of their disease risk and they may not show any signs of AMD yet. 
It seems counterintuitive not to advise the use of nutritional supplements in these patients 
but further research is warranted to prove the beneficial effect in selected subgroups of 
individuals known to be at high risk of development of end-stage AMD.
Complement inhibitors
Modulation of the complement system by targeting the regulating components is now the 
focus for the development of new treatment modalities for AMD and especially GA. Several 
clinical trials have been initiated to study the effect of complement inhibition on dry AMD. 
Table 2 gives an overview of the complement inhibiting therapies for AMD and their stage of 
development. Until recently, results were not very promising, if any results were published at 
all. Events took another turn when the first results from the phase II study on lampalizumab 
were published, suggesting that intravitreally administered lampalizumab, an antigen-bind-
ing fragment against factor D, could successfully slow down the progression of GA. At the 
moment, several phase III studies for lampalizumab are ongoing. 
The progression rate of GA is highly variable among different studies and ranges from 1.2 to 
2.8 mm2 per year.127 A clinical trial designed to detect a decline in the progression rate needs 
to be well powered. A possible explanation for the disappointing results so far may be due 
to underpowered study designs.
In addition, we need to determine the optimal timeframe to initiate complement inhibition. 
As shown in table 2, almost all trials included only patients with end-stage AMD, and eval-
uated the effect on the progression rate of GA. However, we do not know whether comple-
ment activation has an influence on GA progression. Maybe the role of complement (over)
activation in the pathogenesis of dry AMD involves the earlier stages of the disease. We ob-
serve in our study in Chapter 8 that patients with intermediate AMD have levels of comple-
ment activation that are as high as the levels in patients with GA. We therefore propose that 
clinical trials should also include patients in nonadvanced AMD stages in order to determine 
if complement inhibitors can prevent or slow down development of GA. This requires an 
accurate identification of those patients at the highest risk of progressing toward end-stage 
AMD, because the majority of intermediate AMD patients never develops GA or CNV.
We further highlight the importance of genetics. As shown in this thesis, the relationship 
between AMD stage and complement activation was only observed in individuals with a high 
genetic risk (and thus a higher baseline complement activity). This is in line with our previous 
finding in our study on zinc supplementation: only in patients with a high level of comple-
ment activation at baseline was zinc supplementation successful in lowering complement 
activity.126 It is therefore likely that there is a subgroup of patients who would benefit most 
from complement inhibition, and they might be identified through genetic testing.
Besides the presence of high risk variants, high baseline levels of complement activity could 
help in identifying these subgroups. We should not only evaluate genetic polymorphisms of 
complement genes, but should also bear in mind that patients with low baseline levels of 
complement activity might benefit less from complement inhibition. Since systemic comple-
ment measurements are greatly influenced by viral or bacterial infections and disease activ-
ity of other inflammatory conditions, alternative approaches may be needed to determine 
an individual’s level of complement activity when using such a measure to select individual 
patients for treatment. For example, complement activation levels may be measured at mul-
tiple timepoints, or selection of patients for treatment could be based on a prediction rule 
which should not only be based on a single measurement of the C3d/C3 ratio, but should 
also include genetic variants, disease stage and other factors influencing complement ac-
tivity.
It is important that future clinical trials evaluating complement inhibitors are well powered 
and include a sample size that is large enough for these kind of subanalyses.
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SUMMARY
Age-related macular degeneration (AMD) is a disease affecting the central retina and the 
most common cause of blindness in developed countries. AMD is a multifactorial disease 
and both environmental and genetic risk factors are involved in the pathogenesis. The aim 
of this thesis is to gain more insight in risk factors for disease development and progression 
and to characterize different subgroups of patients, such as individuals from AMD families. 
In addition, the role of the complement system in the course of the disease is evaluated. 
Chapter 1 serves as an introduction to the clinical and pathophysiological characteristics of 
AMD. It also provides the reader with basic knowledge on risk factors and available treatment 
and prevention strategies.
Chapters 2-4 focus on the identification of risk factors for AMD.
In Chapter 2 we report our findings on risk factors for an earlier age at onset of neovascular 
AMD. We evaluate a retrospective cohort of 275 patients with an average age at onset of 75 
years of age and show that in individuals homozygous for CFH and ARMS2 risk alleles and 
who smoke cigarettes, the onset of neovascular AMD may be accelerated by as much as one 
or two decades. These patients should be identified at an early age, in order to benefit from 
possible countermeasures as early as possible.
Patients who have already developed end-stage AMD in one eye are at increased risk of 
developing choroidal neovascularization (CNV) or geographic atrophy (GA) in the second eye. 
In Chapter 3 we determine risk factors for this second eye progression. Female sex, a higher 
age, a body mass index (BMI) above 30kg/m2 and smoking are all associated with a faster 
progression toward end-stage AMD in the fellow eye. In addition, genetic polymorphisms in 
the CFI and LPL genes also increase the risk of second eye progression. No increased risk 
is observed for polymorphisms in the CFH and ARMS2 genes, the two major genes for AMD 
development and progression in one eye. 
The presumed association of polymorphisms in the glutathione-S transferase (GST) genes 
and AMD is discussed in Chapter 4. A few studies, all characterized by small study popula-
tions, identified a relationship between GST polymorphisms and AMD. In a larger sample size 
of 477 AMD patients and 359 controls, we cannot confirm these associations. 
Patients with a positive family history for AMD are at increased risk to develop AMD. We 
focus in more detail on familial AMD in Chapters 5 and 6.
We know that certain lifestyle factors are significantly associated with AMD in non-familial 
cases, but not in familial cases. In Chapter 5 we investigate whether the contribution of com-
mon genetic variants and complement activation levels differs between familial and sporad-
ic cases with AMD. The A69S polymorphism in the ARMS2 gene is more strongly associated 
with sporadic AMD compared with familial AMD. In contrast, systemic complement activation 
is more associated with familial AMD, especially in patients with a densely affected family. 
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Our results point toward a more important role of the complement system in familial AMD.
Several groups have developed a prediction model for AMD. In clinical practice, individuals 
with a positive family history for AMD are particularly interested in their disease risk. In 
Chapter 6 we evaluate if these prediction models – that are mostly based on common en-
vironmental and genetic risk factors – can be applied to individuals from families affected 
with AMD. For most families, clustering of common risk factors explains the high frequency 
of disease. However, in a subset of densely affected families, we observed low predicted risk 
scores for all affected family members, suggesting that other risk factors, such as rare genet-
ic variants, explain the aggregation of AMD in these families.
In Chapter 7 we present an automatic computer system that allows for drusen detection and 
quantification with a performance equal to that of human observers. Automatic detection 
systems can be of additional value in research programs and screening settings. 
The alternative pathway of the complement system is thought to be the most important 
pathway involved in AMD. AMD patients have higher levels of complement activation com-
pared to controls and several polymorphisms in complement genes are associated with 
AMD. Chapters 8 and 9 discuss the role of the complement pathway in AMD.
Chapter 8 describes the levels of complement activation in different stages of AMD. Com-
plement activation in AMD appears to increase with local disease activity, with the lowest 
levels in controls and patients with inactive CNV and higher levels in patients with interme-
diate AMD, GA and active CNV. These results are only observed in a subgroup of patients with 
a high genetic risk, based on variants in several complement genes. Our results have impli-
cations for patient selection and time of initiation of treatment with complement inhibitors 
and should be evaluated in a prospective setting.
In Chapter 9 we report our finding of a novel complotype – a combination of three single 
nucleotide polymorphisms (SNPs) in genes of the complement system – that is strongly 
associated with AMD and complement activation. The complotype is composed of 2 SNPs in 
CFB and one SNP in CFH. It is important to identify these complotypes because they can aid 
in the stratification of patients in subgroups that might be more eligible for complement-in-
hibiting therapies in AMD. 
Chapter 10 discusses the findings of this thesis in a broader context. Research focused on the 
identification of risk factors for AMD is very important, since it will allow us to identify high risk 
individuals for disease development or progression. These individuals should be identified at an 
early age and provided with the proper tools and education to limit their risk of losing vision from 
advanced AMD. An overview of the currently available prediction models for AMD is presented. 
Because of the multifactorial etiology of the disease, it is likely that not all patients will 
benefit from the same treatment. Stratification of patients in subgroups based on their 
genetic risk profile or complement activity is important for the proper selection of eligible 
candidates for treatment with complement inhibitors. 
SAMENVATTING
Leeftijdsgebonden maculadegeneratie (LMD) is een ziekte van het centrale deel van de re-
tina en de meest voorkomende oorzaak van blindheid in ontwikkelde landen. LMD is een 
multifactoriële aandoening en zowel omgevingsfactoren als genetische risico factoren spe-
len een rol in the pathogenese. Het doel van dit proefschrift is meer te weten te komen over 
risico factoren voor LMD ontwikkeling en progressie en om verschillende subgroepen van 
patiënten te karakteriseren, zoals individuen uit LMD families. Daarnaast wordt ook de rol van 
het complement systeem in het beloop van de ziekte bekeken.
Hoofdstuk 1 dient als introductie in de klinische en pathofysiologische karakteristieken van 
LMD. Het verschaft de lezer de basiskennis over risico factoren en beschikbare behandelin-
gen en preventieve maatregelen.
Hoofdstuk 2-4 gaan dieper in op het identificeren van risico factoren voor LMD.
In Hoofdstuk 2 rapporteren we onze bevindingen over risico factoren voor een jongere leef-
tijd van ontstaan van neovasculaire LMD. We evalueren een retrospectief cohort van 275 
patiënten met een gemiddelde leeftijd van 75 jaar bij het ontstaan van neovasculaire LMD 
en we laten zien dat in individuen die homozygoot zijn voor risico allelen in CFH en ARMS2 
en ook roken, de beginleeftijd tot wel een of twee decaden vervroegd wordt. Deze patiënten 
zouden op jonge leeftijd geïdentificeerd moeten worden, om in een zo vroeg mogelijk stadi-
um te kunnen profiteren van mogelijke tegenmaatregelen. 
Patiënten die reeds in een oog eindstadium LMD hebben ontwikkeld, hebben verhoogd risico 
op het ontwikkelen van een choroidale neovascularizatie (CNV) of geografische atrofie (GA) 
in het tweede oog. In Hoofdstuk 3 bepalen we risico factoren voor deze progressie in het 
tweede oog. Vrouwelijk geslacht, een hogere leeftijd, een body mass index (BMI) boven de 
30 kg/m2 en roken zijn allemaal geassocieerd met een snellere progressie naar eindstadium 
LMD in het tweede oog. Daarnaast verhogen ook genetische polymorfismen in de CFI en LPL 
genen het risico op progressie in het tweede oog. Er wordt geen verhoogd risico gezien voor 
polymorfismen in de CFH en ARMS2 genen, de twee belangrijkste genen voor LMD ontwik-
keling en progressie in het eerste oog.
De veronderstelde associatie tussen polymorfismen in de glutathion-S transferase (GST) ge-
nen en LMD wordt bediscussieerd in Hoofdstuk 4. Een aantal studies, allen gekenmerkt door 
kleine studie populaties, beschreven een relatie tussen GST polymorfismen en LMD. In een 
grotere studie groep van 477 LMD patiënten en 359 controles, kunnen wij deze associaties 
niet bevestigen.
Patiënten met een positieve familie voorgeschiedenis voor LMD hebben verhoogd risico om 
LMD te ontwikkelen. We gaan nader in op familaire LMD in Hoofdstuk 5 en 6.
We weten dat bepaalde leefstijl factoren significant geassocieerd zijn met LMD in niet-fami-
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liaire patiënten, maar niet in familiaire patiënten. In Hoofdstuk 5 onderzoeken we of de bij-
drage van veelvoorkomende genetische varianten en complement activatie levels verschillen 
tussen familaire en sporadische patiënten met LMD. Het A69S polymorfisme in het ARMS2 
gen is sterker geassocieerd met sporadische LMD dan met familiaire LMD. Tegengesteld 
hieraan lijkt systemische complement activatie meer geassocieerd met familiaire LMD, met 
name in patiënten met een sterk belaste familie. Onze resultaten wijzen op een belangrijkere 
rol van het complement systeem in familiaire LMD.
Verschillende groepen hebben een predictiemodel voor LMD ontwikkeld. In de klinische 
praktijk, zijn het individuen met een positieve familie voorgeschiedenis voor LMD die vooral 
geïnteresseerd zijn in hun risico op ziekte. In Hoofdstuk 6 evalueren we of deze predictie-
modellen – die meestal gebaseerd zijn op veelvoorkomende omgevingsfactoren en geneti-
sche risico factoren – toegepast kunnen worden op individuen van LMD families. In de mees-
te families kan clustering van veelvoorkomende risico factoren het veelvuldig voorkomen van 
LMD verklaren. Echter, in een subset van sterk belaste families, zien we lage voorspelde risico 
scores voor alle aangedane familieleden, wat suggereert dat andere risico factoren, zoals 
zeldzame genetische varianten, het voorkomen van LMD in deze families verklaren.
In Hoofdstuk 7 presenteren we een automatisch computer system dat in staat is om drusen 
te detecteren en kwantificeren op een niveau gelijk aan dat van menselijke graders. Automa-
tische detectie systemen kunnen van toegevoegde waarde zijn in onderzoeksprogramma’s en 
screenings programma’s.
De alternatieve route van het complement systeem wordt geduid als de meest belangrijkste 
‘pathway’ die betrokken is bij LMD. LMD patiënten hebben hogere complement activatie le-
vels dan controles en verschillende polymorfismen in complement genen zijn geassocieerd 
met LMD. Hoofdstuk 8 en 9 bediscussiëren de rol van het complement systeem in LMD.
Hoofdstuk 8 beschrijft complement activatie levels in verschillende stadia van LMD. Com-
plement activatie lijkt toe te nemen met de lokale ziekte activiteit bij LMD, waarbij de laagste 
levels gevonden worden in controles en patiënten met inactieve CNV en de hoogste levels in 
patiënten met intermediaire LMD, GA en actieve CNV. Deze resultaten worden alleen gezien 
in een subgroep van patiënten met een hoog genetisch risico, gebaseerd op varianten in 
verschillende complement genen. Onze resultaten hebben implicaties voor de selectie van 
patiënten voor behandeling met complement inhibitoren en voor de timing van de start van 
behandeling, en zouden in een prospectieve setting moeten worden geëvalueerd.
In Hoofdstuk 9 rapporteren we onze bevindingen over een nieuw complotype – een combi-
natie van drie ‘single nucleotide polymorphisms’ (SNPs) in genen van het complement sys-
teem – die sterk geassocieerd is met LMD en complement activatie. Dit complotype bestaat 
uit 2 SNPs in CFB en een SNP in CFH. Het is belangrijk om deze complotypes te identificeren 
omdat zij kunnen helpen bij de stratificatie van patiënten in subgroepen die mogelijk meer 
in aanmerking komen voor complement-inhiberende behandelingen voor LMD.
Hoofdstuk 10 plaatst de bevindingen uit dit proefschrift in een bredere context. Onderzoek 
dat zich richt op de identificatie van risico factoren voor LMD is erg belangrijk, aangezien het 
ons in staat stelt individuen te identificeren met een hoog risico voor ziekte ontwikkeling 
of progressie. Deze individuen zouden we op jonge leeftijd moeten identificeren en moeten 
voorzien van de juiste handvatten en informatie om hun risico op verlies van gezichtsvermo-
gen door LMD te beperken. Een overzicht van de huidige predictiemodellen voor LMD wordt 
gepresenteerd.
Vanwege de multifactoriële aard van de ziekte, is het aannemelijk dat niet alle patiënten 
baat zullen hebben bij dezelfde behandeling. Stratificatie van patiënten in subgroepen geba-
seerd op hun genetisch risico profiel of op basis van complement activiteit is belangrijk voor 
de juiste selectie van geschikte kandidaten voor behandeling met complement remmers.
CHAPTER 11 SUMMARY - SAMENVATTING - LIST OF PUBLICATIONS - CURRICULUM VITAE - DANKWOORD
189188
11
LIST OF PUBLICATIONS
Genotypes in glutathione S-transferase are not associated with age-related macular de-
generation in a caucasian population.
Lechanteur YT, Peters WH, te Morsche RH, Hoyng CB, Klevering BJ, den Hollander AI.
Submitted
Prediction in families with age-related macular degeneration: Clustering of risk factors or 
rare genetic variants? 
Kersten E, Lechanteur YT, Saksens NT, Geerlings MJ, Schick T, Fauser S, Boon CF, den Hol-
lander AI, Hoyng CB.
Submitted
Complement activation levels are related to disease stage in age-related macular degen-
eration.
Lechanteur YT, Schick T, Daha MR, Altay L, Liakopoulos S, Smailhodzic D, den Hollander AI, 
Hoyng CB, Klevering BJ.
Submitted
Rare variants in CFH and CFI result in decreased C3b degradation in patients with age-re-
lated macular degeneration
Geerlings MJ, Kremlitzka M, Bakker B, Nilsson SC, Saksens NT, Lechanteur YT, Pauper M, 
Corominas J, Fauser S, Hoyng CB, Blom AM, de Jong EK, den Hollander AI.
Submitted
Analysis of risk alleles and complement activation levels in familial and non-familial 
age-related macular degeneration.
Saksens NT, Lechanteur YT, Verbakel SK, Groenewoud JM, Daha MR, Schick T, Fauser S, 
Boon CJ, Hoyng CB, den Hollander AI.
PLoS One 2016;11:e0144367
A novel complotype combination associates with age-related macular degeneration and 
high complement activation levels in vivo.
Paun CC, Lechanteur YT, Groenewoud JM, Altay L, Schick T, Daha MR, Fauser S, Hoyng CB, 
den Hollander AI, de Jong EK.
Sci Rep 2016;6:26568
A large genome-wide association study of age-related macular degeneration highlights 
contributions of rare and common variants.
Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, Burdon KP, Heb-
bring SJ, Wen C, Gorski M, Kim IK, Cho D, Zack D, Souied E, Scholl HP, Bala E, Lee KE, Hunter 
DJ, Sardell RJ, Mitchell P, Merriam JE, Cipriani V, Hoffman JD, Schick T, Lechanteur YT, 
Guymer RH, Johnson MP, Jiang Y, Stanton CM, Buitendijk GH, Zhan X, Kwong AM, Boleda 
A, Brooks M, Gieser L, Ratnapriya R, Branham KE, Foerster JR, Heckenlively JR, Othman MI, 
Vote BJ, Liang HH, Souzeau E, McAllister IL, Isaacs T, Hall J, Lake S, Mackey DA, Constable 
IJ, Craig JE, Kitchner TE, Yang Z, Su Z, Luo H, Chen D, Ouyang H, Flagg K, Lin D, Mao G, Fer-
reyra H, Stark K, von Strachwitz CN, Wolf A, Brandl C, Rudolph G, Olden M, Morrison MA, 
Morgan DJ, Schu M, Ahn J, Silvestri G, Tsironi EE, Park KH, Farrer LA, Orlin A, Brucker A, Li M, 
Curcio CA, Mohand-Saïd S, Sahel JA, Audo I, Benchaboune M, Cree AJ, Rennie CA, Goverd-
han SV, Grunin M, Hagbi-Levi S, Campochiaro P, Katsanis N, Holz FG, Blond F, Blanché H, 
Deleuze JF, Igo RP Jr, Truitt B, Peachey NS, Meuer SM, Myers CE, Moore EL, Klein R, Hauser 
MA, Postel EA, Courtenay MD, Schwartz SG, Kovach JL, Scott WK, Liew G, Tan AG, Gopinath 
B, Merriam JC, Smith RT, Khan JC, Shahid H, Moore AT, McGrath JA, Laux R, Brantley MA Jr, 
Agarwal A, Ersoy L, Caramoy A, Langmann T, Saksens NT, de Jong EK, Hoyng CB, Cain MS, 
Richardson AJ, Martin TM, Blangero J, Weeks DE, Dhillon B, van Duijn CM, Doheny KF, Romm 
J, Klaver CC, Hayward C, Gorin MB, Klein ML, Baird PN, den Hollander AI, Fauser S, Yates JR, 
Allikmets R, Wang JJ, Schaumberg DA, Klein BE, Hagstrom SA, Chowers I, Lotery AJ, Léveil-
lard T, Zhang K, Brilliant MH, Hewitt AW, Swaroop A, Chew EY, Pericak-Vance MA, DeAngelis 
M, Stambolian D, Haines JL, Iyengar SK, Weber BH, Abecasis GR, Heid IM.
Nat Genet 2016;48:134-43
Genetic variants and systemic complement activation levels are associated with serum 
lipoprotein levels in age-related macular degeneration.
Paun CC, Ersoy L, Schick T, Groenewoud JM, Lechanteur YT, Fauser S, Hoyng CB, de Jong 
EK, den Hollander AI.
Invest Ophthalmol Vis Sci 2015;56:7766-73
History of sunlight exposure is a risk factor for age-related macular degeneration.
Schick T, Ersoy L, Lechanteur YT, Saksens NT, Hoyng CB, den Hollander AI, Kirchhof B,  
Fauser S.
Retina 2016;36:787-90
Association of smoking and CFH and ARMS2 risk variants with younger age at onset of 
neovascular age-related macular degeneration.
Lechanteur YT, van de Camp PL, Smailhodzic D, van de Ven JP, Buitendijk GH, Klaver CC, 
Groenewoud JM, den Hollander AI, Hoyng CB, Klevering BJ.
JAMA Ophthalmol 2015;133:533-41
CHAPTER 11 SUMMARY - SAMENVATTING - LIST OF PUBLICATIONS - CURRICULUM VITAE - DANKWOORD
191190
11
Zinc supplementation inhibits complement activation in age-related macular degeneration.
Smailhodzic D, van Asten F, Blom AM, Mohlin FC, den Hollander AI, van de Ven JP, van Huet 
RA, Groenewoud JM, Tian Y, Berendschot TT, Lechanteur YT, Fauser S, de Bruijn C, Daha 
MR, van der Wilt GJ, Hoyng CB, Klevering BJ.
PLoS One 2014;9:e112682
Predicting non-response to ranibizumab in patients with neovascular age-related macular 
degeneration.
van Asten F, Rovers MM, Lechanteur YT, Smailhodzic D, Muether PS, Chen J, den Hollander 
AI, Fauser S, Hoyng CB, van der Wilt GJ, Klevering BJ.
Ophthalmic Epidemiol 2014;21:347-55
Nutritional risk factors for age-related macular degeneration.
Ersoy L, Ristau T, Lechanteur YT, Hahn M, Hoyng CB, Kirchhof B, den Hollander AI, Fauser S.
Biomed Res Int 2014;2014:413150
Environmental and genetic risk factors for retinal angiomatous proliferation.
Caramoy A, Ristau T, Lechanteur YT, Ersoy L, Müller S, Gelisken F, Hoyng CB, Kirchhof B, den 
Hollander AI, Fauser S.
Acta Ophthalmol 2014;92:745-8
Impact of the common genetic associations of age-related macular degeneration upon 
systemic complement component C3d levels.
Ristau T, Paun C, Ersoy L, Hahn M, Lechanteur YT, Hoyng C, de Jong EK, Daha MR, Kirchhof 
B, den Hollander AI, Fauser S.
PLoS One 2014;9:e93459
Allergy is a protective factor against age-related macular degeneration.
Ristau T, Ersoy L, Lechanteur YT, den Hollander AI, Daha MR, Hahn M, Hoyng CB, Fauser S.
Invest Ophthalmol Vis Sci 2014;55:210-4
Automatic drusen quantification and risk assessment of age-related macular degeneration 
on color fundus images.
van Grinsven MJ, Lechanteur YT, van de Ven JP, van Ginneken B, Hoyng CB, Theelen T, 
Sánchez CI.
Invest Ophthalmol Vis Sci 2013;54:3019-27
 
Genetic, behavioral, and sociodemographic risk factors for second eye progression in 
age-related macular degeneration.
Lechanteur YT, van de Ven JP, Smailhodzic D, Boon CJ, Klevering BJ, Fauser S, Groenewoud 
JM, van der Wilt GJ, den Hollander AI, Hoyng CB.
Invest Ophthalmol Vis Sci 2012;53:5846-52
Short-term changes of Basal laminar drusen on spectral-domain optical coherence to-
mography.
van de Ven JP, Boon CJ, Smailhodzic D, Lechanteur YT, den Hollander AI, Hoyng CB, Theel-
en T.
Am J Ophthalmol 2012;154:560-7
CHAPTER 11 SUMMARY - SAMENVATTING - LIST OF PUBLICATIONS - CURRICULUM VITAE - DANKWOORD
193192
11
CURRICULUM VITAE
Yara Terefech Esther Lechanteur was born on november 28th, 1986 in Addis Abeba, Ethiopia. 
She was adopted by Dutch parents in 1988. In 2004 she graduated from secondary school 
at “Liemers College” in Zevenaar, and started her medical studies in the same year at the 
Radboud University Nijmegen. It was during her internship in ophthalmology, that her par-
ticular interest in ophthalmology emerged. This was further reinforced during her scientific 
internship under the supervision of prof. dr. C.B. Hoyng at the department of ophthalmology 
at the Radboud university medical center. After graduation in 2010, she became a member 
of the scientific research group of prof. dr. C.B. Hoyng when she started her Ph.D. project on 
age-related macular degeneration. Her research results are presented in this thesis.
In January 2015, she started a residency in ophthalmology at the same institute.
DANKWOORD
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